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Background: The endothelin (ET) system, implicated in the pathogenesis of several
cardiovascular diseases, acts through two receptors; ETA and ETB. Both are present on
myocardial cells and vascular smooth muscle cells mediating vasoconstriction while
the ETb is also present on endothelial cells mediating vasodilatation. Thus, the
cardiovascular effects of ET will depend, in part, on the balance of action at these 2
receptors. In addition, the ETB receptor may also act as a clearance receptor. ET
receptor antagonists (ETRAs) are being developed as clinical therapies. The role of the
ETb receptor may determine which will be most beneficial. Recently, a novel form of
ET has been described; ET [1-31]. It is unclear whether this is vasoactive in its own
right, or is further processed to ET-1 suggesting a novel pathway of ET-1 production.
Aims: To investigate: 1. The vascular effects of ET [1-31], and whether there are
increased plasma concentrations in patients with chronic heart failure (CHF). 2. The
effects of ET-1 and its antagonists on isolated human myocardium and its interaction
with the beta-adrenergic system. 3. The role of the ETB receptor in CHF and whether
selective ETaRA have different haemodynamic effects than dual ETA/BRA. 4. The role
of the ETB in conditions of endothelial dysfunction (hypercholesterolaemia) and
whether any dysfunction is reversible with 'statin' therapy.
Methods: Skin blood flow after intra-dermal injection of ET ligands was developed
and assessed using laser Doppler flowmetry. Forearm blood flow after intra-arterial
infusion of ET ligands was measured by venous occlusion plethysmography. Large
artery stiffness was assessed by pulse wave analysis. Systemic haemodynamics were
determined invasively by the thermodilution method and non-invasively by thoracic
bioimpedence. Direct ET effects on human myocardium were developed and assessed
in isolated human right atrial trabeculae. The effects of lowering plasma cholesterol
was assessed following 8 weeks of 'statin' therapy. Plasma ET concentrations were
determined using immunoassays.
Results: ET-1 vasoconstricts in the skin microcirculation and it appears that
endothelin converting enzyme (ECE) activity is present as big ET-1 also
vasoconstricts. ECE and neutral endopeptidase (NEP) blockade both cause
vasodilatation suggesting skin basal resting ET tone. ET-1 [1.31] is also a
vasoconstrictor in the skin microcirculation. Plasma concentrations of ET-1 [1.31] are
not elevated in patients with CHF. ETaRA improves systemic haemodynamics in
patients with CHF while concomitant ETBRA attenuates this effect. In the isolated
human myocardium ET is positively inotropic but there is no resting ET inotropy with
no effect on basal twitch force with ETRA. In addition, ET attenuates beta-adrenergic
activation in isolated human myocardium. In hypercholesterolaemia, forearm vascular
effects are similar to those previously reported in healthy volunteers. Treatment with
statin therapy for 8 weeks caused a trend towards an increase in ETA mediated
vasodilatation.
Conclusions: The novel finding that ET £i_3ij is a vasoconstrictor in the skin
microcirculation may represent a novel pathway of ET production. The haemodynamic
benefits of selective ETaRA over dual ETa/BRA is a unique finding with considerable
importance and supports the development of selective ETaRAs as clinical therapies in
CHF. The finding of antagonism between the ET system and the beta-adrenergic
stimulation may represent a protective adaptation in conditions where there beta-
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Chapter 1
Introduction - the endothelin system
Leslie SJ, Webb DJ. Endothelin and its Inhibitors. In: Endothelin Ligands and their
Experimental Effects within the Human Circulation. Handbook ofPhysiology. Springer
2001 Chapter 19.
1
1.1 THE ENDOTHELIN SYSTEM
Endothelin (ET) was discovered in 1988 [Yanagisawa et al 1988]. It is a 21 amino-acid
polypeptide with two disulphide bonds which has three isoforms, ET-1, ET-2 and ET-3
[Inoue et al 1989] (Figure 1.1). Two receptor subtypes have been identified ETA and
ETb (Figure 1.2). ET-1 and ET-2 have a higher affinity than ET-3 for the ETA receptor
while all three have a similar affinity for the ETb receptor. The different isoforms are
produced by a variety of cells but the most important isoform, predominantly produced
by the endothelial cell, is ET-1. ET-1 is the most potent vasoconstrictor yet discovered
in humans. In addition, it has mitogenic properties and is positively inotropic [Meyer et
al 1996]. A substantial body of evidence has developed implicating the ET system in
basal vascular tone and the pathogenesis of several cardiovascular conditions in humans
including, hypertension [Haynes et al 1994a], renal failure [Bussemaker et al 1998,
Ferro et al 1998], pulmonary hypertension [McCulloch et al 1995 & 1998] and chronic
heart failure (CHF) [Cavero et al 1990]. Endothelin receptor antagonists (ETRAs) and
converting enzyme inhibitors have been developed and many ETRAs are now under
development as potential therapies for a variety of conditions [Douglas et'al 1997].
However, despite this intensive research effort, several important questions remain
unanswered.
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Figure 1.1 Diagram of endothelin isoforms, illustrating amino acid sequence and
presence of 2 disulphide bonds. The shaded circles denote differences
in amino acid structure of ET-2 and ET -3 compared with ET -1.
3
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1.2 ENDOGENOUS SYNTHESIS OF ENDOTHELIN
1.2.1 Endothelin gene product
The production of ET-1 is regulated at the level of the gene product located on
chromosome 6 by many factors (Table 1.1). After transcription and removal of the signal
peptide a 212 amino acid peptide, preproendothelin-1 is produced (Figure 1.3). Prepro-
ET-1 mRNA is found in the highest concentrations in lung although it can found in most
organs including the heart, kidney, brain, pancreas and spleen. In general, basal
physiological production of ET-1 is low but it is inducible [Redington et al 1997, Woods
et al 1999], In disease conditions, such as atherosclerotic plaques, basal ET-1 production
from endothelial cells is increased and this may have important clinical consequences,
especially in vascular beds in the heart, brain and kidneys. Preproendothelin-1 is
subsequently processed by several enzymes to a 38 amino acid derivative, big ET-1
[Yanagisawa et al 1988].
1.2.2 Big endothelin-1
Big ET-1, the 38 amino acid precursor to ET-1, is relatively inactive compared with ET-
1 [Kashiwabara et al 1989, Hirata et al 1990], with a receptor affinity at the ETa
receptor -1000 times less than ET-1 [Gray et al 1996], However, when injected
intravenously it has similar vascular effects to ET-1 suggesting prompt vascular
conversion [Gardiner et al 1993]. This conversion is mediated by endothelin converting
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Table 1.1 Factors influencing endothelin gene product synthesis. (ANP - atrial
natriuretic peptide, BNP - brain natriuretic peptide, CNP - c-type





Figure 1.3 Amino acid sequence of preproendothelin and putative signal
sequence illustrating cleavage point for endothelin converting enzyme
(Adapted from Endothelin Ligands and their Experimental Effects
Within the Human Circulation. Handbook of Physiology. Springer
2001)
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1.2.3 Endothelin converting enzymes
There are at least 25 proteases which can convert ET precursors into active ETs (Table
1.2). However, the 'endothelin converting enzymes' (ECEs) [Shimada et al 1994, Xu et
al 1994] are thought to be the most important. ECE-1 consists of at least 4 isoforms
although their exact specificities for big ET-1, big ET-2 and big ET-3 are not known.
The 4 isoforms currently characterized are ECE-la, ECE-lb, ECE-lc and ECE-ld and
are produced from the same gene products with differences in exon splicing of the 5'
region [Valdenaire et al 1995 & 1999, Schweizer et al 1997]. ECE-2 has similarities
with ECE-1 with 59% homology [Emoto & Yanagisawa 1995], There are several other
related peptides, including human mast cell chymase (see below), although their exact
number and whether they are physiologically important in ET-1 production is, as yet,
unclear (Table 1.2).
1.2.4 Endothelin-1
Endothelin-1 is a potent vasoconstrictor agent released most importantly by endothelial
cells but also by other cell types including myocytes and fibroblasts. Due to its
vasoconstrictor actions, ET-1 has been implicated in a number of cardiovascular
diseases including chronic heart failure, hypertension and pulmonary hypertension (see
below). The actions of ET-1 are mediated through 2 receptor subtypes in humans; the
ETa and the ETB. ET-1 causes vasoconstriction via the ETa and ETb receptors located
on vascular smooth muscle cells and a prostanoid and nitric oxide (NO) mediated
vasodilatation via the ETb receptor on endothelial cells. Thus, ETa blockade causes
8
vasodilatation while the effects of ETB blockade will depend, in part, on the balance
between the vasodilating and vasoconstricting effects at different sites. In healthy
volunteers this balance appears to be in favour of vasodilatation as ETB receptor
blockade causes vasoconstriction (see below).
1.2.5 Endothelin-l[i_3i]
Recently, new derivatives of big ETs have been characterised in humans; ET-1 [ 1 -31 ] is
-51 -3^
generated following the cleavage of big ET-1 at the Tyr -Gly ~ bond by human
chymase [Nakano et al 1997] (Figure 1.1). The discovery of a new isoform of ET may
be of clinical importance in conditions where there is systemically increased chymase
activity such as CHF [Urata et al 1990] and local increases in coronary artery plaque
rupture [Kovanen et al 1995, Kaartinen et al 1994], In vitro studies have shown that ET-
1 [i-31] is vasoactive in several animal vascular beds with a potency similar to ET-1 [Kishi
et al 1998, Hanson et al 1997, Takai et al 1998], In cultured human coronary artery
smooth muscle cells ET-lp.31] increases intracellular calcium [Inui et al 1999] consistent



































Rat lung mast cell chymase I,
chymostatin sensitive
Eluman mast cell chymase
Monkey chymase,
chymostatinsensitive
Xu et al 1994, Ikura et al 1994,
Shimada et al 1995
Schmidt et al 1994, Shimada et al 1995,
Valdenaire et al 1995
Schweizer et al 1997
Valdenaire et al 1999
Emoto and Yanagisawa 1995
Nakahara et al 1999
Hasegawa et al 1998
Ikeda et al 1999
Schweizer et al 1999
Takaoda et al 1990
Sawamura et al 1990
Ikegawa et al 1990
Lees et al 1990
Ohnaka et al 1990
Pons et al 1991
Wu-wong et al 1990, Shiosaki et al 1993
Knap et al 1993
Deng et al1992
McMahon et al 1989
Takaoka et al 1990
Pons et al 1991
Wypij et al 1992
Nakano et al 1997, Kido et al 1998
Takai et al 1998
Table 1.2 List of proteases able to convert ET precursors into active endothelin
isoforms (adapted from Endothelin Ligands and their Experimental




There are two specific ET receptors (ETRs) in mammals. The ETA [Aria et al 1990] has
a higher affinity for ET-1 and ET-2 whereas the ETb [Sakurai et al 1990] has equal
binding affinity for ET-1, ET-2 and ET-3. The ETA and ETb receptors, encoded by
genes on chromosomes 4 and 13 respectively, are classic G protein coupled receptors
with seven hydrophobic helical transmembrane loops [Ogawa et al 1991, Elshourbagy et
al 1992], There are some functional data suggesting different subtypes of each receptor
but this has not yet been confirmed by molecular or genetic studies. In addition, ETRs
may undergo post translational modifications such as glycosylation and palmitoylation,
which may explain functional differences in disease states. Further differences in
physiological and pathophysiological actions may be a result of changes in second
messenger signaling systems (see below).
1.3.1 Vascular endothelin receptors
Both the ETa and ETb receptor types are found on vascular smooth muscle cells,
binding to these causes a rise in intracellular calcium and a subsequent contraction. ETb
receptors are also found on endothelial cells where binding results in a prostanoid and
nitric oxide mediated vasodilatation (Figure 1.3).
1.3.2 Cardiac endothelin receptors
Both ETa and ETb receptors are found in human myocardium [Ponicke et al 1998],
However, distribution of the receptor type and number is not uniform and there may be
differences in receptor distribution in specific pathological conditions. In situ
11
hybridization studies have demonstrated both receptor types in atrial and ventriclar
myocardium, atrioventricular conducting system and the endocardial cell [Molenaar et al
1992], In general, the ratio of ETA to ETB receptors in terms of number is approximately
60:40% [Peter & Davenport 1996] and receptor density is 1.5 to 2 fold higher in the
atrium compared to the ventricle [Ponicke et al 1998], In addition, a higher proportion of
ETb receptors are found in the AV node and the penetrating bundles of His compared
with the surrounding myocardium [Molenaar et al 1992] suggesting involvement of the
ETb receptor in neural control of the heart.
1.3.3 Intracellular second messenger signalling
Binding to the ETR results in activation of a number of intracellular signaling processes.
More than one second messenger signalling system may be stimulated simultaneously
depending on the cell type and level of expression of G protein subtypes. G protein
subtypes coupled to ETRs include Gq, Gu, Gs and Gj2 [Takigawa et al 1995].
Downstream signal transduction pathways include enzymes such as nitric oxide
synthase, adenylate and guanylate cyclase, protein kinase C, protein tyrosine kinase, and
phospholipase A2, C and D, ion channels such as calcium and chloride channels and ion
transporters (Figure 1.4). Therefore effects of binding to ETRs will also depend on
which second messenger pathways are activated and this will change within and
between cell types. In addition, many of these second messenger pathways are shared
with other neuroendocrine systems and therefore post receptor cross talk may influence
responses. One such potential interaction is in the myocardium where beta-adrenergic
stimulation increases adenylate cyclase while endothelin reduces it (Figure 1.4). Thus,
there is a potential antagonism between these systems.
1.3.4 Myocardial mast cells
As previously discussed in this chapter, chymase from human mast cells has been shown
to convert big ET-1 to ET[i_3i] [Kido et al 1998]. Mast cells are important mediator of
inflammation and are present in human myocardium. Cardiac diseases such as unstable
coronary artery disease and heart failure are characterised by local and general increase
in inflammatory markers and increased chymase activity. However, the interaction
between cardiac mast cells and ET is likely to be complicated. Recent work has
demonstrated that ET-1 itself causes mast cell degranulation and down stream release of
vasoactive mediators. These mediators could increase coronary arterial tone
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1.4 ENDOTHELIN AGONISTS
Synthetic ET-1, ET-2, ET-3 and sarafotoxin 6c (SX6c), an ETb agonist, are available
commercially. The ETA receptors have a high affinity for ET-1 and ET-2 and lower
affinity for ET-3 whereas the ETB receptor has equal affinity for ET-1, ET-2 and ET-3.
ET-3 and especially SX6c have been used as tools to investigate the ETb receptor as ET-
3 is 2000 fold selective for the ETB receptor and SX6c is 30,000 fold selective for the
ETb receptor (Table 1.3).
Agonist studies have been useful in defining the target organs and the receptor subtypes
involved in physiological responses to the endothelins, however, as the endothelins acts
predominantly via autocrine and paracrine mechanisms [Hocher et al 1997],
administration of exogenous agonist is unlikely to reproduce physiological responses
and results from such studies may be misleading. Therefore, it has been the study of the
effects of ETAs which has been central to unravelling the complexities of the
pathophysiology of the endothelin system in man (See below).
1.5 ENDOTHELIN RECEPTOR ANTAGONISTS
A number of ET receptor antagonists have been developed as research tools and as
potential medicines [Douglas et al 1997]. Some of these are selective for the ETA or ETb
receptor while others are mixed ETA/B receptor antagonists. Some, such as BQ-123,
2000 fold selectivity for the ETA receptor [Ihara et al 1992] and BQ-788, 200-fold
selectivity for the ETb receptor [Ishikawa et al 1994] are peptides and therefore inactive
when given orally (Figure 1.5 a and b). However, other non-peptide ET antagonists such
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as bosentan, a mixed ETA/b receptor antagonist, are orally active, have been developed
as potential therapies (Figure 1.5 c). With the current optimism regarding the ET system
as a target in a number of pathological conditions, there are many other ET antagonists
undergoing pre-clinical and clinical studies [Ferro et al 1996, Douglas et al 1997].
Details of endothelin antagonists used the studies contained in this thesis are found in
Chapter 2.
1.5.1 Toxicology of endothelin antagonists
In general endothelin antagonists are well tolerated although they can cause the
predicted side-effects of hypotension, nausea and headache [Weber et al 1996, Krum et
al 1998]. Administration of bosentan, a dual ET receptor antagonist, in recent clinical
trials, resulted in adverse clinical events such as raised alanine and asparate
aminotransferases, flushing, peripheral oedema and headache [Packer et al 1998].
Flowever, there are no data suggesting these effects occur with short term administration
of BQ-123 or BQ-788 and the administration of these compounds even in systemic
doses in the following studies was extremely well tolerated with no adverse events. The
ET system is intimately involved in foetal development and therefore it is not surprising
that BQ-123 and BQ-788 have been shown to be teratogenic in animals. In particular,
BQ-123 has been shown to increase the incidence of several cardiac outflow tract
abnormalities in a mouse model of ETA receptor deficiency [Kurihara et al 1995], Due
to their, as yet, limited long term usage in clinical trials there are no data on
teratogenicity in humans. Therefore only men and post-menopausal women were
enrolled in the following studies. In addition, in all of the studies involving intravenous
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infusion of BQ-123 or BQ-788, safety blood tests were performed before and after
infusion, measuring full blood count, sodium, potassium, urea and creatinine and liver
function tests. There were no adverse events in any of the studies.
1.6 ENDOTHELIN CONVERTING ENZYME INHIBITORS
There are no selective endothelin converting enzyme (ECE) inhibitors available for
clinical studies. In general ECE inhibitors affect many other enzymes to a varying
degree, which can confound study results. Two enzyme inhibitors phosphoramidon, a
ECE and neutral endopeptidase (NEP) inhibitor and thiorphan, a selective NEP inhibitor
have been useful in determining pathways of ET production.
Phosphoramidon (Figure 1.5 d) is a metalloendopeptidase that acts as an ECE inhibitor
inhibiting the conversion of big ET to ET-1 [Ikegawa et al 1991]. Its principal effect in
humans is to cause a decrease in vascular tone, due to inhibition of the endogenous
production of ET-1. Local vasodilatation occurs after intra-arterial infusion of locally
active doses of phosphoramidon. Intra-arterial infusion of phosphoramidon at
concentrations of 30nmol/min has been shown to cause a 40% increase in blood flow in
the infused arm with no systemic effects noted [Haynes et al 1994b]. Thiorphan (Figure
1.5e) is a selective NEP inhibitor that does not inhibit endothelial cell ECE [Matsumura
et al 1990, Okada et al 1990, Davenport et al 1998],
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Figure 1.5 a -BQ123
Figure 1.5 b - BQ788













Figure 1.5 e - Thiorphan

















































1.7 ENDOTHELIN LIGANDS AND THEIR EXPERIMENTAL EFFECTS IN
HEALTHY VOLUNTEERS
1.7.1 Local ET activation in healthy volunteers
1.7.1.1 Resistance vessels
Infusion of ET-1 (5 pmol/min) into the brachial artery caused a slow onset, dose-
dependent sustained reduction in blood flow of 40% at 60 min in the forearm of healthy
volunteers. This persisted for up to 2 hours following discontinuation of the infusion
[Clark et al 1989], Similar vasoconstriction has been demonstrated by other groups and
in addition ET-1 caused a non-significant trend towards causing early vasodilatation
[Haynes et al 1995a], In one study, sustained vasodilatation has been described with ET-
1 at low concentrations (0.2 pmol/min/100 ml forearm tissue) [Kiowski et al 1990]. The
low doses used in this study may have been insufficient to cause the sustained
vasoconstriction response seen in other studies but at the same time sufficient to cause
the initial vasodilatation. The mechanisms behind this are not clearly understood.
SX6c and ET-3, both ETb agonists, also caused constriction of forearm resistance
vessels in vivo but to a lesser degree than ET-1 [Haynes et al 1995b], thus implicating
the ETr receptor in vasoconstriction. However, ET-1, ET-3 and SX6c caused a transient
vasodilatation prior to a sustained vasoconstriction. The transient vasodilatation is more
marked with ET-3 and SX6c suggesting that this is mediated via endothelial ETb
receptors [Haynes et al 1995b]. Thus, it seems that ETB receptors can mediate both
vasodilatation and vasoconstriction.
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It is postulated that the ETb receptors on the vascular smooth muscle cells cause
vasoconstriction [Williams et al 1991, Moreland et al 1992, Sumner et al 1992] while
the endothelial cell receptors mediate vasodilatation [Takayanagi et al 1991] possibly
also acting as clearance receptors for ET-1.
The exact mechanism of ET-3 and SX6c vasoconstriction is unclear. It may be mediated
by direct binding to the ETb receptors on the vascular smooth muscle cells resulting in
vasoconstriction. However, it may be that ETb binding causes displacement of ET-1 thus
increasing stimulation at the ETa receptor resulting in vasoconstriction. In addition,
there is animal evidence that SX6c may act through non-endothelin dependent
mechanisms, and the pressor responses may be independent of the endothelin system
[Flynn et al 1995].
Local infusions of big ET-1 (50 pmol/min) produce vasoconstriction which can be
blocked by phosphoramidon, a combined ECE and NEP inhibitor [Haynes et al 1994b].
There is limited plasma ECE activity [Watanabe et al 1991] and this result, therefore,
suggests that forearm resistance vessels have local ECE activity.
1.7.1.2 Capacitance vessels
Constriction of dorsal hand veins is seen with ET-1 infusions of 5 pmol/min [Clark et al
1989, Haynes et al 1993a, 1995b]. There is no venoconstriction to local infusion of big
ET-1 (50 pmol/min) suggesting no local ECE activity in hand veins [Haynes et al
1995b]. The mechanism of action of ET-1 in hand veins is thought to mediated via both
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^ I Ithe opening of voltage operated Ca channels and the closure of ATP sensitive K
channels thus offering other targets for therapeutic intervention [Haynes et al 1993b],
Sarafotoxin (SX6c) and ET-3 (ETb agonists) also caused constriction of hand
capacitance vessels in vivo but to a lesser degree than ET-1 [Elaynes et al 1995b], thus
implicating the ETb receptor in venoconstriction.
Dorsal hand veins have no intrinsic tone, however, in preconstricted human hand veins,
as in arteries, ET-1, ET-3 and SX6c also caused a transient vasodilatation prior to a
sustained vasoconstriction. The transient vasodilatation was more marked with ET-3 and
SX6c suggesting that it is mediated via endothelial ETB receptors [Haynes et al 1995b].
This effect is blocked by Aspirin and therefore it is postulated that it is prostanoid
dependent [Haynes et al 1994a].
1.7.1.3 Microcirculation
Intra-dermal injection of ET-1 results in vasoconstriction of the microcirculation
[Wenzel et al 1994], Intra-dermal ET-3 injection does not cause vasoconstriction
suggesting that vasoconstriction in the skin microcirculation is an ETA mediated
response. More recently, studies have demonstrated vasodilatation, 1-2 cm from the site
of injection [Wenzel et al 1998a], It appears that this is an ETA receptor mediated effect
through stimulation of polimodal nociceptor fibres leading to nitric oxide release
because this effect is blocked by BQ-123 and pre-treatment with L-NMMA, lignocaine
and capsaicin. This potentially, implicates endothelins in the process of neurogenic
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inflammation, suggesting ETAs may possibly have a role to play in the treatment of
inflammatory conditions.
The overall effect of ET-1 at the ETb receptor will therefore be determined by the
balance of effects between its actions at the endothelial and vascular smooth muscle ETb
receptors. As previously discussed, the results of agonist studies should be interpreted
with caution as the endothelins act in a paracrine and autocrine fashion and the
administration of supra-physiological concentrations of exogenous agonists may not
mimic in vivo physiology. The results of antagonist studies are likely to be much more
illuminating.
1.7.2 Local ET inhibition in health volunteers
1.7.2.1 Resistance vessels
Local infusion of BQ-123 [Haynes et al 1994a, Berrazueta et al 1997, Verhaar et al
1998] and TAK-044 [Haynes et al 1996] results in vasodilatation in the forearm arteries
of healthy volunteers. The larger effect seen with BQ-123 suggests that vasoconstriction
to ET-1 is mediated predominantly through the ETa receptor located on vascular smooth
muscle cells. Thus, the net effect of inhibition of the ETb receptor is vasoconstriction.
The role of the ETb receptor is further clarified by studies with the ETB receptor
selective antagonist, BQ-788 [Ishikawa et al 1994], BQ-788 causes vasoconstriction in
the forearm vessels of healthy volunteers [Verhaar et al 1998], This vasoconstriction
persists on a background of ETa antagonism [Verhaar et al 1998], reinforcing the
hypothesis that ET-1 stimulation of the endothelial ETB receptor causes dilatation, and is
23
likely to be a direct effect, whereas the vascular smooth muscle ETb receptor causes
vasoconstriction.
1.7.2.2 Microcirculation
In the skin microcirculation, in healthy volunteers, intradermal injection of a mixed
ETa/b antagonist caused a vasodilatation which was no greater than that seen with a
selective ETa antagonist suggesting vasoconstriction to endothelin is solely ETa
receptor mediated [Wenzel et al 1994], However, in patients with coronary artery
disease there was increased vasodilatation with mixed ETa/b antagonism over ETa
antagonism, suggesting there may be ETb receptor mediated vasoconstriction in these
patients [Wenzel et al 1996], In addition, intravenous administration of Bosentan
reversed the vasoconstrictor effect of ET-1 measured in the skin microcirculation
[Weber et al 1996]. This study did not report a distal flare following intra-dermal ET-1
administration. However, in a more recent study, pretreatment with intra-dermal ETA
receptor antagonist prevented the ET-1 induced vasoconstriction and also the 'flare
reaction' caused by vasodilatation in the surrounding area. There was no additional
effect with mixed ETa/b antagonist suggesting that the flare reaction is an ETa receptor
mediated response [Wenzel et al 1998]. Thus, in the skin microcirculation in healthy
volunteers, ETA receptors appear to be involved in ET mediated vasoconstriction and to
mediate the distal vasodilatation.
1.7.3 Systemic ET activation in healthy volunteers
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1.7.3.1 Cardiovascular effects
The administration of ET-1 (5ng/kg/min for 15 min) to healthy volunteers results in an
increase in mean blood pressure of 5-10 mmHg and a reduction in heart rate, which is
probably reflex in nature. This dose of ET-1 increased plasma concentrations by 50 fold
[Vierhapper et al 1990]. In more recent studies, both ET-1 (8 pmol/kg/min for 10 min)
and big ET (8 pmol/kg/min) infusions, sufficient to cause increases in plasma ET-1 of 30
and 2.4 fold respectively, caused similar increases in blood pressure (BP) and a
reduction in heart rate which persisted following cessation of the infusion for 30 and 90
min respectively. These doses of ET-1 and big ET-1 also reduced coronary sinus blood
flow, by a maximum of -25%, and increased coronary vascular resistance by -50 and
100% respectively [Pernow et al 1996]. In other studies, similar haemodynamic changes
following big ET-1 infusion (8 pmol/min for 20 min; 2 fold increase in plasma ET-1)
persisted for up to 2 hours [Ahlborg et al 1994]. Further studies have shown that doses
of ET-1 insufficient to cause systemic or pulmonary pressor effects (0.75 pmol/kg/min)
can impair left and right diastolic dysfunction and are negatively inotropic [Kiely et al
1997],
1.7.3.2 Renovascular effects
A reduction in splanchnic and renal blood flow by 34 and 26% respectively is seen
following ET-1 infusion (4 pmol/kg/min for 20 min; 12 fold increase in plasma ET-1)
which persisted for 1 and 3 hours respectively [Weitzberg et al 1991]. More recently,
changes in renal parameters have been demonstrated following administration of lower
doses of ET-1 (1 pmol/kg/min for 60 min: 11 fold increase in plasma ET-1) to healthy
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volunteers causing an increase in diastolic BP of 8% and decrease in heart rate of 14%
but no significant change in systolic BP. This reduction in heart rate is probably 'reflex'
in response to reduced systemic vascular resistance. Renal plasma flow and glomerular
filtration rate (GFR) were both reduced, by ~35 and 16% respectively. Urine flow was
reduced by 40% and urinary sodium excretion by 58%. Lithium clearance in these
subjects suggested that the reduction in sodium excretion occurred at the distal rather
than proximal tubule [Sorensen et al 1994], Infusion of lower doses of ET-1 (0.4
pmol/kg/min) for a longer period (6 hours) results in decreased renal blood flow by 43%,
associated with a 10% decrease in heart rate. This dose of ET-1 increased plasma ET
concentration by -300% [Jilma et al 1997]. In a similar study the administration of
exogenous ET-1 (2.5ng/kg/min) to healthy volunteers sufficient to cause a 3 fold
increase in plasma ET concentrations caused renal vasoconstriction and sodium
retention. In this study, administration of a comparable dose of ET-3 produced no effect
on blood pressure, renal blood flow or electrolyte excretion suggesting that these
responses are predominantly ETa mediated [Kaasjager et al 1997], Interestingly, ET-1
produced sodium retention in humans even at doses insufficient to reduce renal plasma
flow or glomerular filtration rate [Rabelink et al 1994] suggesting that ET may have
subtle intra-renal effects on sodium handling.
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1.7.4 Systemic ET inhibition in healthy volunteers
1.7.4.1 Cardiovascular effects
The results of systemic studies with ETAs have, in general, confirmed the predictions
made from the results of local vascular studies.
1.7.4.1.1 Non-selective inhibition
The administration of the ETa/b antagonist TAK-044 (1000 mg over 15 min) reduced
systolic blood pressure, diastolic blood pressure and systemic vascular resistance by 4%,
18% and 26% respectively and resulted in an increase in both heart rate and cardiac
index. Plasma ET concentrations increased by 9-fold following administration of TAK-
044 (lOOOmg). These results suggest an effect predominantly in resistance vessels
[Haynes et al 1996]. The increase in plasma ET is thought to be the result of
displacement of bound ET-1 and reduced ET-1 clearance as there is no associated
increase in big ET-1 or its C-terminal fragment [Plumpton et al 1996]. Similar results
are found in healthy volunteers given oral and intra-venous bosentan. Bosentan, 2400
mg administered orally, resulted in a maximal decrease in systolic blood pressure of 9
mmHg two hours after dosing [Weber et al 1996]. This study also demonstrated a dose-
dependent increase in plasma ET-1 after administration of bosentan; 2-fold following
2400 mg (oral) and 3-fold following 750 mg (IV).
1.7.4.1.2 Selective inhibition
BQ-123 (3000 nmol/min for 15 min) administered to healthy volunteers resulted in a
reduction in mean arterial blood pressure and systemic vascular resistance index of 12%
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and 23% respectively with an associated increase in cardiac index and a non significant
increase in heart rate. Similar effects were seen with lower doses (1000 nmol/min for.15
min) [Spratt et al 2001]. Forearm vasoconstriction to local infusions of ET-1 is blocked
with the higher systemic doses of BQ-123 (3000nmol/min for 15 min), in this study,
thus confirming the dominant role of the ETa receptor as a vasoconstrictor in peripheral
resistance vessels. Interestingly, there was no consistent increase in plasma big ET-1 or
plasma ET-1 with systemic blockade of the ETA receptor.
The administration of BQ-788, a selective ETb receptor blocker, at systemic doses (300
nmol/min for 15 min) to healthy men causes systemic vasoconstriction with a reduction
of heart rate and cardiac index but no effect on mean arterial blood pressure, again
suggesting that endogenous activity at the vascular ETb receptors mediates a
predominantly vasodilator tone [Strachan et al 1999]. In common with previous studies
plasma ET-1 increased, 2-fold, with ETB receptor blockade.
1.7.4.2 Renovascular effects
BQ-123 (-100 nmol/min IV for 60 min) administered to healthy men had no renal or
systemic effects but did prevent ET-1 (1 pmol/kg/min for 120 min) induced reductions
in renal plasma flow and GFR [Schmetterer et al 1998]. These results suggest that the
vasoconstriction of renal vessels caused by ET-1 are mediated through the ETA receptor
and are more sensitive to ETRAs than the peripheral vasculature. The authors claim that
the lack of change in renal parameters following administration of BQ-123 suggests
there is no ET mediated resting tone in the renal vasculature. However, despite reversing
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the effects of exogenous ET-1, the lack of a systemic effect with this dose of BQ-123
would suggest that this dose may be insufficient to cause renal effects.
More recently, administration of the mixed ETa/b receptor antagonist, TAK-044 resulted
in a decrease in effective renal vascular resistance, suggesting there may be ET mediated
resting vascular tone in the kidney. However there was a decrease in GFR and a
significant decrease in the filtration fraction with both doses of TAK-044 [Ferro et al
1998],
Thus, the question as to whether there is basal endothelin mediated tone and the role of
the ETa and ETb receptor in the renal vasculature remain to be clarified.
1.8 ENDOTHELIN LIGANDS AND THEIR EFFECTS IN PATIENTS
1.8.1 Heart disease
1.8.1.1 Chronic heartfailure
The first clinical trial of an ET antagonist in CHF involved the systemic administration
of bosentan (100 mg IV followed by 200 mg IV after 60 min) and resulted in a reduction
of mean arterial pressure, systemic and pulmonary vascular resistance and an increase in
cardiac output without reflex increases in heart rate and importantly no increase in
plasma angiotensin II or noradrenaline [Kiowski et al 1995]. Pulmonary vascular
resistance was decreased to a greater degree than systemic vascular resistance, in
contrast to the effect usually seen with other vasodilators. These patients, however, do
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not reflect the general patient population as they were not being treated with angiotensin
converting enzyme (ACE) inhibitors.
Subsequently, local studies were performed in CHF patients on standard treatments
(including ACE inhibitors). Local brachial artery infusion of ET-1 (5 pmol/min for 60
min) caused less vasoconstriction compared with matched controls in resistance [Love et
al 1996b] and capacitance vessels [Love et al 1996c], In these patients potentially
beneficial haemodynamic effects are seen with local brachial artery infusion of BQ-123
(100 nmol/min for 60 min) which causes vasodilatation. Although there is increased
vasoconstriction to the ETb receptor agonist, S6Xc (5 pmol/min for 60 min), in CHF
patients when compared with matched controls, BQ-788 also causes vasoconstriction,
suggesting the net effect of stimulation of the ETb receptor is vasodilatation. The effects
of S6Xc have been discussed previously.
Systemic studies in patients on treatment including ACE inhibitors, digitalis glycosides
and diuretics demonstrating similar haemodynamic improvements in the short term with
a small increase in heart rate when given bosentan orally (0.5g twice a day for 14 days)
[Sutsch et al 1997], A further study demonstrated improved haemodynamic parameters
in CHF patients treated with oral bosentan (lg twice daily) with an increase in cardiac
output of 15% and a decrease in systemic and pulmonary vascular resistance each of
-10% respectively. This is important, as these beneficial effects were seen in patients
already treated with ACE inhibitors, diuretics and digoxin [Sutsch et al 1998].
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More recently the results from a larger study, REACH-1, were reported. 370 patients
with NYHA class IIIB-IV on standard treatments, including ACE inhibitors, received
either bosentan 500 mg bd or placebo for 6 months. The bosentan group had a reduction
in the numbers of hospital admissions for any reason by 41%. The trial was stopped
early due to concerns over raised hepatic transaminases. However, in patients followed
for the intended duration of the study (6 months) bosentan significantly increased the
likelihood of clinical improvement and decreased the likelihood of CHF deterioration
[Packer et al 1998].
These studies have demonstrated the beneficial haemodynamics of short term non¬
selective ET receptor blockade in CHF patients. In order to investigate whether selective
antagonism will confer clinical benefit, BQ-123 (200 nmol/min for 60 min) was
administered by intravenous infusion to 10 CHF patients. This caused a systemic
vasodilatation and rise in cardiac index (CI), with no change in heart rate (HR). There
was a non-significant fall in pulmonary vascular resistance (PVR) [Cowburn et al
1998a],
In further studies, consistent with predictions from local studies in CHF patients [Fove
et al 1996a and 1996b], effects of a selective ETb receptor antagonist in 8 CHF patients
were investigated. BQ-788 (50-100 nmol/min for 45 min) caused systemic
vasoconstriction, a rise in MAP and SVR, with a reduction in cardiac index. The
subsequent infusion of the selective ETA receptor antagonist BQ-123 resulted in a
reversal of these effects and an increase in cardiac index [Cowburn et al 1998b],
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A further study of 24 CHF patients with the selective ETA antagonist TBC11251
(3mg/kg/min for 15 min) demonstrate a significant fall in mean pulmonary artery
pressure of 12% and PVR of 39% following systemic administration of the study drug
for 15 min. An effect was seen at 15 min, becoming significant at 1 hour and maximal at
2-3 hours. Conversely, there was no significant change in HR, MAP, SV, pulmonary
capillary wedge pressure (PCWP) or SVR [Givertz et al 1998].
Thus, the evidence currently suggests that selective ETb receptor blockade has
deliterious effects on the haemodynamics of patients with CHF. However, it is still
unclear, when the ETA receptor is blocked, whether ETb blockade will improve systemic
haemodynamics in these patients.
1.8.1.2 Coronary artery disease
There have been few studies performed specifically in patients with coronary artery
disease (CAD). In healthy volunteers, intradermal injection of mixed ET^b receptor
antagonist caused a similar vasodilatation compared with selective ETA receptor
antagonism in the skin microcirculation. However, in patients with CAD, mixed
inhibition caused a greater vasodilatation [Wenzel et al 1996], This suggests that the
ETb receptor may have increased functional significance in patients with CAD.
In a recent systemic study, 28 patients with angiographically documented coronary
artery disease were given bosantan 200 mg IV. As may have been predicted from
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previous studies, this resulted in a decrease in systolic blood pressure and a small
increase in heart rate. In addition, there was an increase in coronary artery diameter
which appeared to be maximal as no further increase was noted after treatment with
glyceryl trinitrate. This suggests there is a basal coronary artery vasoconstrictor tone, in
vivo, mediated by endogenous ET [Wenzel et al 1998b]. This has been confirmed by
another study demonstrating endogenous ETa receptor mediated coronary artery tone in
patients undergoing coronary arteriography [Kyriakides et al 2002].
1.8.1.3 Hypertension
In patients with essential hypertension there is an increased venoconstrictor response to
local ET-1 (5 pmol/min) and sympathetically mediated venoconstriction of capacitance
vessels is potentiated by ET-1 [Haynes et al 1994a]. Vasodilatation in patients with
essential hypertension following intra-arterial administration of BQ-123 was shown to
be no different to that in normal healthy volunteers, suggesting that there may be no
major dysfunction of endothelium dependent vasodilatation [Ferro et al 1996b]. Several
animal and in vitro experiments on human tissue have demonstrated close interactions
between the endothelin, renin-angiotensin and sympathetic nervous systems in several
disease states although there is limited human in vivo data.
Results of systemic studies performed with hypertensive patients have recently been
reported. Bosentan treatment for 4 weeks in 293 hypertensive patients caused significant
lowering of blood pressure without reflex neurohormonal stimulation of the sympathetic
nervous system or the renin-angiotensin system. Observation of the effects of 4 doses of
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bosentan demonstrated a plateau reached by 500 mg of bosentan which was similar to




Compared with the vast animal literature concerning endothelin ligands and their effects
on the renal system, there are relatively few human data. Plasma concentrations of ET-1
are raised in chronic haemodialysis patients and in a recent study of preconstricted hand
veins, in this group, infusion of BQ-123 (3mg/kg/min for 45 min) caused an increase in
venodilation of 74% compared with 28% in controls suggesting that responses to
endogenous ET may be increased in patients with CRF [Bussemaker et al 1998].
Administration of the mixed ETa/b receptor antagonist, TAK-044 (lOOmg and 750mg
IV over 15 min) resulted in a reduction of MAP and SVRI of 11% and 24% respectively
and an increase in cardiac output. TAK-044 at both doses had no significant effect on
GFR or effective renal plasma flow. However, effective renal vascular resistance was
lowered by -10% by both doses. Neither dose had any effect on sodium or lithium
clearance [Ferro et al 1998]. This study suggests that there is ET mediated renovascular
tone and that ETAs reduce blood pressure in CRF and may have a potential beneficial
role as vasodilators in these patients.
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1.8.2.2 Hepatorenal syndrome
The hepatorenal syndrome (HRS) is characterised by renal vasospasm in the face of
systemic vasodilatation resulting in sodium retention which persists despite adequate
correction of plasma volume and cardiac output. Plasma ET-1 concentrations are
increase in this condition even when compared with patients with hepatic and renal
failure of different aetiology. Recently, in a small study, 3 patients with HRS received
BQ-123 (10, 25 and 100 nmol/min for 60 min). There was a dose dependent increase in
renal plasma flow and glomerular filtration rate as measured by PAH and inulin
clearance but no significant changes in HR, MAP or SVR [Soper et al 1996], These
results correspond well with the results of studies in healthy volunteers [Rabelink et al
1994].
1.8.2.3 Contrast nephropathy
Despite previous suggestions that contrast-stimulated, endothelin mediated intrarenal
vasoconstriction may contribute to contrast nephrotoxicity, a recent study of 158 high
risk patients undergoing coronary angiography demonstrated that the nori-selective
endothelin antagonist SB 209670 did not protect against contrast nephropathy. Indeed,
more patients in the treatment group compared with the control group developed
contrast nephropathy (56% vs 29%) [Wang et al 1998].
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1.9 CONCLUSIONS
The endothelin system has been extensively studied over the last 10 years. Much of our
understanding of the role of endothelin in normal physiology and pathophysiology
comes as a result of carefully designed clinical studies with ETAs. In addition to their
use in endothelin research, ETAs are now being developed as potential therapeutic
agents in various cardiovascular conditions. It appears that they may be of most use in
clinical conditions which result in chronic vasoconstriction, such as heart failure and
systemic and pulmonary hypertension, as well as in conditions resulting from vasospasm
such as subarachnoid haemorrhage. However, the best target for these potential
medicines is not yet known, and it is unclear whether mixed ETa/b antagonism or
selective ETa antagonism will provide the best clinical treatment, and indeed, this may
differ between conditions. In addition, it remains unclear whether it will be possible to
selectively target the endothelial or vascular smooth muscle ETb receptor.
In conclusion, there is a need for continuing research to further define the roles of the
ETa and ETB receptors in health and disease and for well designed clinical trials to
confirm whether ETAs provide benefits in terms of morbidity and mortality in different
target populations.
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1.10 HYPOTHESES AND AIMS
Endothelin antagonists are being developed as potential therapies in several conditions,
however it is still not clear whether selective ETa antagonism will be better than dual
ETa/b antagonism, and indeed this may differ between conditions. Endothelin-1[ 1.31] is a
newly discovered isoform of endothelin produced by the action of human mast cell
chymase on big ET-1. This may represent a novel pathway of ET-1 production although
animal studies suggest that ET-1 [ 1 -31 ] is vasoactive. This thesis will address the
following hypotheses.
Hypothesis 1: The skin microcirculation is a useful tool for investigating the effects
of vasoactive substances, in vivo, in humans.
The investigation of new, potentially harmful, vasoactive substances, in vivo, in humans
requires safe techniques. The skin microcirculation offers an isolated vascular bed where
substances can be safely investigated using small doses of study compound. The safety,
tolerability and repeatability of this technique were assessed (Chapter 3). In addition, the
effects of endothelin agonist and antagonists with known vascular effects in other
vascular beds were investigated. (Chapter 6)
Hypothesis 2: The Filtrass 2001 is a more accurate and repeatable device for
measuring forearm blood flow than the established Hokanson EC4.
Forearm plethysmography is a useful tool for investigating the vasoactive properties of
compounds in resistance blood vessels. Recently, a new device has been developed
which offers potential advantages over existing devices. However, whether this device
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offered significant advantages over the established Hokanson EC4 for future studies was
unknown. This device was tested against the existing and well validated Hokanson EC4
(Chapter 4).
Hypothesis 3: Thoracic Bioimpedance can be used in controlled studies in CHF
patients.
Due to its non-invasive nature, Thoracic Bioimpedance (TB) has found utility in clinical
studies on healthy volunteers. However, its use in clinical practice, especially in unstable
patients, has been questioned. It's utility in patients with stable heart failure within a
controlled haemodynamic study is not known. TB was compared against the more
invasive thermodilution technique in patients undergoing a systemic clinical study
(Chapter 10) to determine if it could be used in future studies (Chapter 5).
Hypothesis 4: Endothelin-l|i-3i] is vasoactive in the human skin microcirculation.
The above hypothesis was tested in the skin microcirculation of healthy volunteers
(Chapter 6).
Hypothesis 5: Plasma concentrations of endothelin-l[i_3i] are elevated in patients
with chronic heart failure.
Endothelin-l[i_3i] is formed by the action of human chymase on big ET-1. Human
chymase activity is increased in chronic heart failure. A new commercially available
EIA kit for endothelin-l| i_31] was evaluated and used to investigate the above hypothesis
in the plasma of patients with chronic heart failure (Chapter 7).
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Hypothesis 6: Endothelin-1 is positively inotropic and antagonises beta-adrenergic
stimulation of isolated human myocardium.
Both ET-1 and beta adrenoceptor antagonists have previously be shown to be positively
inotropic in isolated human. However, in myocardial membrane preparations beta-
adrenergic stimulation increases adenylate cyclase activity while endothelin reduces it.
The functional consequences of this potential antagonism were investigated (Chapter 8).
Hypothesis 7: Endothelin-1 is positively inotropic and contributes to resting force
of contraction in isolated human myocardium.
Endothlin-1 has previously been shown to cause increased force of contraction in
isolated human myocardium. The effects of endothelin agonism and antagonism on
resting myocardial force of contraction were investigated (Chapter 8).
Hypothesis 8: Treatment of hypercholesterolaemia will reduce arterial stiffness and
increase ET mediated vasodilatation.
Hypercholesterolaemia is a risk factor for atherosclerosis. It is associated with
impairment of nitric oxide mediated vasodilatation and which may be improved by
treatment with lipid lowering therapy. The effects of statin therapy on the endothelin
responses of resistance blood vessels in healthy volunteers with hypercholesterolaemia
has not previously been addressed (Chapter 9).
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Hypothesis 9: Selective ETa antagonism will result in different haemodynamic
changes than dual ETa/b antagonism in patients with chronic heart failure.
Chronic heart failure is associated with an increase in plasma ET and changes in ET
receptor number and function. Previous studies have demonstrated haemodynamic
improvements with both selective and dual ETa/b antagonist. Furthermore, selective
systemic ETg antagonism has been shown to result in adverse haemodynamic changes, a
direct comparison between selective ETA antagonism and dual ETa/b antagonism in




Leslie SJ, Webb DJ. Techniques used in the Clinical Investigation of the Cardiovascular
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2.1 INTRODUCTION
Several in vitro and in vivo techniques for the investigation of the cardiovascular system
in humans have been employed in the generation of this thesis. The general principles
and details have been outlined below with details specific to each study outlined in the
methods sections of subsequent chapters.
2.1.1 In vivo vs in vitro techniques
In general, with some obvious limitations, in-vivo techniques offer an advantage over in-
vitro techniques when investigating cardiovascular responses to vasoactive compounds
in humans as vessels are operating under physiological conditions. However, controlled
manipulations of the surrounding milieu may, in some cases, make in-vitro techniques
preferable. In this thesis, isolated human myocardial trabeculae were used to study the
direct functional effects of ET and ETRAs on the human myocardium isolated from
confounding physiological compensatory mechanism.
2.1.2 Systemic vs local in vivo techniques
Systemic haemodynamic changes, in response to systemic drug dosing, can be measured
by invasive methods such as by pulmonary artery catheterisation or non-invasive
methods such as pulse wave analysis and thoracic bioimpendence. However, some
vascular beds are more sensitive than others to the effects of vasoconstrictor substances
(e.g. renal, coronary and cerebral circulations) and therefore there are potential risks
when administrating vasoactive substances at systemic doses. Local study techniques
such as forearm plethysmography coupled with brachial artery infusion or laser Doppler
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skin flowmetry coupled with intradermal injection, can be used to investigate responses
to compounds in single vascular beds. These techniques have the advantage that they
allow the in-vivo investigation of compounds while using doses which are 10-1000 times
lower than those required to give a systemic effect [Benjamin et al 1995, Webb 1995],
In addition, to increased safety, the use of small and locally active doses minimises
potentially confounding compensatory effects of the heart, kidney and nervous system
which can occur with systemic dosing. However, ultimately the systemic effect of
compounds require to be investigated prior to large scale clinical trials to determine their
clinical utility.
2.1.3 Ethical considerations
All studies were performed with the approval of the Lothian Research Ethics Committee
in accordance with the Declaration of Helsinki of the World Medical Association.
Volunteers and patients, were given as long as required, and at least 24 hours, to decide
whether they wished to take part in the study. Written informed consent was obtained
from each volunteer or patient before entry to the study.
2.1.4 Subject recruitment
Recruitment procedures differed between studies. For healthy volunteer studies the
healthy volunteer database at the Clinical Research Centre, Western General Hospital
was used. Hypercholestreolaemic subjects were identified through a systematic
screening programme of staff and volunteers at the Western General Hospital.
Myocardial tissue was taken from patients undergoing a cardiopulmonary bypass
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procedure, identified from theatre lists and approached on Ward 17 of the Edinburgh's
Royal Infirmary. Patients with left ventricular dysfunction were identified from the
echocardiography database followed by case note review at Edinburgh's Western
General Hospital. Patients were then contacted by letter to ask them if they wished to
participate.
2.1.5 Subject preparation
None of the healthy volunteers were taking regular medication and avoided any
medication for 1 week prior to study. All subjects and patients abstained from alcohol
for 24 hours and from food, tobacco and caffeine containing drinks for at least 5 hours
before each study. Studies were performed in a quiet temperature controlled, draft free,
room (23-25 °C). All studies were preceded by at least 30 min of baseline measurements
(90 min in invasive haemodynamic studies).
2.2 SYSTEMIC HAEMODYNAMIC STUDIES
2.2.1 Pulmonary artery catheter placement
Patients were admitted to the study room (23-25 °C) and had blood pressure, pulse and
electrocardiogram before being taken to the invasive procedures room of the coronary
care unit. A standard clinical approach for pulmonary artery placement is usually from
the subclavian or internal jugular vein. However, we found that for repeated studies
insertion via the femoral vein, while technically more difficult, was well tolerated by
volunteers. The patient was placed supine on the cardiology screening table and the right
groin area was shaved and prepared with antiseptic solution (Betadine, Seton Healthcare
44
group pic, Tubitan House, Oldham, UK). The right femoral vein was cannulated with a
9F desivalve (Vygon GmbH&Co.KG, Prager Ring, Aachen, Germany) under local
anaesthesia with 1% lignocaine (Antigen Pharmaceutical Ltd, Roscrea, Ireland). The
pulmonary artery catheter, (Swan-Ganz CCOmbo - CC0/SV02; Edwards Lifesciences
LLC, Irvine, California, USA), after flushing and checking integrity of the balloon by
inflating under saline, was placed into the right femoral vein and advanced to a proximal
branch of the right pulmonary artery. Placement of the catheter was assisted by
fluoroscopy sceening and simultaneous pressure waveform monitoring (Figure 1).
Adequate and consistent 'wedging' following balloon inflation was verified before the
patient was transferred back to the study room.
2.2.2 Pressure and flow measurements
Pressure measurements from the distal and proximal ports of the pulmonary artery
catheter (PAG) were made using a cardiac computer (Horizon XL, Mennen Medical Inc.
Israel). A continuous cardiac output catheter (Swan-Ganz CCOmbo - CC0/SV02;
Edwards Lifesciences LLC, Irvine California, USA) and computer (Vigilence, Edwards
Critical Care, Baxters Healthcare Corporation, Irvine, CA, USA) were used to measure
cardiac output. This catheter employs a thermistor coil to warm blood and the resultant
rise in temperature can be measured distally and used to calculate 'continuous' cardiac
output estimations. This avoids the need for repeated injections of cold saline thus,
reducing intravenous volume loading during the study and eliminating intra-operator
variability in cold injectate technique. Although termed 'continuous', measurements are
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2.2.3 Data analysis
Data were manually recorded and entered onto a template spreadsheet (Excel vS.O;
Microsoft). Recordings from the first 90 min were not used to allow stabilisation of
pressures after catheter placement. Absolute change, percentage change from baseline
and area under the percentage change from baseline curve were calculated.
2.3 PULSE WAVE ANALYSIS
2.3.1 Placement of tonometer
The development of pulse wave analysis (PWA) is expanding our knowledge of the
stiffness of the arterial tree and its relevance to pathophysiological processes involved in
the development of cardiovascular disease [O'Rourke et al 1996, Cockcroft et al 1997],
PWA is a non-invasive method using a high fidelity tonometer with computer analysis
of the waveform. In theory, PWA can be performed on any artery, but for ease the radial
pulse is usually used because the artery can be compressed against the underlying bony
prominence of the radius bone.
2.3.2 Data analysis
The arterial pressure wave has two main peaks, the first is caused by ventricular
contraction, with a notch caused by aortic valve closure and a second peak caused by the
reflection of the systolic wave from the peripheral vasculature (Figure 2.2). The stiffer
the artery the faster the reflected wave will return. Thus, in young healthy subjects the








Figure 2.2 Diagram of normal radial pulse wave as measured by tonometer
ressure
2 heart beats
Figure 2.3 Measured radial trace from pulse wave analysis tonometer and
determined aortic wave form.
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patients with stiffer arteries the wave returns earlier, in systole, thus further increasing
cardiac work in systole.
2.4 FOREARM VENOUS PLETHYSMOGRAPHY
Bilateral forearm plethysmography coupled with unilateral brachial artery drug infusion
is a powerful tool in the investigation of the vascular responses to study compounds.
This technique has been used safely in our department for many years [Webb 1995].
2.4.1 Experimental Setup
The subject is studied in the supine position with the arms in a comfortable position
above the level of the central venous pressure, thus allowing unimpeded venous
emptying of the forearms. Venous obstruction is achieved by inflating cuffs around the
upper arm to above venous pressure, but below arterial pressure (~40 mmHg) for 10 sec,
then deflated for 5 sec. This cycle is repeated for 3 min at each study time period. The
hands are excluded from the circulation by inflating cuffs around the wrists to above
systolic pressure (-200 mmHg) during forearm blood flow measurements, as they have a
non-linear response to occlusion compared to the forearm. Hand blood flow is
predominantly through the skin and has different control mechanisms than FBF, which
is predominantly through skeletal muscle [Whitney 1953, Whelan 1967], It takes about 1
min following wrist exclusion for stable blood flow to occur. Cuffs were inflated using




Mercury-in-silastic strain gauges EC4 (D.E.Hokanson, Incorporated, Bellevue, WA,
USA) were applied to both forearms at the point of greatest circumference to measure
the rate of expansion of the forearm during venous occlusion. Analogue voltage output
from the strain gauge was processed by a MacLab® analogue-to-digital converter and
Chart v3.3 software (AD Instruments, New Zealand) and recorded onto a Macintosh
Classic II computer (Apple Computers Inc, Cupertino, USA). The rate of increase in
circumference of the forearm is proportional to the blood flow and thus the vasoactive
properties of compounds can be examined. Vasodilators will increase the forearm blood
flow, measured as a steepening of the gradient of the curve of increasing forearm
circumference, whereas vasoconstrictors have the opposite effect. A period of at least 30
minutes is usually required to establish steady baseline readings.
2.4.2 Intra-arterial drug administration
The brachial artery of the non-dominant arm was cannulated with a 27-G steel needle
(Cooper's Needle Works Ltd, Birmingham, UK) under local anaesthesia 1% lignocaine
(Antigen Pharmaceutical Ltd, Roscrea, Ireland). The cannula was attached to a 16-G
epidural catheter (Portex Ltd, Hythe, UK) and secured with sealing wax ('sticky wax'
Cottrell and Co., London, UK). The catheter was perfused with 0.9% saline (Baxter
Healthcare Ltd, Thetford, UK) via a 50 ml syringe in an IVAC PI000 syringe pump
(IVAC Ltd, Basingstoke, UK). The total rate of intra-arterial infusions was maintained at
1 mL/min in all studies. Repeated studies in the same subject were performed at no less
than 1 week intervals.
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2.4.3 Data analysis
Data from plethysmography studies were extracted from Chart™ data files into a
template spreadsheet (Excel v5.0; Microsoft). The last 5 flow recording in each 3 minute
measurement period were selected and averaged for each arm. The dominant arm acts as
a contemporaneous control for the infused arm [Benjamin et al 1995],
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2.5 SKIN MICROCIRCULATION FLOWMETRY
The effects of compounds on the skin microcirculation can be investigated using intra¬
dermal injection of study compound and a laser Doppler flowmeter [Nilsson et al 1980],
2.5.1 Experimental Setup
The subject was studied supine, with the arms supported and the volar aspect of the
forearm upwards (Figure 2.5). The laser probe holder was attached to the skin with
adhesive tape to ensure no movement of the probe throughout the study. Care was taken
to avoid underlying veins which can create considerable 'noise' in the system. The
subject was allowed to stabilise for at least 30 mins before the study protocol was
started.
2.5.2 Laser Doppler flowmetry
The laser Doppler flowmeter employs the concept of Doppler shift. Light hitting a
moving object will be reflected with a change in its wavelength. The wavelength will be
shortened if it is reflected from an object moving towards it and vice versa. The laser
Doppler flowmeter will therefore give an estimation not only of the speed of movement
of red blood cells but also their number, this combination is termed 'flux' and is
proportional to blood flow.
2.5.3 Intra-dermal drug administration
Study compounds are injected intra-dermally using a 1ml syringe with a 0.33mm needle
(Becton-Dickson, Ireland). Any injection site which did not give a characteristic weal
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was rejected. The volume of injectate was small (lOjal) and the repeatability of this
technique has been assessed and shown to be highly repeatable (Chapter 3). The
injection of this small volume was well tolerated by subjects. This technique uses very
small doses of study compound and therefore has a high degree of safety.
2.5.4 Data analysis
Analogue voltage from the laser Doppler flowmeter was processed by a MacLab
analogue-to-digital converter and Chart™ v3.3.8 software (AD Instruments Ltd, New
Zealand) and recorded onto a personal computer (Classic II, Apple Computer Inc).
Calibration was achieved by use of a standard flux solution (Moor Intruments Ltd, UK).
20 seconds of averaged signal were extracted from the Chart™ data files to a template
spreadsheet (Excel v5.0; Microsoft).
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Figure 2.5 Experimental setup for measurement of skin blood flow
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2.6 ISOLATED MYOCARDIAL TRABECULAE
2.6.1 Sample collection and preparation
During the initiation of cardiopulmonary bypass the right atrium is cannulated to direct
circulating blood from the patient to the bypass device. At the time of placement of the
right atrial cannulation, while the heart is still beating, the right atrial appendage was
excised and immediately place in cold cardioplegic solution (Chapter 8). The appendage
was immediately transferred to the laboratory where free running trabeculae (length < 4
mm; width < 1mm) were dissected.
2.6.2 Experimental apparatus
Trabeculae were mounted for isometric tension measurement in a vertical 7ml chamber
(Myobath, World Precision Instruments, Stevenage, UK) (Figure 2.6) containing
physiological solution (mM); NaCl 130, KC1 5.4, NaHP04 0.56, MgCl6H20 3.5, CaCl2,
Glucose 10 HEPES 5 and corrected to pH 7.4 with NaOH. This was continuously
bubbled with 100% 02 at 35°C. The lower end of the muscle was secured by a clip and
the upper end tied with 5.0 silk and attached to a force transducer (Fort 10, World
Precision Instruments, Stevenage, UK). The preparation was electrically stimulated with
platinum point stimulation electrodes at 1 Hz at a voltage ~ 10% above threshold with
rectangular pulses of 10 ms duration.
2.6.3 Data analysis
Isometric twitches were detected by a force transducer (FORT 10, World Precision
Instruments, Stevenage, UK), connected to an amplifier (Transbridge™) and recorded
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Figure 2.6 Myobath 7 ml chamber with atrial myocardial trabecula.
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Figure 2.7 Twitch parameters. Time to peak (TTP), time to 50% relaxation
(RT50), time to 95% relaxation (RT95)
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on a Power Macintosh 7200/90 personal computer using the MacLabTM analogue-to-
digital converter (AD Instruments, New Zealand). The force of contraction and twitch
parameters were analysed using the software 'CHART' and ink and paper traces from a
chart recorder. Statistical analyses were performed using the software 'Excel'.
2.7 BLOOD PRESSURE, HEART RATE AND OXYGEN OXIMETRY
Mean arterial pressure (MAP) and heart rate (HR) in the forearm plethysmography and
skin microcirculation studies were measured using a validated semi-automatic digital
blood pressure monitor (Omron Hem-705, Omron, Matsusaka, Japan)[0'Brien 1996], In
the systemic haemodynamic studies MAP, HR and pulse oximetry were measured using
DynamapTM compact TS (CRITIKON LLC, Coronation Road, Ascot, UK).
2.8 DRUG PREPARATION
All drugs were prepared in a sterile manner. Physiological 0.9% saline (Baxter
Healthcare Ltd, Thetford, UK) was used to dissolve study drugs for intra-arterial, intra¬
venous and intra-dermal injection.
2.9 BLOOD SAMPLING AND PLASMA ASSAYS
Venous blood samples for all hormone assay were collected into EDTA tubes (Sarstedt,
Aktiengesell schaft & Co, Germany) on ice and immediately separated by centrifugation
(2,500 rpm for 20 minutes at 4 C). The resultant plasma was carefully pipetted into vials
which were frozen and stored at -80°C until analysed. Most of the plasma assays were
performed by Mr Neil Johnston.
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2.9.1 Plasma ET-1, big ET-1 and ET-1 [1.31] extraction *"
At the time of analysis, plasma samples were thawed and immediately acidified with an
equal volume of 20% acetic acid. This acidified plasma sample was extracted using
Bond Elut CI8 columns (Varian, Harbor City, CA, USA) which had been activated with
methanol, followed by washing with deionised water and 10% acetic acid. After the
addition of samples to the columns, the columns were washed with 10% acetic acid and
ethyl acetate, the bound ET-1 [ 1.31 ] was eluted with 80% methanol: 20% ammonium
bicarbonate. The eluate was dried down under a continuous stream of nitrogen at 37°C
and the dried eluates reconsituted with assay buffer.
2.9.2 Endothelin -1 assay
At the time of analysis, plasma samples were thawed, immediately acidified with an
equal volume of 20% acetic acid. This acidified plasma sample was extracted using
Bond Elut CI8 columns (Varian, Harbor City, CA, USA) that had been activated with
methanol, followed by washing with deionised water and 10% acetic acid. After the
addition of samples to the columns, the columns were washed with 10% acetic acid and
ethyl acetate, the bound ET-1 and big ET-1 was eluted with 80% methanol: 20%
ammonium bicarbonate. The eluate was dried down under a continuous stream of
nitrogen at 37°C and the dried eluates reconsituted with assay buffer. Recovery of
endothelin-1 and big endothelin-1 during extraction was 89% and 91%, respectively, as
assessed by calculating recovery of known amounts of endothelin-1 and big endothelin-
1, which had been added to plasma. Radioimmunoassay was performed on reconstituted
61
samples by using rabbit anti-human ET-1 or big ET-1 (Peninsula Laboratories, Europe).
Briefly, lOOpl of sample extract, standard or quality control along with lOOpl of either
ET-1 or big ET-1 antibody was incubated for 24 hours at 4°C. Following incubation,
I132-labelled ET-1 (NEN Life Science Products, Boston, MA, USA) or big ET-1
(Peninsula Laboratories, Europe) was added and incubation was continued for an
additional 20 hours at 4°C. The immune complexes formed were precipitated with
Amerlex donkey anti-rabbit antibody (Amersham) and the precipitates counted for
radioactivity. All ET values were expressed as picograms per millilitre. Intra- and inter-
assay variation was 6.3 and 7.2%, respectively; sensitivity of the assay for ET-1 was
0.25pg/ml and lpg/ml for big ET-1.
2.9.3 Endothelin-l|t_3i] assay
A commercially available solid phase sandwich enzyme linked immunosorbent assay for
ET-1 [i-3i] (Immuno-Biological Laboratories Co Ltd., Tokyo, Japan) was used following
the manufacturers instructions. This technique was performed on reconstituted samples
by using anti-human ET - 1 [25-31] Rabbit IgG. Briefly, lOOpl of sample extract, standard
or quality control along with lOOpl of ET-1 £i_3i] antibody was incubated for 24 hours at
4°C. Following incubation, the wells were vigorously washed with wash buffer. 100 pi
of labelled antibody was added to each well and incubated for a further 30 min at 37 °C.
After further washing Tetramethyl Benzidine buffer was added, turning the solution
blue, and incubated for 30 min in the dark. 100 pi of stop solution was then added,




Validation of laser Doppler flowmetry coupled with intra-dermal
injection for investigating effects of vasoactive agents on the skin
microcirculation in man
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3.1 SUMMARY
This study was designed to determine the repeatability of laser Doppler flowmetry
coupled with intra-dermal saline delivery. Two operators each performed 100
injections. Delivery of saline was judged 'by eye' using a graduated syringe (Becton-
Dickinson) by injecting onto a weighing boat. Volume was assessed by weight. Skin
blood flow following intra-dermal injection of saline was assessed in 18 healthy
volunteers; 10 attended twice to assess between-day repeatability, and 8 attended
once to assess between-site repeatability. There was no difference in mean injection
weight between operators (both being 10.3 ± O.lmg, n=100, p=0.9). Intra-dermal
delivery of saline was well tolerated with only mild discomfort experienced during
the injection at some of the sites. Intra-dermal saline caused a 9 fold increase in
blood flow (0.03 ± 0.003 to 0.27 ± 0.02 perfusion units, n=18, p<0.001). This
response was rapid in onset with the maximal effect seen at 4 min and apparent
duration of greater than 30 min. There was no difference in the magnitude of the
response between the dominant and non-dominant arms (AUC: 2.9 ± 0.4 vs 2.9 ± 0.4
respectively, n=18, p=0.93). However, there was no statistical difference between
study visits 1 and 2 (AUC: 3.2 ± 0.6 vs 2.0 ± 0.5 respectively, n=10, p=0.7]. There
was no difference in the magnitude of responses between different sites on the
forearm (p=0.6). These studies demonstrate that the technique of laser Doppler
flowmetry coupled with intra-dermal injection is a safe, well-tolerated technique with
good repeatability. A trend towards reduced between-day repeatability emphasises
the importance of vehicle control sites when investigating the effects of vasoactive
. compounds. This technique provides a reliable method for the intra-dermal delivery
of drugs, despite the direct effect of injection of saline on blood flow.
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3.2 BACKGROUND
Laser Doppler flowmetry is a well validated technique [Nilsson et al 1980] used for
the investigation of the effects of vasoactive substances on the skin microcirculation
[Hovell et al 1987, Haynes et al 1991, Wenzel et al 1994,1996 and 1998a]. Saline is
widely used as a vehicle for drug administration in other vascular beds and it has
been previously demonstrated that intra-dermal injection of saline, when used alone,
causes an increase in laser Doppler flowmeter signal [Wenzel et al 1998a].
Laser Doppler flowmetry has several potential advantages over other techniques for
the initial study of drugs in humans in that it is minimally invasive and relatively safe
because it uses very small doses of study compounds with a mainly local action. It
allows separate sites on the skin to be studied simultaneously and thus the
investigation of a range of concentrations on the same occasion. While it is possible
to deliver some vasoactive substances, such as acetylcholine and noradrenaline, by
skin iontophoresis, many peptides cannot be delivered by this means due to their
large size, poor solubility or lack of electrical charge. In these situations, intra-dermal
injection can be used. However, this technique has the theoretical disadvantage that it
results in a small degree of skin trauma [Holloway et al 1980] and delivery of the
small volumes used may increase errors and variability in responses. Physiological
saline is commonly used in studies as a drug vehicle and there are a variety of high
precision syringes that can be used for intra-dermal injection. However, these are
expensive and, when used in human studies can, by necessity, be used only for a
single subject. In the current studies we used standard clinical insulin syringes with a
29.5 SWG gauge needle to administer local intra-dermal injections. The advantages
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of these syringes are that they are relatively inexpensive and easy to use. These
syringes have been used by other groups in skin blood flow studies [Wenzel et al
1998a] but have not been validated for use for intra-dermal injection in
pharmacological studies. There are potential sources of error in the injection
technique because the plunger is depressed by only 1 mm to deliver 10 pi and is
judged 'by eye'. The repeatability of intra-dermal delivery in terms of volume
delivered and the effect of intra-dermal saline injection on skin blood flow using
these syringes has not previously been reported.
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3.3 AIMS
The aim of these studies was to determine the intra- and inter-operator repeatability
of saline administration in terms of injection volume, and to determine repeatability




Eighteen, right handed, healthy men (22 - 45 years) were studied. Studies were
performed with the approval of the local research ethics committee and in
accordance with the Declaration of Helsinki of the World Medical Association.
Written informed consent was obtained from each subject before entry to the study.
None of the subjects were taking regular medication and all avoided any medication
for 1 week prior to study. All subjects abstained from alcohol for 24 hours and from
food, tobacco and caffeine containing drinks for at least 12 hours before each study.
3.4.2 Injection volume
Graduated 29.5 SWG syringes (Becton-Dickinson, Dublin, Ireland) were used for
saline delivery. Each 1 mm graduation on the 0.5 ml syringe represents 10 pi, thus to
deliver this volume the syringe plunger was depressed by 1 mm. The repeatability of
injection volume was assessed by injecting 10 pi saline judged by depressing the
syringe plunger by one graduation, onto a weighing boat placed on a balance
(Mettler Toledo* MT5). This balance has an accuracy and precision of I pg and
therefore can measure changes of 1 nl assuming a specific gravity of saline of 1.00.
A new syringe was used for each injection and care was taken, as in our clinical
studies, to expel any air bubbles from the syringe before injecting. The balance was
set to zero before each injection. Two blinded operators each performed 100
injections.
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3.4.3 Laser Doppler flowmetry and intra-dermal injection
Subjects lay supine with the arms supported and the volar aspect of the forearm
facing upwards. Sites for injection were chosen taking care to avoid underlying
arteries (assessed by palpation and pulsatile Doppler signal) or veins (assessed
visually and by high baseline Doppler signal). Four laser probe holders were attached
to the skin of each forearm with adhesive tape to ensure no displacement of the probe
during the study.
3.4.4 Protocol
Studies were performed in a quiet, temperature controlled, draught free room (23 - 25
°C). Each subject was allowed to rest for at least 20 min before the study protocol
was started. Baseline recordings were made. Subjects then received a number of
intra-dermal injections of. 10 pi saline (0.9 %; Baxter Healthcare Ltd, Thetford, UK)
and laser Doppler signal recorded every 2 min for the first 10 min and subsequently
every 5 min until 30 min. To assess between-day repeatability, 10 subjects attended
for 2 study visits. To assess between-site repeatability, 8 of the subjects received 4
intra-dermal injections of saline on the volar aspect of each forearm.
3.4.5 Data handling and statistical analysis
Increases in weight on the balance following saline injection were recorded manually
and entered onto a spreadsheet (Excel v5.0; Microsoft). The accuracy was assessed
by mean values and repeatability by assessing the spread of results. Results are
expressed as mean ± SEM. Differences between results were assessed using 2 tailed,
paired Student's Mest. Statistical significance was taken at the 5% level.
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For the skin blood flow studies, analogue voltage output from the laser Doppler
flowmeter was processed by a MacLab® analogue-to-digital converter and Chart v3.3
software (AD Instruments, Castle Hill, Australia) and recorded onto a Macintosh
Classic II computer (Apple Computers Inc, Cupertino, USA). Further analysis was
performed offline. The average signal for 30 sec at each time point was recorded and
entered into a spreadsheet (Excel v5.0; Microsoft). Area under the curve (AUC) over
30 min was calculated for each skin blood flow response curve and used to determine
differences between them and expressed in arbitrary perfusion units (PU). These
were assessed using the method of Bland and Altman [Bland et al 1986], Bland-
Altman analysis allows the assessment for agreement and systematic bias.
Coefficients of repeatability were determined for 95% confidence intervals (CI).
Other results are expressed as mean ± SEM. Statistical analysis was performed using
2 tailed, paired Student's /-test and single factor ANOVA for between-site
repeatability. Statistical significance was taken at the 5% level.
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3.5 RESULTS
3.5.1 Accuracy and Repeatability of Injection Volume
Two operators performed 100 injections each. There was no difference in mean
injection weight between operators, both being 10.3 ± O.lmg [0.08, -0.23 to 0.39 mg:
mean difference, 95% confidence interval, n=100, p=0.9] (Figure 3.1).
3.5.2 Tolerability of intra-dermal drug delivery
The technique was well tolerated by subjects with only mild discomfort experienced
during the injection of saline at some of the sites. This discomfort was variable in
intensity. In the majority subjects the trauma from intra-dermal injection did not
leave any discernable mark on the skin by the end of the study although several
injections did cause a small degree of bleeding along the track of the needle. This did
not appear to affect the results in terms of repeatability.
3.5.3 Skin Blood Flow Responses:
3.5.3.1 Effect of intra-dermal injection ofsaline
Saline caused a 9 fold increase in skin blood flow [0.03 ± 0.003 to 0.27 ± 0.02 PU,
n=18, p<0.001]. This effect was rapid in onset with maximal response seen at 4 min
(Figure 3.2)
3.5.3.2 Between-site repeatability
Area under the curve was constructed for the responses at 4 different sites on each
forearm in 8 subjects. There was no difference in the magnitude of responses
between sites on the forearm as assessed by AUC (p=0.6)(Figure 3.3).
71
3.5.3.3 Between-arm repeatability
There was no difference in the magnitude of the response between the dominant and
non-dominant arms, AUC was 2.9 ± 0.4 and 2.9 ± 0.4 respectively [-0.05, -0.8 to
0.73 PU: mean difference and 95% CI, n=18, p=0.93] (Figure 3.4a). Bland-Altman
analysis was performed demonstrating no systematic bias and a co-efficient of
repeatability of 3.54 (Figure 3.4b).
3.5.3.4 Between-day repeatability
There was a trend towards a difference between study visits 1 and 2, AUC was 3.2
±0.6 and 2.0 ± 0.5 respectively [1.2, -0.03 to 2.43 PU: mean difference and 95% CI
n=10, p=0.7] (Figure 3.5a). Bland-Altman analysis was performed and tended to

























Figure 3.1a Scatter plot of injection weights demonstrating spread of results. Both
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Figure 3.1b Bland - Altman plot of injection volumes by 2 observers
demonstrating good repeatability of results. The confidence limits are
marked at mean difference ± 2SD.
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Time (min)
Figure 3.2 Effect of skin blood flow in response to intra-arterial saline (0.9%).
This graph represent all measurement for studies 2 and 3. Biological zero (bz).
Saline AUC for each site (n=8)
1 2 3 4 5 6 7 8
Site number
Figure 3.3 Between site variation in skin blood flow
(p=0.6, single factor ANOVA)
■ Non-dominant Arm
• Dominant Arm
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Figure 3.4a Skin blood flow response to intra-dermal saline
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Figure 3.5a Skin blood flow responses to intra-dermal saline between visit 1 and 2


















Figure 3.5b Bland-Altman for between-day repeatability
3.6 DISCUSSION
In this study we have demonstrated that saline delivery using the Becton-Dickinson
syringe is accurate and repeatable with low intra-operator variability. In addition, we
have demonstrated that intra-dermal injection of saline causes a clear increase in
Doppler signal but that the magnitude of this increase is similar between different
sites on the forearm. There is good within-day and between arm repeatability.
There was occasionally mild discomfort, of variable intensity, experienced by the
subjects at the time of injection. However, there did not appear to be any pattern to
explain the fact that some sites developed more pain than others. Although the non¬
uniform distribution of cutaneous nerves may explain this finding, this was not
formally assessed but did not appear to affect the results in terms of repeatability.
While there is often greater interest in the systemic effects of vasoactive compounds,
there are potential risks with administration of systemic doses of vasoactive
compounds. The use of local techniques, such as intra-dermal administration with
laser Doppler microcirculatory blood flow measurement has allowed the relatively
safe observation of the in vivo effects of vasoactive compounds, without causing
confounding compensatory systemic effects. While the skin blood flow may be under
different mechanisms of control than other vascular beds, and responses can differ
[Weber et al 1997], in general, effects of compounds in the skin have been reflected
in other less accessible vascular beds [Wenzel et al 1996 and 1998a]. Therefore, the
skin microcirculation offers a safe, well tolerated, easy to use approach to the initial
investigation of vasoactive compounds.
The Becton-Dickinson syringe is commonly used to delivery intra-dermal injections
in clinical practice. Although it has the advantage that it is inexpensive and easy to
use, its accuracy has not previously been described. Here, we found good agreement
between operators as seen by mean values that were similar and close to the intended
volume of 10 pi with most injections very close to this volume (Figure 1). We
conclude that this syringe can be used to deliver intra-dermal injections in a clinical
research setting with sufficient accuracy and repeatability.
Intra-dermal injection of saline causes an increase in laser Doppler signal. In this
study, we have demonstrated that the technique of laser Doppler flowmetry coupled
with intra-dermal injection is a repeatable technique and that responses between
subjects are similar. There was no difference in SBF in response to intra-dermal
saline injection between sites on the same arm or in the same patient on different
study visits. There was, however, a trend towards a small difference in SBF between
study visits which emphasises the importance of vehicle control when investigating
the effects of vasoactive compounds. The reasons for this between-day variability are
not clear as ambient temperature was controlled, subjects were fasted and studied
under similar conditions during each study visit. Although careful attempts were
made to keep room temperature and conditions constant, the skin is more sensitive
than other vascular beds to changes in ambient conditions and small temperature
changes, draughts or emotional factors may be more important than in other vascular
beds. Nevertheless, these between day differences did not reach statistical
significance and the within-subject and between-day coefficients of repeatability
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were similar (3.54 vs. 3.48). However, this finding may represent a type II statistical
error as it is clearly seen on Figure 3.5a that there is a difference between results on
different days. Therefore despite no statistical difference noted between days we
believe that vehicle injections should be performed as controls during each study
visit.
In conclusion, the technique of intra-dermal drug delivery with saline vehicle
coupled with laser Doppler flowmetry to measure skin microcirculatory blood flow
offers a safe, well-tolerated, repeatable technique for the investigation of vasoactive
compounds in human in vivo.
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Chapter 4
Comparison of two plethysmography systems in assessment
of forearm blood flow
Leslie SJ, Attina T, Hultsch E, Bolscher L, Grossman M, Denvir MA, Webb DJ.
Comparison of two forearm plethysmography systems, in assessment of forearm
blood flow. JAppl Physiol 2004;96:1794-1799.
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4.1 SUMMARY
Venous occlusion plethysmography is widely used to assess forearm blood flow
(FBF). Recently a new device has been developed, we compared the established
Flokanson (HEC4) system with the Filtrass 2001 (F2001) to determine if this new
device would offer significant advantages in future studies. The HEC4 uses
'mercury-in-silastic' strain gauges while F2001 detects volume changes using a non-
mercury linear displacement device. The aim of this study was to evaluate the new
F2001 against the HEC4 in terms of repeatability and systematic bias. 10 subjects
were studied on 4 separate days in random order using either the HEC4 on both arms
(H/FI), the F2001 on both arms (F/F), the HEC4 on the right arm with the F2001 on
the left (H/F) or the F2001 on the right arm and the HEC4 on the left (F/H). Stroop's
coloured word conflict test (SCWT) and post-occlusive hyperaemia were used to
increase FBF and lower body negative pressure (LBNP) was used to lower FBF.
SCWT and LBNP increased (24.6 ± 1.5%, n = 240, P < 0.0001) and decreased (18.7
± 0.8%, n = 240, P < 0.0001) FBF respectively. Post occlusive hyperaemia following
occlusion times of 5, 8 and 13 mins substantially increased FBF by 390 ± 86%, 756
± 217% and 851 + 132% respectively. Repeatability was not different between the
devices (0.10 ± 2.37 vs -0.47 ± 1.92 1/min, n = 125, P > 0.05) and there was no
systematic bias. The F2001 is a newly developed plethysmography system that does
not utilise mercury and which is suitable for assessing changes of FBF in
physiological studies. However, there appeared to be no significant improvements in
repeatability over the HEC4, which is the established device in our department, and
thus the HEC4 was used in subsequent studies.
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4.2 BACKGROUND
Venous occlusion plethysmography has been used to study forearm blood flow
(FBF) for almost 100 years [Brodie et al 1905], The underlying principle is simple;
by obstructing venous outflow, but not arterial inflow, the forearm volume initially
increases in proportion to the FBF. The standard technique for the assessment of this
change in FBF, using a circumferential mercury-in-silastic strain gauge as part of a
Wheatstone bridge to detect increases in forearm circumference and derive volume
changes, has remained essentially unchanged for 50 years [Whitney 1953]. Venous
occlusion plethysmography is now a well validated [Roberts et al 1986] and widely
used tool to study mechanisms of human vascular control, particularly when coupled
with brachial artery infusion to study effects of drugs and mediators on the forearm
vasculature [Joyner et al 2001]. In man, this approach to vascular pharmacology has
a distinct advantage over other techniques in that vessels are studied in their
physiological environment [Benjamin et al 1995, Joyner et al 2001]. A commonly
used and well validated device employing the above principles is the Flokanson EC4
(HEC4) [Hokanson et al 1975, Chang et al 1987, Petrie et al 1998, Fehling et al
1999, Rongen et al 1999, Strachan et al 2002],
Recently, a new device, the Filtrass 2001 (F2001) has been developed, particularly to
measure capillary permeability. However, this device may also be useful for
measuring FBF. It is based on similar principles, but with some important
differences. Here, forearm circumferential measurement is measured by
displacement of a freely moveable core of a linear variable displacement transducer
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(LVDT) attached to a circumferential plastic monofilament (Fig 4.1). A linear
relationship exists over a large range of calibration movements [Christ 2000]. The
system is mechanically and electrically calibrated to measure differences of 10 pm
and undergoes internal calibration for changes in temperature and tissue compliance
at each time point. The potential utility of this device in forearm venous occlusion
plethysmography has not previously been assessed.
The aim of this study was to compare the F2001 against the established F1EC4 in
terms of repeatability, systematic bias and ease of use. In order to compare the
F2001, subjects underwent simple, non-invasive systemic interventions to reduce or
increase FBF. It was assumed that systemic haemodynamic changes would result in
similar changes in FBF simultaneously in both arms [Greenfield et al 1954], In order
to assess higher blood flows post-occlusive hyperaemia was used. In this study the
repeatability of each individual device could be assessed when the same device was
used on both arms. Comparison of one system against the other on different arms




Ten healthy subjects (9 male) aged 22-30 years were recruited for this study, which
was undertaken in accordance with the Declaration of Helsinki and with the approval
of the local research ethics committee. Written informed consent was obtained from
each subject. All subjects abstained from vaso-active drugs for at least 1 week, from
alcohol and cigarettes for 24 hours, and from food and caffeine for at least 3 hours
before each study visit.
4.3.2 Study design
Volunteers attended for 2 separate study periods, each of 4 visits. The protocol was
similar on each of the first 4 study days except for the plethymography device used.
The devices were studied in random order using either the HEC4 on both arms
(H/H), the F2001 on both arms (F/F), the HEC4 on the right arm with the F2001 on
the left arm (H/F) or the F2001 on the right arm and the HEC4 on the left arm (F/H).
During the second 4 study visits, post occlusive hyperaemia was employed to cause a
range of increases in FBF.
4.3.3 Study protocol
The study visits were performed on different days in a quiet, draught free,
temperature controlled room (22-24 °C). During the 'low flow' experiments the
volunteer was subjected to either SCWT, LBNP or a rest period. Mean arterial
pressure and heart rate were measured during the 6th min, and FBF measured during
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the last 3 min, of each 10 min time period. During the 'high flow' experiments
volunteers were exposed to 5, 8 and 13 mins of arterial occlusion resulting in post
occlusive reactive hyperaemia.
4.3.4 Venous occlusion forearm plethysmography
Both devices were employed in a similar manner using the standard methodology
employed in our unit [Wilkinson & Webb 2001]. In brief, venous occlusion was
achieved by inflating cuffs around the upper arm to above venous, but below arterial,
pressure (-40 mmHg). The arm was placed above the level of the right atrium and
the upper arm cuff inflated for 10 sec, then deflated for 5 sec. This cycle was
repeated for the last 3 min of each 10 min study time period. Hand blood flow is
predominantly through skin blood vessels rather than skeletal muscle and thus has
different control mechanisms than FBF [Whitney 1953, Scroop et al 1965, Whelan et
al 1967]. Therefore, the hands were excluded from the circulation by inflating cuffs
around the wrists to above systolic pressure (-200 mmHg) before FBF measurement.
The strain gauges were placed around the forearm at the point of greatest
circumference.
There were some features unique to each device. The HEC4 system (D. E. Hokanson
Inc, Bellevue, WA, USA) consists of several discrete components: 2 -HEC4
plethysmographs, 2 Hokanson E20 rapid cuff inflators, a Hokanson AG 101 cuff
inflator air resource, strain gauges, and Hokanson wrist and upper arm cuffs. The
HEC4 system uses electrically calibrated mercury-in-silastic strain gauges that were
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calibrated at the beginning of each study. The HEC4 occupies a total volume of
1.4m3.
The F2001 LVDT (DOMED Medizintechnik, Munich, Germany) was positioned on
the forearm skin at a similar position to the mercury-in-silastic strain gauges, and
fixed to the forearm with adhesive tape. The plastic monofilament component
surrounding the forearm is supported on the skin by a 'zig-zag band' (Figure 4.1).
Before the start of measurements, the surface of the monofilament was coated with
synthetic oil (DOMED Medizintechnik, Munich, Germany) to reduce friction and
then inserted into the main body of the LVDT. The LVDT was calibrated at the
beginning of each study and the resting tension on the monofilament adjusted
automatically at each time point. The F2001 is a smaller, more compact, device than
the HEC4 with all components contained within a single housing with a volume of
0.22 m3.
4.3.5 Lower body negative pressure (LBNP)
The lower body of the subject was placed in an airtight steel chamber and sealed with
a pneumatic belt around the waist (Figure 4.2). Suction was applied using a low
pressure vacuum device and the negative pressure within the chamber kept constant
by a servomechanical pressure regulator (Department of Medical Physics, Western
General Hospital, Edinburgh, UK). LBNP (15mm Hg) was applied for 10 min to
reduce FBF. LBNP causes venous pooling which, via baroreceptor unloading and
selective activation of elements of.the sympathetic nervous system, results in an
increase in systemic vascular resistance, forearm vascular resistance and thus a
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reduction in FBF. Previous studies have shown that there is no effect on mean





Figure 4. 1 Filtrass 2001 plethysmography device and Filtrass 2001
'zig zag' band and linear displacement device
Figure 4.2 Lower body negative pressure chamber.
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4.3.6 Stroop's coloured word conflict test (SCWT)
The SCWT consists of several pages of the words: 'blue', 'red', 'yellow', and
'green' each printed in different colours of ink (blue, red, yellow and green) in a
random order (Figure 4.4). The subject is asked to state the colour of the ink in which
the word is printed not the printed word. Mental conflict arises because the learned
response is to read the word rather than report the colour. This task was performed at
a steady rate of ~ 100 words per min, with a metronome and observer acting as a
guide to encourage volunteers to keep to this pace. In order to induce reproducible
mental stress in our subjects we applied the SCWT for 10 min. Responses to the
SCWT include a decrease in forearm vascular resistance and a marked increase in
FBF [Lindqvist et al 1997], SCWT also causes an increase in mean arterial pressure,
heart rate, cardiac output and a fall in systemic vascular resistance. Increases in FBF
are stable and reproducible after 9 min [Freyschuss et al 1988]. However, forearm
vasodilator responses to SCWT may become diminished with repeated exposure
[Joyner et al 1997] and, in order to cause a range of FBF changes, three 10 min
exposures to SCWT were performed at each study visit.
4.3.7 Post occlusive hyperaemia (POH)
Brachial artery occlusion was applied by manually inflating an upper arm cuff to at
least 60mmHg above systolic pressure. Post occlusive hyperaemia of the forearm
resulted after the occlusion was released. A range of occlusion times (5, 8 and 13
mins) were used to assess the devices over a range of FBF.
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Figure 4.3
Stroop's coloured word test
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4.3.8 Data acquisition and statistical analysis
FBF was obtained from the mean of the last 5 consecutive recordings of each period.
Both systems allow the manual rejection of curves if rendered unsuitable for analysis
by movement artefact. Each slope recording was taken from the steep linear part of
the response curve. In the high flow experiments the plateau phase was reached more
quickly but the steep linear portion of the curve was still easily identified and
assessed over 3 or more heart beats. Data obtained from the Hokanson
plethysmograph were stored on a Macintosh computer, using the Chart v3.3 software
(Maclab, AD instruments, New Zealand). The data were further analysed off line
using the Chart v3.3 software and a template spreadsheet (Excel 5.0; Microsoft). The
data from the F2001 were analysed in a similar manner using a PC-based automatic
analysis programme, which fits a curve to the measured slope and produces a mean
value for FBF.
There is no 'gold standard' for the non-invasive measurement of FBF. Repeatability
of the devices was quantified by the average difference between the changes in FBF,
from the preceding rest period, in response to stimuli, measured by the same device
when used simultaneously on left and right arms (El/H and F/F). Therefore, assuming
stimuli will affect the FBF in each arm to a similar degree, the closer to zero the
difference in FBF between each arm and the smaller the standard deviation of results,
the more repeatable the device. Systematic bias between devices was determined by
the average of the differences from the mean when different devices were
simultaneous used to measure the changes in FBF (H/F and F/H) and presented as
Bland-Altman plots [Bland 1986].
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The effects of the SCWT, LBNP and post occlusive hyperaemia on FBF were
assessed using all data from both devices on left and right arms and expressed as
mean percentage changes from baseline ± SEM. Mean differences were assessed
using paired, 2 tailed, Student's t-test. Statistical significance was taken at the 5%
level. The study had 80% power to show a 7.5% difference between the devices
assuming a 15% standard deviation in FBF measurement.
94
4.4 RESULTS
None of the subjects were obese. All were right handed with correspondingly larger
right forearm circumferences (264 ± 5 vs 259 ± 5 mm, P < 0.01). However, there was
no difference between baseline blood flow between the left and right arms (3.1 ± 0.2
vs 2.6 ±0.1 mL/lOOmL/min, P = 0.1). The HEC4 cuff is broader than the F2001 cuff
and inflates in less than 1 second whereas the F2001 cuff takes 3-4 seconds to inflate.
There did not appear to be any difference in cuff 'artifact' between the two systems as
a result.
LBNP and SCWT caused the expected changes in FBF, which were repeatable
within study visits (Figure 4.4a). LBNP caused a decrease in FBF (-18.7 ± 0.8%, n =
240, P < 0.0001) and SCWT caused an increase in FBF (24.6 ± 1.5%, n = 240, P <
0.0001). Forearm hyperaemia following occlusion times of 5, 8 and 13 mins
substantially increased FBF by 390 ± 86%, 756 ± 217% and 851 ± 132%
respectively (all P < 0.0001)(Figure 4.4b).
4.4.1 Comparison between HEC4 and F2001
When used to measure changes in the left and right arm, the HEC4 showed no
difference in the absolute change in FBF between arms (0.10 ± 2.37 1/min n = 125, P
> 0.05). When used to measure simultaneous changes in the left and right arm, the
F2001 showed no difference in absolute changes in FBF between arms (-0.47 ± 1.92
1/min, n = 125, P > 0.05). There was no difference between the HEC4 and F2001
(0.10 ± 2.37 vs -0.47 ± 1.92 1/min, n = 125, P > 0.05). There was good correlation
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between the devices (Figure 4.5). Bland-Altman plots reveal no systematic bias
between the devices or in relation to flow values when used to measure simultaneous






a) Effect of lower body negative pressure (LBNP) and Stroop's colour word test (SCWT)
on forearm blood flow, b) Effect ofpost-occlusive hyperaemia on forearm blood flow.
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Figure 4.5
Correlation graphs of (a) Hokanson EC4 (right arm) vs Hokanson EC4 (left
arm) (b) Filtrass 2001 (right arm) vs Filtrass 2001 (left arm) (c) Filtrass 2001
(right arm) vs Flokanson EC4 (left arm) (d) Hokanson EC4 (right arm) vs
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Figure 4.6
Bland-Altman comparison of (a) Hokanson EC4 (right arm) vs Hokanson
EC4 (left arm) (b) Filtrass 2001 (right arm) vs Filtrass 2001 (left arm) (c)
Filtrass 2001 (right arm) vs Hokanson EC4 (left arm) (d) Hokanson EC4
(right arm) vs Filtrass 2001 (left arm). Light dotted line indicates mean value
with heavy dotted line indicates 95% confidence limits.
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4.5 DISCUSSION
This study was designed to assess repeatability and systematic bias of a new device
for measuring forearm blood flow by venous occlusion plethysmography. We have
demonstrated that there was no significant difference in repeatability, as measured by
difference in the changes in blood flow between left and right arms, when using the
F2001 as compared to the HEC4. In addition, there was no systemic bias between the
devices as assessed by Bland-Altman plots.
4.5.1 Forearm plethysmography
Forearm venous plethysmography has been used for nearly 100 years to assess
forearm blood flow and is now a widely used and well validated technique (Joyner et
al 2001). It has remained essentially unchanged over the last 50 years although
advances have been made in certain areas to improve durability of equipment, ease
of use and repeatability of results. The use of blood flow in the dominant forearm as
a contemporaneous control for the effects on blood flow in the non-dominant arm
and of intra-arterial drug infusion is widely used in the technique of forearm
plethysmography [Benjamin et al 1995, Wilkinson & Webb 2001], Indeed, it has
been supported by this study with only ~ 1% difference in percentage change in FBF
from baseline between left and right arms when measured by the HEC4. However,
although the average difference between the arms was small, there was a spread of
values which may reduce the power of studies to detect small absolute changes in
FBF.
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4.5.2 Potential advantages of the F2001
The F2001 is designed to measure forearm blood flow and among many potential
improvements on previous devices. The F2001 device is more compact and portable
than the HEC4. This may be of advantage in certain circumstances, such as in
intensive care units or in studies where the equipment has to be moved between
locations. Both types of strain gauge were easy to use, although the F2001 required
greater manual dexterity to insert the monofilament into the body of the LVDT. The
subject must remain still throughout the study because movement of the forearm can
dislodge the strain gauges with either device. However, the HEC4 strain gauge may
be simply replaced with little disruption to the study while disruption of the F2001
strain gauge requires re-calibration. This might be problematic if displacement
occurred during a critical part of an interventional study. In terms of mechanical
reliability, one F2001 strain gauge failed during the study (total 40 study days) while
there were no failures of the HEC4 strain gauges. The upper cuff air inlet of the
F2001 mechanically interfered with the strain gauge on inflation and the rate of arm
and wrist cuff inflations were slower than the HEC4 (3-4 sec vs <1 sec). Slow
inflating cuffs can result in venous engorgement if arterial occlusion is significantly
delayed which can cause discomfort and could potentially affect results. However,
neither of these problems appeared to occur in our study, suggesting the slower rate
of cuff inflation is not of practical importance, at least with relatively low flows.
Although there may be local variations, there was no significant cost difference
between the two devices. In addition the F2001 does not use mercury in its
construction and, therefore, has the advantage that its use would not be restricted in
the future, were mercury in medical instruments to be banned [Padfield 1998],
Chapter 5
Non-invasive measurement of cardiac output in patients
with chronic heart failure
Leslie SJ, McKee S, Newby DE, Webb DJ, Denvir MA. Non-invasive measurement




The measurement of cardiac output by thoracic bioimpedance has been assessed in
several studies. However, there continues to be disagreement as to whether this
technique is sufficiently accurate for use in clinical practice or research. The current
study aimed to compare thoracic bioimpedance (COtb) with thermodilution (COtd)
in 11 patients with stable chronic heart failure. Data are expressed as mean (SEM). A
total of 282 measurements of cardiac output were analysed. Bland Altman analysis
revealed an average difference between values of 0.3(2.2) L/min (p = 0.02),
suggesting a small average bias but marked variability in results. Similarly analysis
of percentage change from baseline demonstrated a significant average difference
between values of 10.1(30.1)%. There was no difference in between day repeatability
between thermodilution and thoracic bioimpedance (-0.2(1.2) vs 0.1(1.0) L/min, p =
0.7). This study demonstrates a correlation between the techniques but shows a poor
level of agreement. The method of COtb underestimated cardiac output compared
with COtd, and this difference appeared greater with higher cardiac outputs.
Agreement was worse when results were expressed as change from baseline. This
present study does not support the use of thoracic bioimpedance as an alternative to
thermodilution in stable patients with chronic heart failure.
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5.2 BACKGROUND
Measurement of cardiac output using the thermodilution technique is generally
accepted as the 'gold standard' although it may not be suitable for use in certain
situations, such as volunteer research studies, because of its invasive nature. In
contrast, thoracic bioimpedance is a relatively simple, non-invasive technique for
measuring cardiac output which has been employed in several clinical studies.
However, there continues to be disagreement as to whether this technique is
sufficiently accurate and precise to be of use in clinical practice or research.
Since the development of continuous cardiac output thermodilution catheters their
use has become routine, not only in clinical practice but as a standard by which other
less invasive techniques have been compared [Jacquet et al 1996, Lichtenthal et al
1996, Cariou et al 1998, Medin et al 1998, Neto et al 1999, Rocca et al 2001, Mets et
al 2002, Bein et al 2004],
Many studies have supported the use of thoracic bioimpedence [Northridge et al
1990, Thomas et al 1992, Koobi et al 1997, Salandin et al 1988, Belardine'lli et al
1996, Barin et al 2000], while others suggest it is not sufficiently accurate [Doering
et al 1995, Marik et al 1997, Spiering et al 1998], The applicability of thoracic
bioimpedance has been assessed in groups of unstable patients such as those
following cardiac surgery [Koobi et al 1997], in acute heart failure [Northridge 1990]
and in critically ill patients on intensive care units [Koobi et al 1997], In addition,
some workers have based assessment of clinical applicability on single point
measurements rather than trends, [Salandin et al 1988, Marik et al 1997]. This may
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limit their applicability as thoracic bioimpedance may be more accurate at measuring
changes in cardiac output rather than absolute values [Thomas et al 1992],
There are few studies comparing thoracic bioimpedance with thermodilution for
determining absolute, as well as relative changes in cardiac output in stable patients
with chronic heart failure. The aim of this study was to compare the techniques of
thoracic bioimpedance and thermodilution for the measurement of cardiac output in





Eleven patients with chronic heart failure (New York Heart Association Grade II/III)
due to left ventricular dysfunction attended for a total of 30 visits (maximum 3 visits
per patient). All patients had an ejection fraction <35% (by echocardiography using
the biplanar Simpson's rule) and were stable on treatment for at least 3 months. All
patients were in sinus rhythm and none had a cardiac pacemaker. The study was
undertaken with the approval of the local research ethics committee and in
accordance with the Declaration of Helsinki. Written informed consent was obtained
from each subject before entry into the study.
5.3.2 Measurements
5.3.2.1 Thermodilution
Cardiac output was measured by the thermodilution technique using the semi-
continuous single multi-lumen thermodilution cardiac output pulmonary artery
catheter (Swan-Ganz CCOmbo - CC0/SV02; Edwards Lifesciences LLC, Irvine,
CA, USA) [Bottiger et al 1996, Ditmyer et al 1995], This device has a thermal
filament which transfers a safe level of heat to the surrounding blood in a pulsed, on-
off manner every 30 s. Changes in the temperature of the blood distal to this are
measured by a distal rapid-response thermistor in the pulmonary artery. The cardiac
output is then calculated automatically using a modified Stewart-Hamilton equation
[Yelderman et al 1993],
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5.3.2.2 Thoracic bioimpedence
Thoracic bioimpedance was performed using the BoMed® NCCOM3 system.
(BoMed Medical Manufacturer Ltd., Irvine, CA, USA). Four pairs of low impedance
electrodes are used, 2 on either side of the thorax at the level of the xiphoid sternum
in the mid axillary line and 2 on the lateral aspect of the base of the neck. In each
pair, the upper electrode delivers a small current which is sensed by the lower
electrode, thus impedance is measured and the cardiac output can be calculated.
5.3.3 Protocol
Patients were asked to attend after an overnight fast and to omit their regular
medications on the morning of the study. The studies were conducted in a quiet room
maintained at a constant temperature (22-24 °C). A pulmonary artery catheter was
inserted, via a 9F femoral venous sheath, into the right pulmonary artery. Before
starting the drug infusion, patients underwent an equilibration period of > 90 min
until blood pressure, heart rate and cardiac output were stable, with 3 consecutive
measurements within 10%. Systemic concentrations of endothelin antagonists were
administered intravenously at low dose then high dose over 15 mins, 1 hour apart.
Endothelin blockade causes vasodilatation and in patients with heart failure an
increase in cardiac output (Chapter 10).
5.3.4 Data analysis and statistics
Near simultaneous measurements of CO were obtained from the mean of 3
consecutive recordings at each period for both COtd and COtb- Data are expressed
as mean value (standard error of the mean; SEM). Percentage changes in cardiac
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output from baseline were also studied. Within device repeatability was assessed by
analysing baseline measurements of cardiac output in the same patient on difference
days. The method of Bland and Altman was used to describe the relationship
between COtd and COjb. Bland-Altman analysis can be used to evaluate 2
techniques where the mean of the differences between 2 values is a measure of
accuracy (or bias) and the standard deviation of these values gives a measure of
precision [Bland 1996]. To avoid potential problems with linked data, individual
measurements from patients at baseline and 75 mins were plotted. Statistical analysis
was performed using paired, 2 tailed, Student's /-test. Statistical significance was
taken at the 5% level.
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5.4 RESULTS
There were no adverse events and the study was well tolerated by all patients. Ten
(91%) of the patients were male, and three (27%) had a NYHA score of II with the
remaining 8 (73%) having a score of III. The other characteristics of the patients are
presented in Table 1. The results of the haemodynamic effects of the study have been
reported in Chapter 10. In brief, administration of systemic doses of endothelin
antagonist resulted in peripheral vasodilation and an increase in cardiac output by a
maximum of -30%. The use of both selective and non-selective endothelin blockade
at low and high dose allowed for a range of changes in cardiac output to be
investigated.
5.4.1 Comparison between thoracic bioimpendance and thermodilution
Correlation statistics demonstrated revealed reasonable correlation between the
techniques (r=0.76), however, Bland Altman analysis revealed an average difference
between values of 0.3 (2.2) L/min (p = 0.02), suggesting a small average bias but
marked variability in results (Figure 5.1). Similarly analysis of percentage change
from baseline demonstrated a significant average difference between values of 10.1
(30.1)% (Figure 5.2).
5.4.2 Repeatability of baseline measurements
Within device repeatability was assessed by analysing baseline measurements of
cardiac output in the same patient on difference days. There was no difference in
between day repeatability between thermodilution and thoracic bioimpedance (-0.2
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Figure 5.1 Correlation and Bland Altman graphs of
absolute cardiac output measurements.
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Figure 5.2 Correlation and Bland Altman graphs of percentage














Figure 5.3 Correlation and Bland Altman graphs of absolute cardiac output
measurements at baseline and peak average cardiac output (t=75)
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5.5 DISCUSSION
There is no 'perfect' method for measuring cardiac output although the technique of
thermodilution is considered the 'gold standard'. However, due to the invasive nature
of pulmonary artery catheterisation there is considerable interest in the non-invasive
technique of thoracic bioimpedance. Thoracic bioimpedance has the advantage that it
is relatively inexpensive and easy to use, however, its accuracy has been questioned.
This study has compared the techniques of thoracic bioimpedance against
thermodilution in stable patients with chronic heart failure undergoing an acute
haemodynamic intervention study. A meta-analysis of thoracic bioimpedance studies
found a good correlation between thoracic bioimpedance and reference techniques (r
= 0.66) [Fuller et al 1992]. In keeping with these studies we have found a good
correlation between thoracic bioimpedance and a thermodilution technique (r =
0.76). However, while there is a positive correlation between the techniques, there is
a poor level of agreement. The method of thoracic bioimpedance systematically
underestimated cardiac output compared with thermodilution, and this difference
appeared to be greater with higher cardiac output. Several studies have supported the
use of thoracic bioimpedance when measuring trends in cardiac output [Northridge et
al 1990, Thomas et al 1992, Koobi et al 1997, Salandin et al 1988, Belardinelli et al
1996, Barin et al 2000], However, the current study does not support this finding
with poor agreement between values when expressed as percentage change from
baseline despite reasonable repeatability ofbaseline measurements.
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We observed an unacceptably low level of agreement both for absolute and changes
in cardiac output. Previous studies have assessed thoracic bioimpedance in critically
ill patients or patients after mechanical ventilation or undergoing cardiac surgery.
Pulmonary oedema and mechanical ventilation can affect thoracic bioimpedance and
many previously studied patients may have been unsuitable for measurement of
cardiac output by thoracic bioimpedance. The patients in this present study had stable
chronic heart failure, were in sinus rhythm and in the controlled setting of an acute
haemodynamic intervention study. It would have been expected that these optimal
conditions would provide the best opportunity for thoracic bioimpedance to be
comparable with the gold standard of thermodilution, given that patients were stable,
self-ventilating and had no pulmonary oedema. However, the findings suggest that
thoracic bioimpedance is not comparable to thermodilution in patients with stable
chronic heart failure. In addition, invasive monitoring using pulmonary artery
catheters may have additional benefits over non-invasive thermodilution in that they
allow direct measurement of blood pressure and allow sampling of blood from the
pulmonary artery.
One of the most important confounding features in heart failure patients when
measuring cardiac output by thoracic bioimpedance is changes in fluid status and the
presence of pulmonary oedema. It would have been of interest to compare thoracic
fluid volume against pulmonary capillary wedge pressure, but these data were not
collected during the study.
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Some of the differences noted in our study may be due to slight difference in the
timing of cardiac output measurements, as thoracic bioimpedance cannot be
measured at exactly the same time as thermodilution. However, measurements were
made within 60s of each other and such a small difference in time is unlikely to
explain the degree of poor agreement between these two techniques.
In conclusion, thoracic bioimpedance using the BoMed system, does not appear to
sufficiently agree with invasive thermodilution techniques for measuring cardiac
output in patients with stable chronic heart failure. Therefore, it should not be
routinely used as an alternative to thermodilution in patients with heart failure even
in the controlled setting of a clinical study. However, there continues to be
improvements in the technology associated with the technique of thoracic
bioimpedance, which, combined with its non-invasive nature may make it suitable
for use in the future.
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Chapter 6
Endothelins and their inhibition in the human skin microcirculation:
ET[1.31] a new vasoconstrictor peptide
Leslie SJ, Rahman M, Denvir MA, Newby DE, Webb DJ. Endothelins and their




Endothelin-1 (ET-l[i_2i]) is an extremely potent vasoconstrictor in the human skin
microcirculation and is generated from larger precursor peptides. The aims of the
present study were to assess the vasoactive effects of these precursors as well as
endothelin blockade in the human skin microcirculation, in vivo. Six healthy
volunteers received intradermal injections of a range of doses of big ET-1 [i_3g], ET-
1 [i-31], ET-1 [i_2i], BQ-123 (ETa receptor antagonist), BQ-788 (ETB receptor
antagonist), phosphoramidon (endothelin converting enzyme (ECE) inhibitor) or
saline control (0.9 %). Skin blood flow (SBF) was measured using standard laser
Doppler flowmetry. Big ET-l[i.38], ET-l[i_3i] and ET-l[i_2i] reduced SBF when
compared with saline control (p < 0.01 for all). Big ET-l[i_38] was -30 fold, and ET-
1 [i-3i] -150 fold less potent than ET-l[i_2i] as defined by skin vasoconstriction.
Phosphoramidon, BQ-123 and BQ-788, given alone, all caused vasodilatation in the
human skin microcirculation (p < 0.01 for all). In the human skin microcirculation,
big ET-1 [i-38] and ET-l[i_3i] are less potent vasoconstrictors than ET-l[i_2i]. The
effects of big ET-l[i_38] and phosphoramidon suggest the presence of endogenous
ECE activity in the skin. In contrast to skeletal muscle resistance vessels, ET-1 [i_21 ]




Endothelin-l[i„2i] (ET-1) is a potent vasoconstrictor in several vascular beds
including the skin microcirculation [Wenzel 1994 & 1996]. It is formed by the action
of endothelin converting enzyme (ECE) on its inactive precursor ET-1 [i-38] (big ET-
1) (Figure 6.1). There are 2 distinct endothelin receptors subtypes; ETA and ETB.
Both are present on vascular smooth muscle cells mediating vasoconstriction while
ETb is also present on endothelial cells mediating vasodilatation. Thus, the
cardiovascular effects of ET-1 [i_2i] will depend, in part, on the balance of action at
these 2 receptors and in particular the balance between the vasodilating and
vasoconstricting actions of the ETB receptor.
The endothelin system may involved in the pathophysiology of several
cardiovascular diseases including hypertension [Haynes et al 1994], renal failure
[Hand et al 1999], pulmonary hypertension [McCulloch et al 1998] and chronic heart
failure [Wei et al 1994], Blockade of the system remains an area of major interest. In
particular, whether selective or dual receptor antagonism or ECE inhibition will
provide the best treatment strategy remains unclear. Initial efforts have been focused
mainly on endothelin receptor blockade. Endothelin receptor antagonists have
benefits in patients with primary pulmonary hypertension [Channick et al 2001]
although results in patients with chronic heart failure have so far been disappointing
[Coletta et al 2002], Clinical development of ECE inhibitors continues but there are,
as yet, no fully published data on their clinical efficacy.
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Recently, ET-1 a new derivative of big ET-1, has been identified in humans. It
is generated following the cleavage of big ET-1 at the Tyr - Gly 32 bond by human
chymase [Nakano et al 1997] and may represent an active intermediary in an
alternative pathway of ET-1 production (Figure 1). In cultured human coronary
artery smooth muscle cells [Yoshizumi et al 1998, Inui et al 1999] and human
mesangial cells [Yasuoka et al 1999], ET-1 [i_3i] increases intracellular calcium. ET-
1 [1-31] causes vasoconstriction in isolated porcine coronary arteries [Kishi et al 1998],
monkey trachea [Takai et al 1998], human umbilical arteries [Takeji et al 2000] as
well as human coronary and mammary arteries [Maguire et al 2001]. Data suggest
that ET-1 [i_3i] may be cleaved to ET-1 [1-21] for its biological activity in cultured
bronchial smooth muscle cells [Hayasaki-Kajiwara et al 1999] and in both guinea-
pig [Honore et al 2002] and human arteries [Maguire et al 2001]. However, to date
there have been no in vivo clinical studies to assess the cardiovascular effects of ET-
1[1-31].
The aims of this study were to investigate the in vivo vascular effects of ET-1 [ 1.21 ], its
precursors big ET-l[i.3g] and ET-l[i_3i], and blockade of endogenous ET-1 activity by
BQ-123 (a selective ETA receptor antagonist) [Ihara et al 1992], BQ-788 (a selective
ETb receptor antagonist) [Ishikawa et al 1994] and ET-1 generation by
phosphoramidon (an ECE inhibitor) in the human skin microcirculation.
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Six healthy men (age range 20 - 30 years), with no risk factors for vascular disease,
participated in each study. Written informed consent was obtained and studies were
performed with the approval of the local research ethics committee and in
accordance with the Declaration of Helsinki. None of the subjects were taking
regular medication and all avoided medication for 1 week before each study. All
subjects abstained from alcohol for 24 hours and from food, caffeine and tobacco for
at least 12 hours before each study.
6.3.2 Skin blood flow measurement
Skin blood flow was assessed using standard laser Doppler skin flowmetry (2
channel, MBF 3D, Moor Instruments Ltd, UK) at baseline and every 2 min for the
first 10 min and then every 5 min up to 60 min. Voltage output from the Doppler
flowmeter was calibrated with standard flux solution (Moor Instruments Ltd, UK)
and transferred to a Macintosh personal computer (Classic II, Apple Computer Inc,
USA) with a MacLab analogue-to digital converter and 'CHART' software (v.3.28,
AD Instruments, New Zealand). Signals were averaged over 20 seconds at each time
point.
6.3.3 Study drugs
ET—1 [i-3i] (Peptide Institute, Osaka, Japan), and big ET-l[i_38], ET—1 [i-2i], BQ-123,
BQ-788 and phosphoramidon (Clinalfa, Laufelfmgen, Switzerland) were dissolved in
physiological saline (0.9%; Baxter Healthcare Ltd., Thetford, UK), which was also
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used as the vehicle control. Phosphoramidon was poorly soluble allowing a limited
dose-range to be examined.
6.3.4 Study protocol
Subjects rested recumbent in a quiet room maintained at a constant temperature of 22
- 24 °C for 15 min to allow stabilisation of skin blood flow. Four sites for injection
were identified and marked on the volar aspect of each forearm. Care was taken to
avoid underlying veins (demonstrated by high baseline Doppler signals) and arteries
(demonstrated by pulsatile Doppler signals). A laser probe holder was attached to
each of the 4 sites on the forearm the skin using adhesive tape designed to reduce
probe movement during the study. Baseline blood flow was measured. A measure of
'biological zero was obtained by arterial occlusion by inflating an upper arm cuff to
supra-systolic pressures. Sufficient time -15 min was allowed after arterial
occlusion to allow a return to baseline blood flow. All study drugs were administered
by 10 pL intradermal injection (0.33 mm [29.5 SWG] needle; Becton-Dickinson,
Dublin, Ireland). Following dose-ranging pilot studies, subjects received, in random
order, either saline control or study drug over a range of concentrations; big ET-l[i_
38] (0.1 to 30 pmol), ET-1 [i_3i] (1 pmol to 0.3 nmol), ET-lp.21] (1 amol to 1 pmol),
BQ-123 (0.1 to 30 nmol), BQ-788 (0.1 to 30 nmol) and phosphoramidon (0.1 to 10
nmol). The maximum dose of phosphoramidon was limited by solubility.
6.3.5 Data handling and statistical analysis
Results are expressed in arbitrary perfusion units (PU). Intradermal injection of
saline placebo causes an increase in laser Doppler signal [Wenzel et al 1994] and
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therefore all results are presented as placebo corrected mean ± SEM. Area under the
curve (AUC) for the response between 0 and 30 min was used to determine potency.
Potency was estimated as the dose required to cause a significant vasoconstriction in
the skin compared with saline placebo. Statistical difference was tested by ANOVA
with repeated measures over time and paired, 2 tailed, Student's /-test with correction




Intradermal drug delivery was well tolerated by all volunteers. Transient discomfort
occurred at some injection sites but was unrelated to injectate and did not persist for
longer than 10 seconds. This discomfort was not associated with impaired tissue
viability and did not appear to affect responses.
6.4.1 Effect of endothelin agonists
Big ET-1 [i-38], ET-1 [i-3i] and ET-1 [i_2i] caused vasoconstriction that was visually
evident on the skin, causing a marked area of pallor. Big ET-1 [i_38] was ~ 30 fold and
ET-1 [i_3i] was -150 fold less potent than ET-l[i_2i] (Figure 6.2a). Compared with
control, sustained reduction in blood flow was caused by big ET-1 [i-38] (30 pmol;
maximum decrease 25 ± 8 PU, p = 0.04), ET-1 [1.31] (0.3 nmol; maximum decrease
13 ± 3 PU, p = 0.04) and ET-1 [i_2i] (1 pmol; maximum decrease 17 ± 4 PU, p =
0.003) (Figure 6.2b). At these concentrations, vasoconstriction was sustained and
was still visibly present at 24 hrs, although the duration of response beyond 60 min
was not formally assessed.
6.4.2 Effect of endothelin blockade
BQ-123 and BQ-788 caused vasodilatation and appeared to be equipotent (Figure
6.3a). Compared with control, a sustained increase in blood flow was caused by BQ-
123 (300 nmol; maximum increase 30 ± 5 PU, p = 0.002) and BQ-788 (300 nmol;
maximum increase 18 ± 5 PU, p = 0.004) (Figure 6.3b). Compared with control,
phosphoramidon caused a small increase in blood flow at the highest dose (10 pmol;
maximum increase 11 ± 2 PU, p = 0.009, Figure 6.3a,b).
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Figure 6.2 Effects of ET agonists on skin blood flow.
a) dose ranging study, * = p<0.05, ** p< 0.01. (AUC, ANOVA)
b) time course ofmaximum dose * = p<0.05, ** p< 0.01 two tailed







































Figure 6.3 Effects of ET antagonists on skin blood flow.
a) dose ranging study, * = p<0.05, ** p< 0.01. (AUC, ANOVA)
b) time course of maximum dose * = p<0.05, ** p< 0.01 two tailed
paired Student's /-test with correction for repeated measured
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6.5 DISCUSSION
In the human skin microcirculation, we have confirmed that ET-1 [1-21] is a potent
vasoconstrictor and shown for the first time that ET-1 [i.3i] and big ET-lp-38] also
cause skin vasoconstriction in vivo. Our results suggest that there is ECE activity in
the skin as demonstrated by the vasoconstriction following intradermal
administration of big ET-1 [1.33] and vasodilatation with ECE inhibition. In addition,
we have confirmed that selective blockade of the ETA receptor caused skin
microvasculatory vasodilation [Wenzel et al 1998a] and shown directly that selective
blockade of the ETB receptor also results in vasodilatation. In contrast to
observations in resistance vessels, this suggests that ETB receptors in the skin
contribute to ET-1 mediated vasoconstriction not only in arterial disease [Wenzel et
al 1998a] but also in healthy blood vessels.
The novel finding that ET-1 [1.31] is a vasoconstrictor is of interest, and the first
evidence of its vasoactive properties in vivo in man. If ET-1 [1.31] is converted to ET-1
[1.21] by a non-ECE pathway and if this contributes importantly to ET-1 generation
then specific receptor blockade may offer greater functional activity than ECE
inhibition. Alternatively, ET-1 [i_31] may have vasoconstricting activity of its own at
endothelin receptors. Recently, the vasoconstricting effects of ET-1 [1-31] have been
shown to be mediated via the ETA receptor in rabbit renal resistance vessels [Ozawa
et al 2003], an effect which was unaffected by phosphoramidon. Although ET-1 [i-31]
is less potent than ET-lp.21], as a vasoconstrictor, local production of ET-lp-31] may
occur specifically in tissues that express human chymase, such as from the mast cells
within the shoulder region of coronary atheromatous plaques [Kaartinen et al 1994,
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Kovanen et al 1995]. Therefore, generation of ET-1 [i_3i] could contribute to coronary
artery spasm at the time of plaque rupture. Indeed, ET-1 [1-31] may be cleaved to ET-
1 [1-21] for its biological activity in cultured bronchial smooth muscle cells
[Hayasaki-Kajiwara et al 1999] and in both guinea-pig [Honore et al 2002] and
human arteries [Maguire et al 2001].
Given that big ET-1 [1-38] has affinity for the endothelin A receptor which is 1000 fold
less than ET-1 [i_2i] [Ishikawa et al 1994], that big ET-1 [1-38] was ~30 fold less potent
than ET-l[i_2i] makes it unlikely that big ET-1 [i_3g] caused a major direct
vasoconstrictor action and suggests that there is some conversion of big ET-1 to ET-
1 [1-21] in the skin. It has previously been demonstrated that big ET-1 [ 1.38] is vasoactive
in human arteries [Elaynes et al 1994] but not veins [Haynes et al 1995] and that this
vasoconstriction can be blocked by ECE inhibition [Haynes et al 1994], The
presence of ECE activity in the skin is further supported in this present study by the
vasodilatory effects of phosphoramidon. This is also consistent with preliminary
clinical studies where systemic ECE inhibition caused systemic vasodilatation and a
reduction in blood pressure [de Voogd et al 2001], In our study there appeared to be
a transient vasoconstriction to phosporamidon although this was not consistent and
did not reach statistical significance. This observation may warrant further
investigation as the current study was underpowered to investigate such a small
transient change.
Endothelin antagonists have been studied in the skin by other groups. The selective
ETa receptor antagonist PD147953 and the non-selective endothelin receptor
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antagonist PD145065 caused vasodilatation and attenuated the vasoconstrictor
effects of ET-lfi-21] in the human skin in vivo [Wenzel et al 1994 & 2001]. BQ-123 is
a selective ETA receptor antagonist and has been shown in many vascular beds
[Berrazueta et al 1997], to be a vasodilator by blocking the effects of ET-1 [i-2i]- The
present study demonstrates that BQ-123 causes vasodilatation, confirming that ET-1
contributes to the maintenance of basal vascular tone in the skin of healthy
volunteers. BQ-788 also caused skin vasodilatation. This result was unexpected as
selective ETb receptor antagonism causes vasoconstriction in skeletal muscle
[Verhaar et al 1998] and when given systemically [Strachan et al 1999]. In addition,
previous data in the skin microcirculation have demonstrated that ET-1 mediates
vasoconstriction via the ETA receptor with little contribution from the ETB receptor
[Wenzel et al 2001, Lipa et al 1999]. However, our data indicate that the dominant
effect of ET-l[i_2i] on the ETb receptor is vasoconstriction in the human skin
microcirculation, and that blockade of the ETB receptor results in vasodilatation. It is
possible that some of this effect may be a result of displacement of ET-1 from ETB
receptors and a reduction of available binding sites, thereby increasing
vasoconstriction via the ETA receptor. This finding may require further investigation.
Endothelin receptor antagonists have proven benefits in patients with primary
pulmonary hypertension [Channick et al 2001] and reduce blood pressure in
hypertensive patients [Krum et al 1998]. To date, clinical trials investigating the
potential benefits of endothelin receptor antagonists in CHF have been disappointing
[Coletta et al 2002], ECE inhibitors inhibit endothelin production and provide a
potential alternative to endothelin receptor antagonism. Unlike receptor blockade
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which can increase plasma ET-l[i_2i] concentrations, ECE inhibitors have the
advantage that they block ET-1 [i_2i] production, thus reducing plasma ET-1 [1-21]
concentrations and leaving clearance receptors unblocked. However, the effects of
raised plasma concentration of ET-l[i_2i], associated with ETb receptor blockade
[Verhaar et al 1998], may not be relevant if ETA receptors are also blocked.
However, if there are clinically significant non-ECE pathways of production with
vasoactive intermediary peptides such as ET-1 [1-31] then ECE inhibition may be a less
attractive treatment strategy.
While the doses of peptides used in these experiments are known, the concentration
when injected into the skin cannot be measured, due to the unknown volume of
distribution in the skin. However, as the same volume of injectate was used for each
dose, comparing the relative potencies of each peptide is probably justified.
Furthermore, true potency may vary depending on whether compounds are full or
partial agonists. Highly selective antagonists of each receptor were not available to
us. Although BQ-788 might have blocked ETA receptor function, its 100 fold greater
affinity for the ETB receptor [Russell et al 1996] compared with the ETA receptor,
and the equal potency of BQ-123 and BQ-788 in this study suggests that BQ-788
does indeed mediate vasodilatory effects via blockade of the ETb receptor. Another
limitation is that phosphoramidon is not only an inhibitor of ECE but also an
inhibitor of neutral endopeptidase (NEP). However, whether in health or
cardiovascular disease [Haynes et al 1994, Kentsch et al 1996, Spratt et al 2001] the
inhibition of NEP tends to cause vasoconstriction and therefore if anything led to an
underestimate of the vasodilator effects of selective ECE inhibition.
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In summary, the discovery of a vasoactive intermediary endothelin peptide may have
importance for the further development of endothelin blockers as clinical therapies.
The skin microcirculation provides an opportunity to investigate the vasoactive
properties of compounds, in vivo, in a relatively safe manner due to the small doses
which are administered. However, further studies are required to determine whether
ET-1 [i_3i] is vasoactive in other vascular beds. In particular it will be of interest to
note whether ET-lp-31] causes vasoconstriction in resistance blood vessels.
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Chapter 7
Endothelin-l[i_3i] is not elevated in men with chronic heart failure
Leslie SJ, Johnston N, Strachan FE, Gray GA, Newby DE, Denvir MA, Webb DJ.




Endothelin-l[i_3i] (ET-l[i_3ij) is a recently discovered member of the endothelin
family with vasoactive properties in several animal models and in vivo in man. It is
generated from big endothelin-1 (big ET-lp.38]) by human mast cell chymase and
may be a novel intermediary peptide in the production of ET-lp-21]. Given that both
big ET-1 [i_38] and chymase activity are increased in chronic heart failure (CHF), the
aim of this study was to determine whether plasma ET-l[i_3i] concentrations are
elevated in patients with CHF. Plasma ET-l[i_3i] concentrations were measured by
enzyme linked immunosorbent assay in 9 patients with CHF, and 9 age and sex
matched control subjects. Consistent with previous studies, plasma concentrations of
big ET-1 [1.38] were elevated in patients compared with controls (17.1 ± 4.4 vs 8.9 ±
3.4 pg/ml, p = 0.002), although there were no differences in plasma ET-lp-21] (3.3 ±
0.4 vs 3.4 ± 0.7 pg/ml, p - 0.7) or ET-l[i_3i] (both 1.1 ± 0.1 pg/ml, p = 0.2)
concentrations. We have demonstrated that patients with CHF have normal plasma
ET-1 [1-31] concentrations. This suggests that, in contrast to big ET-lp.38], plasma ET-
1 [1-31] is unlikely to be a useful prognostic marker in patients with CHF.
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7.2 BACKGROUND
New derivatives of endothelin have recently been characterised in humans. In
contrast, to the generation of endothelin -1 (ET-l[i_2i]) by cleavage of the inactive
precursor big ET-lq-38], ET-1 [i_3i] is generated following the cleavage of big ET-1 [ 1 -
38] at the Tyr31-Gly32 bond by human chymase [Nakano et al 1997], This endothelin
intermediary peptide may be of clinical importance in conditions such as chronic
heart failure where there is increased generation of big ET-1 [i_38] and increased
chymase activity in tissues including the heart [Urata et al 1990] and blood vessels
[Urata et al 1995]. In addition, there are increased numbers of mast cells and human
mast cell chymase at the shoulder regions of unstable coronary artery plaques
[Kovanen et al 1995, Kaartinen et al 1994] and ET-1 [ 1.3 q may also contribute to the
pathogenesis of ischaemic heart disease and acute coronary syndromes.
In vitro studies have shown that ET-l[i_3i] is a vasoconstrictor in isolated
porcine coronary arteries [Kishi et al 1998], rabbit pulmonary arteries [Hanson et al
1996] and monkey trachea [Takai et al 1998]. In cultured human coronary artery
smooth muscle cells [Yoshizumi et al 1998, Inui et al 1999] and human mesangial
cells [Yasuoka et al 1999], ET-1 [i_3i] increases intracellular calcium. In addition, ET-
1 [1-31] causes vasoconstriction in human umbilical arteries [Takeji et al 2000] and we
have previously reported that ET-l[i_3i] is a vasoconstrictor in the human skin
microcirculation in vivo [Chapter 6], It is likely that ET-1 [i_3i] causes
vasoconstriction via endothelin A, and perhaps the endothelin B, receptors either
directly or following conversion to ET-1 [1-21]-
Recently, a new sensitive and selective enzyme linked immunosorbent assay
(ELISA) has been developed to detect ET-1 [1-31] [Okishima et al 1999]. The aims of
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this study were, therefore, to validate the measurement of plasma ET-l[i_3i] using this
ELISA, and to quantify circulating plasma ET-1 [1-31] concentrations in patients with




Nine male patients with moderate to severe chronic left ventricular dysfunction who
had been stable on therapy for at least 3 months were recruited. They had a left
ventricular ejection fraction of < 35%, shortening fraction of < 20% or left
ventricular end diastolic diameter > 5.6 cm. Patients were compared with age and sex
matched healthy controls. The study was undertaken with the approval of the local
research ethics committee and in accordance with the Declaration of Helsinki.
Written informed consent was obtained from each subject before entry into the study.
7.3.2 Blood sampling and plasma extraction
All subjects omitted their medications on the day of study and attended after an
overnight fast. Venous blood samples were collected into ethylene diamine
tetraacetic acid (EDTA; Sarstedt, Aktiengesell Schaft & Co, Germany), placed on ice
and plasma immediately separated by centrifugation (2500 g for 20 min at 4°C).
Plasma samples were stored at -80 °C until analysis. Plasma was acidified with an
equal volume of 20% acetic acid before being extracted using methanol activated
Bond Elut CI8 columns (Varian, Harbor City, CA, USA). The columns were
perfused with deionised water and 10% acetic acid prior to the addition of plasma
samples. The columns were then washed with 10% acetic acid and ethyl acetate, and
the bound endothelin was eluted with 80% methanol: 20% ammonium bicarbonate.
The eluate was dried down under a continuous stream of nitrogen at 37°C and the
dried eluates reconstituted with assay buffer. Recovery fraction was estimated by
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adding known quantities of ET-l[i„3i] to plasma. The assays were performed with the
kind assistance of Mr Neil Johnston.
7.3.3 Peptides
ET-l[i_3i] (Peptide Institute Inc., Osaka, Japan), big ET-1 [i-38] (Clinalfa, Laufelfingen,
Switzerland) and ET-1 [i_2i] (Clinalfa) were dissolved in physiological saline (0.9%
Baxter Healthcare Ltd., Thetford, UK) and used to assess assay cross reactivity.
7.3.4 Assays
The assay for plasma big ET-lp.38] and ET-l[i_2i] has been previously described
[Newby et al 1998] with intra-assay coefficients of variability of 7.0 and 7.2%
respectively and inter-assay coefficients of variability of 9.0 and 9.3% respectively.
A commercially available solid phase sandwich enzyme linked immunosorbent assay
for ET-1 [i_3i] (Immuno-Biological Laboratories Co Ltd., Tokyo, Japan) was used.
This technique was performed on reconstituted samples by using anti-human ET-1 [25.
3i] rabbit immunoglobulin G. Briefly, 100 pL of sample extract, standard or quality
control along with 100 pL of ET-lp.31] antibody, was incubated for 24 hours at 4°C.
Following incubation, the wells were vigorously washed with buffer, 100 pL of
labelled antibody added and incubated for a further 30 min at 37 °C. After further
washing, tetramethylbenzidine buffer was added, and incubated for 30 min in the
dark. Finally, 100 pL of 2 M sulphuric acid was added and the wells read using an
automated plate reader at 450 nm.
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7.3.5 Data handling and statistical analysis
Cross reactivity was determined by calculating area under the curves for big ET-1p.
38], ET-1 [1-31], and ET-1 [i_2i], and expressed as a percentage of area under the curve
for ET-1 [i_3i]. Intra-assay co-efficients of variation were calculated from mean values
divided by standard deviation and expressed as a percentage. Plasma concentrations
are expressed as mean ± standard error of the mean. Data were examined by analysis




Patient details are shown in Table 7.1.
7.4.1 Recovery of ET-l[i-3i]
Recovery of ET-1 [i_31j during extraction was 73%. This is comparable to the
extraction efficiency for big ET-1 and ET-1 [Newby et al 1998].
7.4.2 Specificity of ELISA for ET-1,1.31]
Standard curves for big ET-1 fi_38j, ET-1 [].31 j, and ET-l[i_2i] were constructed (Figure
7.1). The cross reactivities for the assay were 3.8% for big ET-l[i_38], 100% for ET-
1 [1-31], and 0% for ET-l[i_2i]. Intra-assay co-efficients of variation were 14.7, 8.8 and
6.7% at plasma ET-1 [i_3i] concentrations of 10, 20 and 40 pg/mL respectively.
7.4.3 Plasma concentrations of big ET-1, ET-1 and ET-l[i_3i]
Plasma big ET-1 [i_38] concentrations were elevated in patients compared with
controls (17.1 ± 4.4 vs 8.9 ± 3.4 pg/mL, p = 0.002). However, there were no
differences in the plasma concentrations of ET-l[].2i] (3.3 ± 0.4 vs 3.4 ± 0.7 pg/mL, p
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Chronic Heart Failure Matched Controls
Concentrations of plasma big ET-1[1_38j, ET-ln 31] and
ET-1 [ i _21 ] *n patients with chronic heart failure and matched controls.
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7.5 DISCUSSION
This small study confirms that a new ELISA has high specificity for ET-1 [1-31], with
low cross-reactivity for both ET-1 [ 1 -21 j and big ET-1 [i_3g]. In addition, we have
demonstrated, for the first time, that ET-1 [i_3i] immunoreactivity is present in human
plasma of both CHF patients and healthy subjects. Despite elevation of the precursor
peptide big ET-l[i.38], plasma ET-l[i.3ij concentrations were normal in patients with
CHF.
We have demonstrated that the commercially available assay for ET-1 [i_3i] has a high
degree of specificity for this form of endothelin compared with big ET-1 [i_38] and ET-
1 [1-21]- The ELISA utilises an antibody that recognises the 7 amino acid carboxy
terminus of ET-l[i_3i]- Given that big ET-1 [1-38] also shares this common sequence, it
may have been anticipated that significant cross reactivity might occur. However, we
report a very low level of cross reactivity and this is likely to reflect differences in
immunoreactivity conferred by the tertiary structure ofbig ET-1 [1-38] and ET-l[i_3ij.
Plasma big ET-1 concentrations are elevated in patients with CHF and correlate with
disease severity [Wei et al 1994]. Our findings are consistent with these prior data,
although plasma ET -1 [i -21] concentrations were not elevated. This was unexpected as
plasma ET-1 [1-21] concentrations are also reported to be elevated in patients with
chronic heart failure [Wei et al 1994], However, big ET-1 [i-38] plasma concentrations
are a more reliable marker of chronic heart failure and, in our study, these were
increased by ~2 fold. We have also recruited stable patients who were well
controlled on medical therapy. It is likely, therefore, that our patient population had
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less neurohormonal activation and may have had less generation of big ET-1 [i-38]
than those enrolled into previous studies.
In patients with chronic heart failure, there does not appear to be a general increase
in generation of ET-1 [1-31]. This study does not however exclude the possibility of
local increases in ET-1 [1-31] production, such as within areas of inflammation.
Moreover, local ET-1 generation may be specific to those tissues with increased
chymase activity such as failing human myocardium [Urata et al 1990]. In addition,
increased chymase activity is seen in mast cells at the shoulder regions of coronary
atheromatous plaques [Kovanen et al 1995, Kaartinen et al 1994], and ET-1 [ 1 -31 ] may
be implicated in the aetiology of coronary artery spasm at the time of plaque rupture.
Further studies are clearly required to determine how ET-1 [1-31] is processed and to
identify situations where increased local ET-1 generation may occur.
It should be noted that these patients were being treated for chronic heart failure in
the late 1990s, and would be considered now to be 'undertreated'. In particular the
poor use of beta-blockers and the persistent hypertension, may affect the
applicability of these results to more contempory cohorts of heart failure patients.
In conclusion, this study has shown that plasma ET-1 [ 1 -31 ] concentrations can be
measured reliably but, in contrast to big ET-1 [i.38], do not appear to be elevated in
patients with heart failure. These data suggest that ET-1 [1-31] is not useful as a
predictive test and that generation is not sufficient to increase circulation plasma
concentrations in patients with stable chronic heart failure.
144
Chapter 8
Endothelin and its antagonists in the isolated human myocardium
Leslie SJ, Webb DJ, Denvir MA. Endothelin-1 antagonises beta-adrenergic




The direct effects of ET blockade on human myocardium in terms of force of
contraction cannot be determined from systemic in vivo studies due to compensatory
mechanisms previously discussed (Chapter 1). Indeed, ET-1 has previously been
shown to be positively inotropic in isolated human myocardium via the ETA receptor.
Beta-adrenergic agonism has positive inotropic effects, mainly via the B] receptor.
These two distinct systems share a common second messenger. In membrane studies
beta-agonists increase adenylate cyclase (AC) while ET-1 reduces it and inhibits
isoprenaline induced AC activity. Thus, there is potential antagonism between the two
systems. The aim of these experiments was to determine the direct effects of ET-1 and
ET blockade on isolated human myocardium and to test the hypothesis that ET-1 can
antagonise the effects of beta-adrenergic stimulation. Right atrial trabeculae were
harvested from 19 beating human hearts, during initiation of cardiac bypass prior to
coronary artery bypass grafting, and mounted for isometric tension experiments. ET-1
(lOnM) increased force by 12.6 ± 5.0%, p=0.04. This was preceded by a transient
non-significant decrease in force. -3.6 ± 1.9%, p=ns. BQ-123 and BQ-788 had no
effect on basal resting tone or force of contraction in electrically stimulated isolated
human right atrial trabeculae. In addition, BQ-123 and BQ-788 did not block the
inotropic effects of supra-physiological concentrations of ET-1. Isoprenaline caused
an increase in force which was of faster onset and larger magnitude than that seen
with ET-1 65.7 ± 29.2%, p=0.01. The increase in force with isoprenaline was of more
rapid onset, with a maximal effect seen after 5 min. When added to maximally beta-
adrenergic stimulated trabeculae, ET-1 significantly attenuated the effect of
isoprenaline causing a reduction in force 96 ± 39%, p<0.01. These results suggest that
ET-1 is positively inotropic but does not contribute to resting inotropic effect in the
146
human myocardium and that ET-1 functionally antagonises the effects of beta-
adrenergic stimulation. This may have important consequences in conditions where
both systems are up regulated. Beta-blockade has recently been shown to have
important prognostic benefits in patients following myocardial infarction and in
patients with CHF. ET-1 is also up regulated in these conditions and may provide
physiological antagonism to catecholamine over-stimulation.
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8.2 BACKGROUND
Plasma concentrations of endothelin-1 (ET-1) are elevated in chronic heart failure
(CHF) and correlate with a poor prognosis [Wei et al 1994], Short-term systemic ET
blockade in CHF patients causes potentially beneficial haemodynamic effects;
increasing cardiac output and reducing vascular resistance [Kiowski et al 2001],
However, the initial results from longer term clinical trials have been disappointing.
In the ENABLE and EARTH clinical trials preliminary reports indicate that there was
no major benefit when an endothelin receptor antagonist (ETRA) was added to
conventional heart failure therapy.
Beta-blockers improve mortality in CHF patients and while the mechanisms for these
benefits are not fully understood they may involve betai-adrenoreceptor upregulation.
Betai-adrenergic stimulation increases adenylate cyclase (AC), increasing cAMP,
activating protein kinase A, resulting in phosphorylation of several intracellular
proteins ultimately leading to an increase in intracellular calcium.
In systemic studies, administration of ET-1 reduces cardiac output, probably due to a
combination of coronary artery constriction, reducing myocardial blood supply, and
systemic vasoconstriction increasing systemic vascular resistance and thus after-load
[Kiely et al 1997], However, ET-1 increases force of contraction in isolated
myocardium, [Beyer et al 1995, Meyer et al 1996, Saetrum Opgaard et al 2000, Dhein
et al 2000], and in isolated human myocardium ETa receptor antagonists have been
shown to inhibit ET-1 mediated inotropy [Meyer et al 1996, Dhein et al 2000,
Saetrum Opgaard et al 2000] although the effects of ETb receptor antagonists have
been less consistent showing no effect [Dhein et al 2000] or blockade of ET inotropy
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[Saetrum Opgaard et al 2000]. The exact mechanism by which ET-1 increases cardiac
contractility is uncertain, however there are several intracellular changes which can
increase force of contraction such as increasing calcium availability, increasing
myofilament sensitivity to calcium and increase of intracellular pH [Meyer et al
1996], Binding to the ETR results in activation of a number of intracellular signalling
processes, it has been suggested than more than one second messenger signalling
system may be stimulated simultaneously depending on the cell type and level of
expression of G protein subtypes. G protein subtypes coupled to ETRs include Gq,
Gn, Gs and Gi2 [Takigawa et al 1995] (Figure 1.4). There are many downstream
signal transduction pathways including nitric oxide synthase, adenylate cyclase,
protein kinase C, and phospholipase A2, C and D, ion channels such as calcium and
chloride channels and ion transporters. Therefore the effects of binding to ETRs will
also depend on which second messenger pathways are activated and this will change
within and between cell types. In addition, many of these second messenger pathways
are shared with other neuroendocrine systems and therefore post receptor cross talk
may influence responses. One such potential interaction is with the beta-adrenergic
system. Beta-adrenergic stimulation results in activation of adenylate cyclase (AC),
resulting in increased intracellular cAMP, activation protein kinase A causing
phosphorylation of several intracellular proteins. This phosphorylation has the effect
of decreasing myofilament sensitivity for calcium but increasing intracellular calcium
by stimulation of sarcoplasmic reticular release as well as increased influx of
extracellular calcium. Membrane studies have demonstrated than isoprenaline (ISO),
a selective beta-1 receptor agonist, increases AC while ET inhibits its activity and can
inhibit ISO stimulated increases in AC [Vogelsang et al 1994, Ponicke et al 1998].
Thus, there is a potential antagonistic interaction between these two systems.
The aim of these experiments was to determine the direct effects of ET-1 and ET
blockade and to examine the hypothesis that ET-1 antagonises the effects of beta-





Nineteen patients undergoing coronary artery bypass grafting for coronary artery
disease requiring cardiopulmonary bypass participated with the approval of the
Lothian Research Ethics Committee and the written informed consent of each subject.
The characteristics of the patients are described in Table 8.1. This group represents
the typical patient undergoing coronary artery bypass grafting.
8.3.2 Study Design
Isometrically twitching right atrial trabeculae were allowed to stabilise for 1 hour
before starting the experiment. Any preparations with an unstable baseline or 'slow'
twitch were discarded. Twelve stable trabeculae were exposed to either BQ-123
(ImM) or BQ-788 (ImM). Responses to ET-1 were then determined where paired
data were possible. In a separate series of experiments, stable trabeculae were exposed
to either isoprenaline (lOmM), ET-1 (lOmM) or ISO followed by ET-1 at the same
concentration.
*
8.3.3 Myocardial trabeculae preparation
Myocardial trabeculae were collected and processed as previously described in
Chapter 2. Free running trabeculae were mounted for electrical stimulation at 1Hz at a
voltage -10% above threshold with rectangular pulses of 10 ms duration and allowed
to stabilise for 1 hour in a vertical 7ml chamber (World Precision Instruments, UK)
containing modified Tyrodes (NaCl 130, KC1 5.4, NaHPCL 0.56, MgClePLO 3.5,
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CaCb 2, Glucose 10, HEPES 5(mM)) corrected to pH 7.4 with NaOH and
continuously bubbled with 100% O2 at 35°C.
8.3.4 Solutions
Physiological solution had the following composition (mM); NaCl 130, KC1 5.4,
NaHP04 0.56, MgCbEEO 3.5, CaCl 2, Glucose 10, HEPES 5. This was corrected to
pH 7.4 with NaOH. Cardioplegic solution consisted of physiological solution with the
addition of the cardioplegic agent 2,3 butane-dione-monoxime 30mM.
8.3.5 Drugs
ET-1, BQ-123 and BQ-788 (Neosystem SNPE England, Croydon, UK) were
reconstituted following the manufacturers instructions with saline 0.9% (Baxter
Healthcare Ltd, Thetford, UK) and diluted in physiological solution. Isoprenaline
(Sigma-Aldrich Chemicals, Poole, UK) was dissolved in physiological solution with
ascorbic acid (ImM) to reduce oxidation. Solutions were kept at room temperature
and protected from light during the experiment. All other chemicals were of analytical
grade (Merck, Magna Park, Leicestershire, UK).
8.3.6 Justification for drug concentration
During systemic dosing studies, the total dose of BQ-123 and BQ-788 administered in
the study was 1000 and 300 nmol/min for 15 min. Assuming a circulating blood
volume of 3L this would give approximate plasma concentrations of 5 and 1.5 pM
respectively. Tissue concentrations are likely to be much lower than this, however, it
is not possible to accurately estimate tissue concentrations of drug in human
myocardium as this will depend on several, difficult to determine variables, such as
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plasma concentrations in coronary arteries, tissue perfusion and permeability.
Previous researchers have demonstrated effects of ET antagonists in vitro, at
concentrations of 0.1 pM and therefore, in order to determine whether endothelin
antagonists would have any direct cardiac effect we exposed isolated human
myocardial trabeculae to concentrations of 1 pM, 10 fold higher than previous
researcher have employed and although these concentrations are lower than the
maximal possible concentration in the systemic studies they are likely to be
significantly higher than physiological tissue concentrations.
8.3.7 Data analysis and statistics
Isometric twitches were detected by a force transducer (FORT 10, World Precision
Instruments, Stevenage, UK) and amplified (Transbridge1M). Analogue voltage output
was processed by a MacLab* analogue-to-digital converter and Chart v3.3 software
(AD Instruments, New Zealand) and recorded onto a Macintosh Classic II computer
(Power Macintosh 7200/90, Apple Computers Inc, Cupertino, USA). Statistical
difference was tested by 2 tailed, paired Student's t-test (Excel v5.0, Microsoft). A
value of p<0.05 was considered to be statistically significant. All values are expressed
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Table 8.1 Patient characteristics
8.4 RESULT
BQ-123 (ImM) caused no increase in force of contraction vs placebo from baseline
(n=7)(Figure 8.1). BQ-788 (ImM) caused no change in force of contraction vs
placebo form baseline (n=2) (Figure 8.2). Neither BQ-123 nor BQ-788 appeared to
block responses to supra-physiological concentrations of ET-1 in our preparations
(Figures 8.3 and 8.4).
Compared with vehicle, ET-1 (lOnM) increased force by 12.6 ± 5.0%, p=0.04.
(Figure 8.5). Compared with vehicle, isoprenaline caused an increase in force which
was of faster onset and larger magnitude than the inotropy seen with ET-1 (65.7 ±
29.2%, p=0.01). The increase in force with isoprenaline was of more rapid onset, with
a maximal effect seen after 5 min. When added to maximally beta-adrenergic
stimulated trabeculae, ET-1 significantly attenuated the effect of isoprenaline causing
a reduction in force 96 ± 39%, p<0.01 (Figure 8.6).
ET-1 resulted in an increase in twitch parameters with a trend towards an increase in
time to peak (160 ± 20 to 216 ± 33 ms, p = ns) and an increase in both RT50 (106 ± 11
to 129 ± 14 ms, p < 0.05) and RT95 (221 ± 24 to 251 ± 21 ms, p < 0.05). Isoprenaline
caused a trend towards a shortening of the twitch parameters, time to peak (180 ± 40
to 163 ± 30 ms, p = ns), RT50 (113 ± 7 to 111 ± 12, p = ns) and RT95 (238 ± 10 to 228
± 12, p = ns)(Table 8.2 and Figure 8.7).
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BQ123 (ImM)





Figure 8.1 Effect of BQ123 on basal force of contraction (actual tracing)
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BQ788 (ImM)









Figure 8.2 Effect of BQ123 on basal force of contraction (actual tracing)
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Figure 8.3 Effect of BQ123 on ET-1 inotropy
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Figure 8.6 Effect of endothelin on maximally isoprenaline stimulated myocardium
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Time Baseline ISO (10 nM) Baseline ET-1 (lOnM)
TTP 180 ±40 163 ±30 160 ±20 216 ±33
RT50 113 ± 7 111 ± 12 106 ±11 129±14*
rt95 238 ± 10 228 ± 12 221 ± 24 251 ±21*
Force 362 ± 69 496±100* 348 ± 67 389 ±89*
Table 8.2 Influence of isoprenaline (ISO) and endothelin-1 (ET-1) on twitch
parameters; time to peak (TTP), RT5o, RT95, and force of contraction
(Force). (* = P<0.05)
*•
Figure8.7Diagramoftheeffectsisoprenalinedendoth li -1ntwitchparam ter(fv l ssTabl8.2)
8.5 DISCUSSION
This study has confirmed that ET-1 and beta-adrenergic stimulation increase force of
contraction in isolated human myocardium. ET antagonism does not affect basal tone
in isolated myocardium suggesting that there is no resting ET-1 mediated inotropy.
ET-1 attenuates the inotropic effects of beta-adrenergic stimulation with isoprenaline.
8.5.1 Effects of ET antagonists on myocardial force of contraction
Both ETa and ETB receptors are present in human myocardium [Ponicke et al 1998].
However, distribution of the receptor type and number is not uniform and there may
be differences in specific pathological conditions. In situ hybridization studies have
demonstrated both receptor types in atrial and ventricular myocardium,
atrioventricular conducting system and the endocardial'cell [Molenaar et al 1992],
The ratio of ETA to ETB receptors in terms of number is approximately 60:40% [Peter
& Davenport 1996]. However, overall, receptor density is 1.5 to 2 fold higher in the
atrium compared to the ventricle [Ponicke et al 1998], In addition, a higher proportion
of ETb receptors are found in the AV node and the penetrating bundles of His
compared with the surrounding myocardium [Molenaar et al 1992] suggesting
involvement of the ETb receptor in the neural control of the heart
In isolated human myocardium, ETA receptor antagonist have been shown to inhibit
ET-1 mediated inotropy [Meyer et al 1996, Dhein et al 2000, Saetrum Opgaard et al
2000] although the effects of ETb receptor antagonists have been less consistant
showing no effect [Dhein et al 2000] or blockade of ET inotropy [Saetrum Opgaard et
al 2000]. The effects of local studies on isolated myocardium contrast with the effect
on cardiac output seen in systemic studies.
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In these experiments we have demonstrated that neither the selective ETA antagonist,
BQ-123, or the selective ETB antagonist, BQ-788 has an effect on force of contraction
on isometrically twitching human myocardium. In addition, pre-treatment with ET
antagonists did not antagonise the effects of ET-1. This was unexpected. As discussed
above, other groups have demonstrated that pre-treatment with ET antagonists can
reduce the potency of ET-1 although responses to maximal doses (Emax) are not
reduced probably due to competitive binding at receptor sites.
There are several possibilities why ET antagonists did not appear to antagonise ET-1
responses in this study. Firstly the dose used may have been inadequate. However,
this is unlikely as the doses used are comparable to estimated plasma concentrations
and are higher than the concentrations of antagonists used by other researchers. It is
possible that the antagonists may have been degraded, however drugs were prepared
in keeping with the manufacturers instruction and stored at -80°C. In addition, it is
our experience that both BQ-123 and BQ-788 are relatively stable compounds even at
room temperature. In a separate experiment (data not shown), the degradation of BQ-
788 was determined after being kept for 24 hours at room temperature (18-20°C)
These data from HPLC were compared with clinical grade BQ-788 and found to be
similar and there was no discernable degradation as measured by HPLC. However,
the biological activity was not measured and therefore we cannot be certain that the
batch of BQ-788 was biologically inert.
Thus, it would appear that in our preparations ET antagonism has no effect on basal
resting tone and, therefore that the effects of ET blockade on cardiac output are
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primarily a result of effects on the peripheral or coronary vasculature rather than
direct effects on the myocardium. It should be noted that these data were gained in
patients with a primary diagnosis of coronary artery disease rather than heart failure.
In addition, they were performed on atrial tissue where clearly the effects on
ventricular tissue are more important with regard to cardiac pump function.
8.5.2 ET-1 and beta-adrenergic interaction
Both ET-1 and isoprenaline increased isometric force in human RA myocardium. ET-
1 increased force following a transient negative inotropic response, and although this
has been described by other groups [Ponicke et al 1998, Dhein et al 2000] the
mechanism remains unclear. In addition ET-1 caused a significant increase in twitch
parameter times, consistent with an increase in myofilament sensitivity. This confirms
results from previous studies where there are increases in myofilament sensitivity via
activation of PKC and activation of the sarcolemmal Na+/H+ exchanger [Meyer et al
1996]. ET-1 has also been shown to increase intracellular Ca2+. The mechanisms
behind this are unclear but increases in intracellular Na+ will reduce Ca2+ extrusion by
the sarcolemmal Na+/Ca2+ exchanger thus increasing intracellular Ca2+ and force of
contraction [Meyer et al 1996].
In these experiments, a transient negative inotropic effect was seen following ET-1
administration although it failed to reach statistical significance. This finding is
consistent with work from previous groups although the mechanism is not clear
[Vogelsang et al 1994, Dhein et al 2000],
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Isoprenaline caused an increase in force of contraction that was of faster onset and
larger magnitude than that seen with ET-1 and caused a non-significant reduction in
twitch duration consistent with reducing myofilament sensitivity. This result was
2_j_
expected as beta-adrenergic stimulation results in an increase in intracellular Ca
secondary to both sarcolemmal channel opening and release from intracellular stores,
resulting in increases in force of contraction.
We have observed, for the first time, that ET-1 functionally attenuates the inotropic
effects of isoprenaline in human myocardium. This reduction in force was observed
after maximal stimulation of the beta-adrenergic system. The underlying mechanism
is likely to be interaction at the level of AC as seen in isolated membrane studies
where ET-1 was shown to inhibit the effect of betai-adrenoreceptor activation on this
enzyme.
Unfortunately the apparatus to measure intracellular Ca2+ was not available at the time
of performing these experiments and therefore no comment can be made about the
effect of this antagonism on intracellular Ca2+. Elowever, it would be expected that
intracellular Ca2+ transients may be decreased by the effects of ET-1 as antagonism at
the level of adenylate cyclase is likely to have a more profound effect on intracellular
Ca2+ through sarcolemmal Ca2+ channels and sarcoplasmic reticular release than the
indirect Ca2+ increases as a result of activation of the Na+/H+ exchanger in response
to ET-1.
These results suggest that, in the human myocardium, ET-1 functionally antagonises
the effects of beta-adrenergic stimulation. However, care should be taken when
interpreting these results as supra-physiological concentrations of agonists were used,
although, it appears that there is functional antagonism between these two hormone
systems, presumably at the level of receptor, or post receptor cross-talk.
This study has some limitations in that we were unable to study normal human
ventricular myocardium due to a lack of suitable samples. Previous isolated
membrane studies have confirmed differences between atrial and ventricular tissue so
ET-1 may not inhibit AC in ventricular tissue [Ponicke et al 1998], In addition, the
concentrations of ET-1 used were higher than those in the plasma of CHF patients but
may be similar to those occurring at a local level in myocardium.
Nevertheless, the results of this study may have important consequences in conditions
such as CHF were both ET-1 and the beta-adrenergic systems are up-regulated and
drugs blocking their actions are being developed. Catecholamine release and therefore
beta-adrenergic stimulation is increased in CHF and also in episodes of acute heart
failure and acute coronary syndromes. This can lead to increases in arrythmias and
sudden cardiac death, the most common cause of death in patients with CHF. In CHF
there is a reduced responsiveness to beta-agonists, probably due to combination of
reduced receptor number and post receptor changes. It could be that some of these
changes are due to an interaction with the ET system which is also up-regulated in
CHF. The importance of this interaction may be that ET-1 while a marker of disease
severity in CHF actually protects against catecholamine stimulation. It is known that
catecholamine blockade with drugs such as beta-blockers confers mortality and
morbidity benefits and with the introduction of ETRAs for the treatment of CHF the
physiological and patho-physiological interactions between these two systems is of
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importance. Indeed, the first trials of endothelin antagonist in patients with heart
failure, many of whom were on beta blocker treatment was negative, demonstrating
no mortality benefit [Coletta et al 2002, Luscher et al 2002].
Clearly these experiments require further investigation but are beyond the scope of
simple isometric force contraction experiments.
Note: Although an attempt to gain ventricular tissue was made by the author, only 4
explanted hearts were collected before the transplant program in Glasgow was
temporarily suspended. Only 2 of these were suitable for experiments. There were




The effect of plasma lipid lowering therapy on resistance vessel tone and
response to endothelin antagonism
Leslie SJ, Spratt JC, Attina T, Denvir MA, Webb DJ. The effect of cerivastatin on vascular
responses to endothelin antagonism. J Cardiovasc Pharmacol 2004;44:S410-412.
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9.1 SUMMARY
Endothelin (ET) blocking drugs have been shown to have beneficial effects mediated at least
in part via the nitric oxide (NO) system. Hypercholesterolaemia is associated with vascular
dysfunction including increased arterial stiffness and impaired NO mediated vasodilatation.
Treatment with HMG CoA reductase inhibitors (statins) has proven mortality benefits in a
range of patient populations. Subjects (n=5) received either placebo or statin (cerivastatin
400mcg) for an 8 week period in a double-blind placebo-controlled cross-over study.
Cerivastatin reduced total plasma cholesterol compared with baseline by 27 % (5.4 ± 0.4 vs
7.3 ± 0.4 mmol/L, p = 0.04). Compared with placebo, cerivastatin caused a trend towards an
increase in forearm blood flow (FBF) in response to selective ETA (18.0 ± 7.2 vs 52.0 ± 19.0
%, p = 0.06). Selective ETb receptor blockade reduced FBF with no difference between
placebo and cerivastatin therapy (-11.0 ± 3.9 vs -13.0 ± 3.6%, p = 0.9). Dual ETa/b receptor
blockade increased FBF with no difference between placebo and cerivastatin therapy (39.8 ±
13.4 vs 42.4 ± 19.0 %, p = 0.7). In conclusion, statin therapy may decrease large artery
stiffness and increase in the vasodilating effects of ETA receptor blockade.
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9.2 BACKGROUND
ET-1 causes vasoconstriction via the ETA and ETB receptors located on vascular smooth
muscle cells and a prostanoid and nitric oxide (NO) mediated vasodilatation via the ETB
receptor on endothelial cells. Thus, ETA receptor blockade causes vasodilatation while the
effects of ETb receptor blockade will depend on the balance between vasodilating and
vasoconstricting effects at different sites.
In healthy subjects, brachial artery administration of BQ-123, a selective ETA antagonist,
results in a forearm vasodilation of -40% [Haynes et al 1994b, Berrazueta et al 1997, Verhaar
et al 1998], whereas administration of BQ-788, a selective ETB antagonist, causes a modest
vasoconstriction of -10% [Verhaar et al 1998], If the mechanism of the vasodilation is NO
mediated, then in an NO-deficient state the dilatation to ET-1 at the endothelial ETB receptor
may be reduced, with less vasoconstriction to BQ-788. Many studies have previously
demonstrated evidence of endothelial dysfunction and a NO deficient state in patients with
hypercholesterolaemia [Creager et al 1990, Celemajer et al 1992, Chowienczyk et al 1993].
Hypercholesterolemia is also associated with a reduction in vascular compliance and a
reduced response to vasoactive therapies such as nitrates. Some of these responses can be
improved following lipid lowering therapy [Stroes et al 1995, O'Driscoll et al 1997]. In
addition, it has been clearly demonstrated that reduction of plasma cholesterol reduces
mortality in several patient groups [Scandinavian Simvastatin Survival Study Group 1994,
Shepherd et al 1995],
The aim of this study was to examine whether treatment of hypercholesterolaemia with an
HMG CoA reductase inhibitor (cerivastatin) could increase vascular compliance and improve
vasodilator responses to ET antagonists.
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9.3 MATERIALS AND METHODS
Five non-smoking, otherwise healthy, hypercholesterolaemic subjects were studied. Subjects
were rejected if they had diabetes mellitus, renal impairment (creatinine; men >180 mmol/1,
women >160 mmol/1), a 10-year coronary heart disease risk of > 30%, a history of severe
allergic reaction, a systolic blood pressure > 180 or < 90 mmHg or were taking any regular
medications. The study was undertaken with the approval of the local research ethics
committee and in accordance with the Declaration of Flelsinki. Written informed consent was
obtained from each subject before entry into the study. Subjects attended fasted for each study
visit which was performed in a quiet, draught free, temperature controlled room (22-24 °C).
The technique of venous occlusion plethysmography to measure forearm blood flow
[Benjamin 1995] and pulse wave analysis to measure augmentation index and arterial stiffness
[Wilkinson 1998] have been described in detail elsewhere.
Subjects received, in a randomised double blind cross-over manner, 8 weeks treatment with
either sucrose placebo or cerivastatin 800 ug nocte (Bayer AG). BQ123 and BQ788 (Clinalfa
AG, Laufelfmgen, Switzerland) were diluted in 0.9% saline (Baxter Healthcare Ltd, Thetford,
UK) and infused via an intra-arterial needle over 80 min. Subjects received BQ123 (10
mol/min), BQ-788 (1 mmol/min) or both in a random order by 80 min intra-arterial infusion at
weeks 6, 7 and 8 and at weeks 14, 15 and 16. The order of intra-arterial drug infusion at the
end of each treatment period was randomised and kept the same within patients, i.e the order
of ET antagonist forearm studies was consistent between treatment periods. Pulse wave
analysis was performed and venous blood samples taken at weeks 0, 8 and 16. Data were
examined by Student's /-test (Excel v5.0, Microsoft). Results are expressed as mean ± SEM.
Forearm blood flow and pulse wave analysis results are expressed as percentage change from
baseline. Statistical significance was taken at the 5% level.
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9.4 RESULTS
Cerivastatin therapy for 8 weeks resulted in a reduction in total plasma cholesterol compared
with baseline of 27 % (5.4 ± 0.4 vs 7.3 ± 0.4 mmol/L, p = 0.04), this was achieved by a
reduction in lower density lipoprotein (LDL) cholesterol (Figure 9.1). There was no effect
after 8 weeks of placebo treatment (7.4 ± 0.4 vs 7.3 ± 0.4 mmol/L, p = 0.9). Compared with
placebo, 8 weeks of cerivastatin therapy caused a trend towards an increase in forearm blood
flow (FBF) in response to selective ETA antagonism (18.0 ± 7.2 vs 52.0 ± 19.0 %, p = 0.06)
(Figure 2). Selective ETb receptor blockade reduced FBF with no difference between placebo
and cerivastatin therapy (11.0 ± 3.9 vs 13.0 ± 3.6%, p = 0.9) (Figure 9.2). Dual ETa/b receptor
blockade increased FBF with no difference between placebo and cerivastatin therapy (39.8 ±
13.4 vs 42.4 ± 19.0 %, p = 0.7). There was a trend towards a reduction in augmentation index
between cerivastatin and placebo (6.2 ± 2.7 vs 9.1 ± 2.4, n = 5, p = 0.4) compared with
baseline (7.2 ± 1.0) (Figure 9.3).
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Figure 9.1 Plasma concentrations of low density lipoprotein (LDL) and
high density lipoprotein (HDL) after 8 weeks treatment with
placebo or cerivastatin.
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a) Placebo b) Cerivastatin
Figure 9.2 Change in forearm blood flow from baseline with infra-arterial
infusion of BQ123 (open circles), BQ788 (open squares) or the
combination of BQ123 and BQ788 (closed circles) following 8
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Figure 9.3 Change in augmentation index
9.5 DISCUSSION
This study has demonstrated that 8 weeks of statin therapy caused a trend towards a reduction
in arterial stiffness and increased vasodilatory responses to selective ETa receptor blockade.
There were no differences in responses to selective ETb receptor or combined ETa/b receptor
between the placebo and statin treatment periods.
Consistent with studies in healthy volunteers, selective ETa receptor blockade with BQ-123
increased forearm blood flow. However, there was a trend towards an increase in this
vasodilation after treatment with cerivastatin. These preliminary results are of interest and
there are several possible explanations. If the balance of effect at the ETB receptor is indeed
vasodilatation then the vasodilatation seen with ETA receptor blockade may have two
components, firstly the reduction in ET-1 tone mediated through the ETA receptor when
blocked and secondly there will be an increase in ETB receptor mediated vasodilatation due to
increased availability of ET-1 due to ET-1 displacement and reduction in the number of target
receptors. The trend towards an increase in ETA mediated vasodilatation following
cerivastatin would support the hypothesis that statin therapy increases NO mediated
vasodilatation via the ETB receptor, given that there is no difference between groups when the
ETB receptor is concomitantly blocked by combine BQ123 and BQ788 infusion. It has been
previously shown that hypercholesterolemia causes an impairment of NO mediated
vasodilation and that this can be at least partially reversed by lipid lowering therapy
[O'Driscoll et al 1997]. However, there may also be structural changes to the arterial wall
which would be less likely to be reversed after 8 weeks of lipid lowering and therefore a
longer treatment period may be expected to have greater effects. The potential interaction
between endothelin antagonists and statin therapy is of interest and deserves further
investigation.
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It should be noted that this was a small, underpowered study. Recruitment for this study was
difficult due to the long duration of the study and multiple study visits with 6 forearm blood
flow experiments in each volunteer. Furthermore, the product cerivasatin was withdrawn from




Differential haemodynamic effects of selective endothelin ETA and
dual ETa/b receptor blockade in patients with chronic heart failure
Leslie SJ, Spratt JC, McKee SP, Strachan FE, Newby DE, Northridge DB, Denvir
MA, Webb DJ. Direct comparison of selective endothelin ETA and non-selective
ETa/b receptor blockade in chronic heart failure. Heart 2004 (in press).
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10.1 SUMMARY
The aim of this study was to investigate the potential differential effects of selective
endothelin A (ETA) and dual endothelin A and B (ETa/b) receptor blockade in
patients with chronic heart failure. Nine patients with chronic heart failure (NYHA
grade II/III) each received intravenous infusions of BQ-123 alone (selective ETA
blockade), and combined BQ-123 and BQ-788 (dual ETa/b blockade) in a
randomized, placebo-controlled, three-way cross-over study. Selective ETA blockade
increased cardiac output (max. 33±12%, p<0.001), and reduced mean arterial
pressure (max. -13±4%, p<0.001) and systemic vascular resistance (max. -26±8%,
p<0.001), without changing heart rate (p=0.38). Dual ETa/b blockade significantly
reduced the changes in all these haemodynamic variables compared with selective
ETa blockade (p<0.05). Selective ETA blockade reduced pulmonary artery pressure
(max. 25±7%, p=0.01) and pulmonary vascular resistance (max. 72±39%, p<0.001).
However, there was no difference between these effects and those seen with dual
ETa/b blockade. Unlike selective ETA blockade, dual ETa/b blockade increased
plasma endothelin-1 concentrations (by 47±4% low dose and 61 ±8% high dose,
p<0.05). Whilst there appeared to be similar reductions in pulmonary pressures with
selective ETA and dual ETa/b blockade, selective ETA blockade causes greater
systemic vasodilatation and did not affect endothelin-1 clearance. We conclude that
there are significant haemodynamic differences between selective ETA and dual
ETa/b blockade, which may determine responses in individual patients.
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10.2 BACKGROUND
Endothelin-1 (ET-1) is a potent endogenous vasoconstrictor in man and contributes
to the maintenance of basal vascular tone [Haynes et al 1994b] and blood pressure
[Haynes et al 1996] in healthy people and patients with hypertension [Krum et al
1998]. It acts through two receptor subtypes; the endothelin A (ETA) and endothelin
B (ETb) receptors. While both receptors are expressed on vascular smooth muscle
cells and mediate vasoconstriction, only the ETB receptor is located on the
endothelium where it produces a prostanoid and nitric oxide mediated vasodilation.
Thus, ETb receptor mediated effects are complex, and include vasoconstriction,
endothelium dependent vasodilation and a role in the clearance of ET-1. In healthy
subjects, in contrast to the vasodilator and vasodepressor effects of ETA receptor
blockade [Verhaar et al 1998, Spratt et al 2001], systemic ETb receptor blockade has
vasoconstrictor and pressor effects [Strachan et al 1999], suggesting that the vascular
balance of basal ETB receptor activation favors vasodilation.
Chronic heart failure is associated with neurohumoral activation as a consequence of
reductions in cardiac reserve, systemic blood pressure and renal perfusion. This leads
to peripheral vasoconstriction, increased systemic vascular resistance, and sodium
and water retention, that together increase cardiac work and further compromise
cardiac performance. Many regulatory mechanisms are involved in this maladaptive
response, including the renin-angiotensin, sympathetic nervous and vasopressin
systems. The endothelin system also appears to contribute to the pathophysiology of
heart failure, which is associated with increased plasma ET-1 concentrations [Hiroe
et al 1991, McMurray et al 1992] that correlate with changes in haemodynamics
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[Cody et al 1992, Wei et al 1994], reduced exercise capacity [Krum et al 1995] and a
poor prognosis [Pousset et al 1997].
In patients with chronic heart failure, systemic administration of both selective ETA
[Cowburn et al 1998a, Givertz et al 2000, Speiker et al 2000] and dual ETa/b
blockade [Kiowski et al 1995, Packer et al 1998, Sutsch et al 1998, Schalcher et al
2001] reduces systemic vascular resistance and increases cardiac output. In patients
with acute decompensated heart failure systemic administration of dual ETa/b
blockade has been shown to have beneficial effects [Torre-Amione et al 2003],
However, systemic ETb blockade increases systemic vascular resistance and has
potentially detrimental effects in patients with chronic heart failure [Cowbum et al
2001]. Therefore, the question arises as to whether selective ETA or dual ETa/b
blockade is likely to be the favored therapeutic approach in patients with heart
failure. However, to date, there have been no direct studies comparing these two
approaches.
10.3 AIMS
The aims of this placebo-controlled study, in patients with stable chronic heart
failure, were to compare in a head-to-head manner the effects of selective ETA




Nine patients with chronic heart failure (New York Heart Association Grade II/III)
due to left ventricular dysfunction were recruited if they had an ejection fraction <
35% (by echocardiography using the biplanar Simpson's rule) and had been stable on
treatment, including angiotensin converting enzyme inhibitor or angiotensin receptor
antagonist therapy, for at least 3 months. Patient were all in sinus rhythm and no
patient had a pacemaker or implantable cardiac defibrillator. Patients were excluded
if they had insulin dependent diabetes mellitus, abnormal liver function, renal
impairment (creatinine > 200 pmol/L for men; >180 umol/L for women) or a
systolic blood pressure > 190 or < 90 mmHg or, within 3 months, had undergone
coronary artery bypass graft surgery, percutaneous coronary intervention or had an
acute coronary syndrome, myocardial infarction or cerebrovascular accident
The study was undertaken with the approval of the local research ethics committee
and in accordance with the Declaration of Helsinki. Written informed consent was
obtained from each subject before entry into the study.
10.4.2 Measurements
Blood pressure and heart rate were measured non-invasively using a DynamapTM
compact TS (Critikon LLC, Ascot, UK). Cardiac output, mean pulmonary artery
pressure, pulmonary artery wedge pressure and central venous pressure were
measured continuously using a single multi-lumen thermodilution cardiac output
pulmonary artery catheter (Swan-Ganz CCOmbo - CCO/SV02; Edwards
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Lifesciences LLC, Irvine California, USA). Cardiac output was calculated
automatically (Vigilence, Edwards Critical Care, Baxter's Healthcare Corporation,
Irvine, CA, USA) and, at each time point, the cardiac output was taken as the mean
of three measurements.
10.4.3 Protocol
All patients attended fasted at 7.30 am on three occasions at least one week apart.
Patients were asked to omit their regular medications on the morning of the study.
The studies were conducted in a quiet, draught free room maintained at a constant
temperature (22-24 °C). A pulmonary artery catheter was inserted, via a 9F femoral
venous sheath, into the right pulmonary artery and was flushed with 0.9%
heparinized saline. Before starting drug administration, patients underwent an
equilibration period of > 90 min until blood pressure, heart rate and cardiac output
were stable, with 3 consecutive measurements within 10%. Study drugs were
administered by 15 min infusion in 2 incremental doses 60 min apart. Although for
safety reasons an attending physician was not blinded to the treatment, all variables
were recorded in a double blind manner by separate investigators.
10.4.4 Drug administration
A venous cannula for drug administration was inserted under local anesthesia.
Pharmaceutical grade BQ-123 and BQ-788 (Clinalfa AG, Laufelfmgen, Switzerland)
were dissolved in 0.9% saline (Baxter Healthcare Ltd, Thetford, UK). On each study
day, patients received a low dose infusion at t = 0 for 15 min followed by a high dose
infusion at t = 60 min for 15 min. On different study days and in random order,
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patients received saline placebo, BQ-123 (low dose, 1.5 pmol; high dose, 15 pmol)
alone or the co-infusion of BQ-123 (low dose, 1.5 pmol; high dose, 15 pmol) and
BQ-788 (low dose, 0.45 pmol; high dose, 4.5 pmol). These doses were selected
following studies in healthy volunteers using BQ-123 and BQ-788. This dose of BQ-
123 was sufficient to reduce systemic vascular resistance and block the effects of
local infusion of ET-1 into the forearm [Spratt et al 2001]. This dose of BQ-788 was
sufficient to reduce systemic vascular resistance [Strachan et al 1999]. The detailed
rationale for these doses has been discussed elsewhere [Goddard et al 2002],
10.4.5 Blood sampling and plasma assays
Venous blood for ET-1 and big-ET-1 (the 38 amino-acid precursor of ET-1) assay
was taken from the femoral vein. Blood was collected into 0.16% EDTA (Sarstedt,
Aktiengesell Schaft & Co, Germany) and immediately separated by centrifugation
(2500 g for 20 min at 4°C) and stored at -80 °C until analysis. Following extraction
using Bond Elut® columns (Varian, Elarbor City, CA, USA), ET-1 (Peninsula
Laboratories Europe Ltd, St Helens, UK) and big ET-1 (Peninsula Laboratories
Europe Ltd) concentrations were determined by radioimmunoassay as previously
described [Newby et al 1998], The intra-assay coefficients of variability were 7.0
and 7.2% respectively and the inter-assay coefficients of variability were 9.0 and
9.3% respectively. These assays were performed by Mr Neil Johnston.
10.4.6 Data analysis and statistics
Data are expressed as change from baseline ± SEM or mean area under the curve
(AUC) ± SEM unless otherwise specified. Data were examined by analysis of
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variance (ANOVA) with repeated measures over time and Student's /-test with
correction for multiple measures where appropriate (Excel v5.0, Microsoft).
Statistical significance was taken at the 5% level.
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10.5 RESULTS
Baseline patient characteristics and medications are shown in Table 10.1. There were
no adverse events and the study was well tolerated by all patients. There were no
significant differences in baseline hemodynamic variables between study visits
(Table 10.2). Placebo administration caused no significant changes in hemodynamic
variables throughout the course of the study (ANOVA p>0.9).
10.5.1 Cardiac output and heart rate
In comparison to placebo, BQ-123 alone (AUC: p<0.001), but not BQ-123/788
(AUC: p=0.08), increased cardiac output with a maximum increase of 33±12% at 75
min. Infusion of BQ-123 alone increased cardiac output compared with BQ-123/788
(AUC: p<0.001) (Figures 10.1c & 10.3). There was no significant change in heart
rate with either BQ123 alone (AUC: p=0.38) or BQ-123/788 (AUC: p=0.39)
(Figures 10.1a & 10.3).
10.5.2 Left ventricular filling pressure and systemic hemodynamics
In comparison to placebo, BQ-123 alone (AUC: p=0.01) and BQ-123/788 (AUC:
p<0.01), reduced pulmonary artery wedge pressure by a maximum of 19±7% at 150
min and 26±7% at 105 min respectively (Figures 10.2c & 10.3). There was no
difference between the magnitude of reduction in pulmonary artery wedge pressure
between BQ-123 alone and BQ-123/788 (AUC: p=0.47). BQ-123 alone (AUC:
p<0.001) and BQ-123/788 (AUC: p<0.05) reduced mean arterial pressure by a
maximum of 14±5% and 12±4% respectively at 150 min. BQ-123 alone reduced
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mean arterial pressure to a greater degree than BQ-123/788 (AUC: p<0.05) (Figures
10.1b & 10.3).
BQ-123 alone (AUC: p<0.001) and BQ-123/788 (AUC: p<0.05) reduced systemic
vascular resistance by a maximum of 26±8% and 16±5% respectively at 75 min in
comparison to placebo. BQ-123 alone reduced systemic vascular resistance to a
greater degree than BQ-123/788 (AUC: p<0.05) (Figures 10.Id & 10.3).
10.5.3 Right ventricular filling pressure and pulmonary hemodynamics
In comparison to placebo, neither BQ-123 alone (AUC: p=0.17) or BQ-123/788
(AUC: p=0.69) changed central venous pressure (Figure 10.2a & 10.3). BQ-123
alone (AUC: p=0.01) and BQ-123/788 (AUC: p=0.02) reduced mean pulmonary
arterial pressure by a maximum of 25±7% and 26±6% respectively at 90 min. There
was no significant difference between these responses (AUC: p=0.98). (Figures
10.2b and 10.3).
In comparison to placebo, both BQ-123 alone and BQ-123/788 (AUC: both p<0.001)
reduced pulmonary vascular resistance by a maximum of 72±39% and 40±16%
respectively at 75 min. There was no significant difference between these responses
(AUC: p=0.49) (Figures 10.2d & 10.3).
10.5.4 Plasma ET-1 and big ET-1
There was no change in plasma concentrations of big ET-1 with placebo, BQ-123
alone or BQ-123/788. There was no significant change in plasma ET-1
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concentrations with placebo or BQ-123 alone, whereas BQ-123/788 caused an
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inmgexceptDigoxin(p )).
Parameter Placebo BQ123 BQ123 + BQ788
(n=9) (n=9) (n=9)
HR (bpm) 64 ±5 62 ±4 63 ±5
MAP (mmHg) 91 ±7 87 ±6 90 ±7
SBP (mmHg) 106 ±8 104 ±9 106 ±9
DBP (mmHg) 69 ±4 68 ±6 71 ±4
CVP (mmHg) 5 ± 1 5 ± 1 3 ± 2
CO (L/min) 5.0 ±0.3 5.5 ±0.4 5.3 ±0.3
SVR (dynes.sec/cm"5) 1462±150 1266±138 1344±138
MPAP (mmHg) 16 ± 1 16 ± 1 17 ± 2
PAWP (mmHg) 11 ±2 11 ± 1 12 ± 3
PVR (dynes.sec/cm"5) 83 ± 12 91 ± 14 78 ± 18
Table 10.2 Baseline parameters
Heart rate (HR), mean arterial pressure (MAP), systolic blood pressure (SBP),
diastolic blood pressure (DBP), central venous pressure (CVP), cardiac output (CO),
systemic vascular resistance (SVR), mean pulmonary artery pressure (MPAP),
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10.6 DISCUSSION
In this randomised placebo-controlled crossover study, we have shown that there are
significant haemodynamic differences between the responses to selective ETA and
dual ETa/b receptor blockade in patients with chronic heart failure. Both selective
ETa and dual ETa/b receptor blockade increased cardiac output and reduced mean
arterial pressure and systemic vascular resistance. However, selective ETA receptor
blockade caused a greater increase in cardiac output and reduction in systemic
vascular resistance than dual ETa/b receptor blockade. In contrast, selective ETA and
dual ETa/b blockade caused similar reductions in both pulmonary artery pressure and
pulmonary vascular resistance. There was a greater reduction in pulmonary artery
pressure with dual blockade compared with selective ETA blockade after low dose
infusion although this difference was not apparent after high dose infusion.
This study directly compared systemic selective ETA and dual ETa/b blockade in
patients with heart failure. Our findings are consistent with other short-term studies
which have demonstrated that both selective ETA [Speiker et al 2000] and dual ETa/b
[Sutsch et al 1998, Schalcher et al 2001, Torre-Amione et al 2003] blockade increase
cardiac output and reduce systemic vascular resistance, importantly with no change
in heart rate. Both selective ETA [Givertz et al 2000, Speiker et al 2000] and dual
ETa/b [Sutsch et al 1998, Schalcher et al 2001, Torre-Amione et al 2003] blockade
also reduce pulmonary vascular resistance and pulmonary artery wedge pressure.
Comparing magnitude of response between different endothelin antagonists in
different patient populations is difficult but we have demonstrated in this head-to-
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head study that selective endothelin blockade had greater effects on the systemic
vasculature than dual endothelin antagonism.
There is increasing evidence that the ETB receptor has a role in the clearance of
plasma ET-1. Plasma ET-1 concentration increases following systemic selective ETB
blockade in healthy subjects [Strachan et al 1999] and following dual ETa/B blockade
in healthy subjects [Plumpton et al 1996, Krum et al 1998] and patients with chronic
heart failure [Kioski et al 1995, Plumpton et al 1996, Krum et al 1998, Sutsch et al
1998]. However, the effects of systemic ETA blockade alone are less consistent with
little, if any, increase in plasma ET-1 concentrations in most studies, [Verhaar et al
1998, Cowburn et al 1998a, Givertz et al 2000] although one study did report an
increase at higher degrees of ETA blockade [Speiker et al 2000]. These results are
confirmed in our study, in which selective ETA receptor blockade had no effect on
plasma ET-1 concentrations whereas they were increased by dual blockade. Because
there was no change in plasma big ET-1 concentration, elevation of plasma ET-1 is
likely to reflect interference with its clearance rather than an increase in its synthesis
and release. Thus, selective ETA blockade has a theoretical benefit of leaving the
endothelin clearance receptor (ETb) functional. Nevertheless, if the ETA receptor is
also effectively blocked, during ETb receptor blockade, then the high circulating
concentrations of ET-1 may not be of clinical importance.
Although selective ETA receptor blockade had greater effects on systemic vascular
resistance, there may be clinical situations in which blockade of the ETB receptor is
desirable. There is a higher density of ETB receptors in the pulmonary vasculature,
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and these may be upregulated in pulmonary arterial hypertension [McCulloch et al
1995]. Also, endothelin-1 release across the pulmonary vascular bed correlates
strongly with the pulmonary vascular resistance in chronic heart failure [Tsutamoto
et al 1994], Raised pulmonary artery pressure is an independent risk factor in chronic
heart failure and responds poorly to conventional therapies. Here, we demonstrated
that both selective ETA and dual ETa/b receptor blockade reduced pulmonary artery
pressures.
Endothelin antagonism might, therefore, be of benefit in patients with heart failure
and raised pulmonary artery pressures. Indeed, the dual antagonist, bosentan, has
recently been approved for use in the treatment of primary pulmonary arterial
hypertension based on its effectiveness in this situation. The long-term clinical
effects of endothelin receptor blockade in patients with pulmonary hypertension
secondary to chronic heart failure are unknown but it is tempting to speculate that it
may also be more effective in this setting. We have failed to demonstrate
convincingly whether there are true haemodynamic differences between selective
ETa and dual ETA/b receptor antagonism in the pulmonary circulation. However,
none of the patients in the present study had significant pulmonary hypertension. We
believe that the role of endothelin antagonism now warrants further careful
assessment in a much larger trial of patients with both heart failure and a significant
degree of pulmonary hypertension.
Many studies use agents that, while termed 'selective' or 'dual' inhibitors of ETA and
ETb receptors, have a range of receptor selectivities, mostly inhibiting the ETA
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receptor at much lower concentrations than at the ETB receptor [Goddard et al 2002],
In this study we have used two receptor antagonists, BQ-123 and BQ-788, given
separately, and with selectivity for the ETA and ETB receptor respectively. Therefore,
it is important to recognize that we have examined mechanistically the influence of
major blockade of the ETB receptor on responses to full ETA blockade. This may not
exactly represent the clinical situation that exists with dual antagonists, such as
bosentan, which are relatively selective for the ETA receptor (ETA : ETB selectivity >
10). The doses of BQ-123 given here have been shown to produce maximum
systemic haemodynamic effects, and block responses to forearm artery infusion of
ET-1, but not to increase plasma ET-1 concentrations. Given that BQ-123 caused
greater systemic vasodilatation than the combination with BQ-788, the overall
hemodynamic effect of ETB blockade in patients with heart failure is likely to be
vasoconstriction, a finding consistent with other work [Love et al 2000, Cowburn et
al 2001].
This was an acute haemodynamic study and we have not assessed whether these
effects are sustained in the long-term. Nevertheless, previous haemodynamic studies
indicate that the acute effects of both selective ETA [Luscher et al 2002] and dual
[Sutsch et al 1997] endothelin receptor blockade are maintained or enhanced over
several weeks and therefore likely to be sustained. The clinical impact of these
haemodynamic changes is, of course, uncertain and can only be clarified in the
context of large-scale clinical outcome studies. We have demonstrated that selective
ETa blockade causes more marked systemic vasodilatation than dual ETA/B receptor
blockade in NYHA grade II/III patients with heart failure. To date, there have been
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only two, as yet unpublished, large scale, randomized controlled trials of endothelin
receptor blockade in patients with heart failure (NYHA grade III/IV), both of which
have demonstrated no major clinical benefit of either bosentan (ETA: ETB selectivity
-10) [Coletta et al 2002] or darusentan (ETA : ETB selectivity > 500) [Luscher et al
2002],
It should be noted that some of these patients would be considered now to be
'undertreated'. In particular the poor use of beta-blockers and the persistent
hypertension, may affect the applicability of these results to more contempory
cohorts of heart failure patients. Furthermore, these patients had mild to moderate
rather than severe heart failure which may limit the applicability of these results to
all heart failure populations. In addition, aspirin use may confound results. Aspirin
by inhibiting cyclo-oxygenase will reduce PGE2 and PGI2 reducing the potential
vasodilator effects of ETB receptor blockade. Nevertheless, the majority of patients
with heart failure will also have coronary artery disease and aspirin is integral to
standard treatment in these patients.
Conclusions
In this study both selective ETA and dual ETA/B blockade caused acute systemic and
pulmonary haemodynamic changes in patients with heart failure. However, important
differences exist and selective ETA blockade causes greater systemic haemodynamic
effects than dual ETA/b blockade. There is now a need for further trials to determine
whether selective or dual endothelin antagonism has greater potential efficacy in the





This thesis represents a study of the role of the endothelin system in health and
disease. In addition to studies of whole body haemodynamics, I have attempted to
assess its role in specific vascular beds (i.e. skin, pulmonary) and in specific tissues
(myocardium). Using a range of techniques, some of which I have developed and
validated, I have demonstrated the diverse and complex role of the endothelin system
in health and disease. The key findings and their implications for therapeutic option
are discussed in this final chapter.
Since its discovery [Yanagisawa et al 1988], the endothelin system has been
extensively investigated and although much is known, important questions remain
unanswered, not least being whether pharmacological manipulation of the endothelin
system in disease states will prove to be beneficial to patients.
11.2 Techniques to investigate the cardiovascular system
In order to investigate vasosactive compounds in the preclinical setting, especially
when the cardiovascular effects are unknown, various techniques are required. The
relative merits of in vitro versus in vivo and local versus systemic techniques in the
investigation of the cardiovascular system were discussed in Chapter 2. This thesis
has used and evaluated several such techniques including isolated myocardial
trabeculae force experiments (Chapter 8), skin blood flowmetry (Chapter 6), forearm
plethysmography (Chapter 9), systemic haemodynamic techniques and
neurohormonal assays (Chapter 10)
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Skin blood flowmetry, forearm plethysmography and systemic haemodynamic
techniques have been validated in Chapters 3, 4 and 5 respectively. In addition, a
new assay for the measurement of ET-l[i_3i] was assessed in Chapter 7.
11.2.1 Skin blood flowmetry
The data in Chapter 3 demonstrated that skin blood flowmetry coupled with intra¬
dermal injection of vasoactive compounds offers a reasonably reproducible technique
when large vasoactive molecules, which cannot be delivered by other techniques
such as iontophoresis. In addition, the skin microcirculation offers an advantage over
systemic studies in that small doses of compound can be used and multiple sites
employed simultaneously, making this a relatively safe and well tolerated technique
for in vivo human studies. This technique was subsequently employed in Chapter 6 to
investigate the vasoactive effects of ET-1, big ET-1, BQ123 (selective ETA receptor
antagonist), BQ788 (selective ETB receptor antagonist), phosphoramidon (ECE/NEP
inhibitor) and the recently discovered ET-l[i_3i].
11.2.2 Forearm plethysmography
There continue to be advances in the design of devices for measuring forearm blood
flow. The advantage of forearm plethysmography, especially when coupled with
intra-arterial brachial infusion is that resistance vessels can be studied, in isolation, in
vivo. In Chapter 4, a newly developed device, Filtrass 2001, was validated against the
established Hokanson HEC4. Each device was compared with itself and the other to
give a measure of repeatability and to assess systematic bias. The devices were
assessed over a range of blood flows. Small (-30%) increases and decreases in blood
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flow were achieved using Stroop's coloured word test and lower body negative
pressure respectively. Greater increases in blood flow (up to 800%) were achieved by
graded arterial occlusion resulting in post occlusive hyperaemia. Although the
Filtrass 2001 offered some practical advantages over the HEC4 such as automated
data analysis and a more compact unit of smaller size, there were no important
advantages in terms of repeatability and therefore for subsequent experiments in
Chapter 9, the established HEC4 was used. The use of blood flow in the dominant
forearm as a contemporaneous control for the effects on blood flow in the non-
dominant arm and of intra-arterial drug infusion is widely used in the technique of
forearm plethysmography [Benjamin et al 1995, Wilkinson & Webb 2001]. This is
supported by this study with only -1% difference in percentage change in FBF from
baseline between left and right arms when measured by the HEC4.
11.2.3 Systemic haemodynamic monitoring
There is no 'perfect' method for measuring cardiac output although the technique of
thermodilution is considered the 'gold standard'. However, due to the invasive nature
of pulmonary artery catheterisation there is considerable interest in the non-invasive
technique of thoracic bioimpedance. Thoracic bioimpedance has the advantage that it
is relatively inexpensive and easy to use. However, its accuracy has been questioned.
In Chapter 10, invasive haemodynamic monitoring using a pulmonary artery catheter
and thermodilution was employed to monitor systemic effects of endothelin
antagonism in patients with CHF. The opportunity was taken to assess the non¬
invasive technique of thoracic bioimpendance against invasive thermodilution
measurements. Thoracic bioimpedance has been previously assessed in unstable
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patients in the clinical setting and in patients with stable patients undergoing routine
investigation. In Chapter 5 the use of thoracic bioimpendance during an acute
pharmacological intervention designed to alter systemic haemodynamics is reported.
This study compared the techniques of thoracic bioimpedance against thermodilution
in stable patients with chronic heart failure undergoing an acute haemodynamic
intervention study (Chapter 10). A previous meta-analysis of thoracic bioimpedance
studies found a correlation between thoracic bioimpedance and reference techniques
(r = 0.66) [Fuller 1992], In keeping with these studies we have found a reasonable
correlation between thoracic bioimpedance and a thermodilution technique (r =
0.76). However, while there is a positive correlation between the techniques, there is
a poor overall level of agreement. The method of thoracic bioimpedance
systematically underestimated cardiac output compared with thermodilution, and this
difference appeared to be greater with higher cardiac output. Several studies have
supported the use of thoracic bioimpedance when measuring intra-patient trends in
cardiac output [Northridge et al 1990, Thomas et al 1992, Koobi et al 1997, Salandin
et al 1988, Belardinelli et al 1996, Barin et al 2000], However, the results in Chapter
5 do not support this finding with poor agreement between values when expressed as
percentage change from baseline despite reasonable repeatability of baseline
measurements.
We observed an unacceptably low level of agreement both for absolute and
percentage changes in cardiac output. Previous studies have assessed thoracic
bioimpedance in critically ill patients or patients after mechanical ventilation or
undergoing cardiac surgery. Pulmonary oedema and mechanical ventilation can
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affect thoracic bioimpedance and many previously studied patients may have been
unsuitable for measurement of cardiac output by thoracic bioimpedance. The patients
in Chapter 5 had stable chronic heart failure, were in sinus rhythm and in the
controlled setting of an acute haemodynamic intervention study. It was expected that
these optimal conditions would provide the best opportunity for thoracic
bioimpedance to be comparable with the gold standard of thermodilution, given that
patients were stable, self-ventilating and had no pulmonary oedema. However, the
poor agreement found suggests that thoracic bioimpedance is not comparable to
thermodilution even in patients with stable chronic heart failure.
11.3 The endothelin system in healthy man
The vascular effects of endothelin are mediated through 2 receptors. The ETa and
ETb receptors are both found on the vascular smooth muscle cell mediating
vasoconstriction. However, the ETB receptor is also found on the endothelial cell
where it causes a nitric oxide and prostanoid mediated vasodilatation. Thus, the net
effect of endothelin agonism will be a balance between these vasoconstricting and
vasodilating effects.
In healthy individuals, under resting conditions, endothelin plays an important role in
the maintenance of normal vascular tone [Haynes et al 1994b], mostly via the ETa
receptor as blockade of the ETA receptor, results in vasodilation in forearm blood
flow studies and in systemic studies a reduction in systemic vascular resistance and
blood pressure. Furthermore, clinical studies have demonstrated that selective ETA
and dual ETa/b receptor blockade results in sustained reductions in blood pressure in
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both healthy patients and patients with essential hypertension. However, to date there
have been no head to head clinical studies comparing selective with dual blockade.
In addition, there are concerns regarding elevations in liver enzymes and currently
there are no endothelin antagonists licensed for hypertension. Due to the large
number of currently available antihypertensive agents, many with good tolerability
and evidence of mortality benefits, it could be argued that it is difficult to envisage a
role for endothelin antagonists in the treatment of systemic hypertension. An
alternative strategy might be the blockade of endothelin production. To date, there
have not been any large scale clinical trials involving selective endothelin converting
enzyme inhibitors although combined ACE, NEP and ECE inhibitors are under
investigation as alternative vasodilator agents. Given the disappointing results of
trials involving endothelin receptor antagonists, this alternative strategy may be of
interest.
11.3.1 Endothelins in the healthy human skin microcirculation
In Chapter 6, in the human skin microcirculation, I have confirmed that ET-1 [1-21] is a
potent vasoconstrictor and shown for the first time that ET-1 [1.31] and big ET-l[i_3g]
also cause skin vasoconstriction in vivo. These results suggest that there is ECE
activity in the skin as demonstrated by the vasoconstriction following intradermal
administration of big ET-lp.38] and vasodilatation with ECE inhibition. In addition,
we have confirmed that selective blockade of the ETA receptor caused skin
microvasculatory vasodilatation [Wenzel et al 1998] and that selective blockade of
the ETb receptor also results in vasodilatation. In contrast to observations in
resistance vessels, this suggests that ETB receptors in the skin contribute to ET-1
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mediated vasoconstriction not only in arterial disease [Wenzel et al 1998] but also in
healthy blood vessels.
11.3.1.1 big ET-1 [i-38i
Given that big ET-1 [i-38] has affinity for the endothelin A receptor which is 1000 fold
less than ET-1 [i_2i] [Ishikawa et al 1994], and that big ET-lp-38] is ~30 fold less
potent than ET-1 [ 1.21] it is unlikely that big ET-1 [i_38] causes a major direct
vasoconstrictor action and suggests that there is some conversion of big ET-1 to ET-
1 [i-2i] in the skin. It has previously been demonstrated that big ET-1 [i-38] is vasoactive
in human arteries [Haynes et al 1994b] but not veins [Haynes et al 1995] and that
this vasoconstriction can be blocked by ECE inhibition [Haynes et al 1994], The
presence of ECE activity in the skin is further supported in this present study by the
vasodilatory effects of phosphoramidon. This is also consistent with preliminary
clinical studies where systemic ECE inhibition caused systemic vasodilatation and a
reduction in blood pressure [de Voogd et al 2001]. In our study there appeared to be
a transient vasoconstriction to phosphoramidon although this was not consistent and
did not reach statistical significance. This observation may warrant further
investigation.
11.3.1.2 ET-lu.3,1
The novel finding that ET-1 [i_3i] is a vasoconstrictor is of interest, and the first
evidence of its vasoactive properties in vivo in man. If ET-1 [1.31] is converted to ET-1
[i-2i] by a non-ECE pathway and if this contributes importantly to ET-1 generation
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then specific receptor blockade may offer greater functional activity than ECE
inhibition. Alternatively, ET-1 [i_3i] may have vasoconstricting activity of its own at
endothelin receptors. Recently, the vasoconstricting effects of ET-1 [i_3i] have been
shown to be mediated via the ETA receptor in rabbit renal resistance vessels [Ozawa
2003], an effect which was unaffected by phosphoramidon. Although ET-1 [i_3i] is
less potent than ET-l[i.2i], as a vasoconstrictor, local production of ET-1 [1-31] may
occur specifically in tissues that express human chymase, such as from the mast cells
within the shoulder region of coronary atheromatous plaques [Kaartinen et al 1994,
Kovanen et al 1995]. Therefore, generation of ET-1 [ 1.31 ] could contribute to coronary
artery spasm at the time of plaque rupture. Indeed, ET-1 [i_3i] may be cleaved to ET-
1 [i-2i] for its biological activity in cultured bronchial smooth muscle cells [Hayasaki-
Kajiwara et al 1999] and in both guinea-pig [Honore et al 2002] and human arteries
[Maguire et al 2001],
11.3.1.3 ET antagonists
Endothelin antagonists have been studied in the skin by other groups. The selective
ETa receptor antagonist PD147953 and the non-selective endothelin receptor
antagonist PD 145065 caused vasodilatation and attenuated the vasoconstrictor
effects of ET-l[i_2i] in the human skin in vivo [Wenzel et al 1994 & 2001]. BQ-123 is
a selective ETA receptor antagonist and has been shown in many vascular beds
[Berrazueta et al 1997] to be a vasodilator by blocking the effects of ET-1 [1-21]- The
data form Chapter 7 demonstrates that BQ-123 causes vasodilatation, confirming that
ET-1 contributes to the maintenance of basal vascular tone in the skin of healthy
volunteers. BQ-788 also caused skin vasodilatation. This result was unexpected as
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selective ETb receptor antagonism causes vasoconstriction in skeletal muscle
[Verhaar et al 1998] and when given systemically [Strachan et al 1999]. In addition,
previous data in the skin microcirculation have demonstrated that ET-1 mediates
vasoconstriction via the ETA receptor with little contribution from the ETb receptor
[Wenzel et al 2001, Lipa et al 1999]. However, our data indicate that the dominant
effect of ET-1 [i-2i] on the ETb receptor is vasoconstriction in the human skin
microcirculation, and that blockade of the ETB receptor results in vasodilatation. It is
possible that some of this effect may be a result of displacement of ET-1 from ETB
receptors and a reduction of available binding sites, thereby increasing
vasoconstriction via the ETA receptor.
Endothelin receptor antagonists have proven benefits in patients with primary
pulmonary hypertension [Channick et al 2001] and reduce blood pressure in
hypertensive patients [Krum et al 1998], To date, clinical trials investigating the
potential benefits of endothelin receptor antagonists in CHF have been disappointing
[Coletta et al 2002], ECE inhibitors inhibit endothelin production and may provide a
potential alternative to endothelin receptor antagonism. Unlike receptor blockade
which can increase plasma ET-1 [1-21] concentrations, ECE inhibitors have the
advantage that they block ET-1 [i_2i] production, thus reducing plasma ET-1 [1-21]
concentrations and leaving clearance receptors unblocked. However, the effects of
raised plasma concentration of ET-1 [1-21], associated with ETb receptor blockade
[Verhaar et al 1998], may not be relevant if ETA receptors are also blocked.
However, if there are clinically significant non-ECE pathways of production with
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vasoactive intermediary peptides such as ET-lp.31] then ECE inhibition may be a less
attractive treatment strategy.
In summary, the discovery of a vasoactive intermediary endothelin peptide may have
importance for the further development of endothelin blockers as clinical therapies.
Further studies are required to determine whether ET-lp.31] is vasoactive in other
vascular beds.
11.4 Endothelin antagonists in cardiovascular disease
While the dual ETa/b receptor antagonist bosentan has been investigated in patients
with essential hypertension and shown to have sustained blood pressure lowering
effects, it has not gained a licence for clinical use, probably due to concerns
regarding liver toxicity and the range of alternative vasodilators of proven efficacy in
this patient group. However, bosentan does have a licence for the treatment of
primary pulmonary hypertension. Primary pulmonary hypertension has a poor
prognosis and current treatment options are limited. However, morbidity benefits
following treatment with Bosentan were recently demonstrated with a reduction in
breathlessness and increased walking distances.
11.4.1 Chronic heart failure: selective vs dual blockade
Chronic heart failure is characterised by increased peripheral vasoconstriction and by
increased concentrations of big ET-1 and ET-1. There have been several studies in
patients with heart failure investigating the effects of selective ETA and dual ETa/b
receptor antagonists although no direct head to head comparisons. In Chapter 10,
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acute haemodyanamic differences were found between selective ETA and dual ETa/b
receptor antagonism. Disappointingly, recent clinical trials were unable to
demonstrate significant clinical benefit with longer term treatment with either
selective ETA or dual ETA/B receptor antagonist. Again, the disappointing results in
patients with CHF on standard therapy makes it unlikely that endothelin antagonists
will ever be used for the general treatment of CHF. However, there may be subsets of
patients who will benefit from endothelin blockade, particularly patients who may be
intolerant of other neuroendocrine blockade such as ACE inhibitors or beta blockers.
In addition, ETRAs may be of use in patients in whom the endothelin system is
particularly elevated or in patients with concomitant pulmonary hypertension. In
Chapter 10, the acute haemodynamic effects of selective ETA versus dual ETA/B
receptor antagonism were studies in patients with stable chronic heart failure on
standard medication. There were significant hemodynamic differences between the
responses to selective ETA and dual ETA/B receptor blockade in patients with chronic
heart failure. Both selective ETA and dual ETa/B receptor blockade increased cardiac
output and reduced mean arterial pressure and systemic vascular resistance.
However, selective ETA receptor blockade caused a greater increase in cardiac output
and reduction in systemic vascular resistance than dual ETa/b receptor blockade. In
contrast, selective ETA and dual ETA/B blockade caused similar reductions in both
pulmonary artery pressure and pulmonary vascular resistance. There was a greater
reduction in pulmonary artery pressure with dual blockade compared with selective
ETa blockade after low dose infusion although this difference was not apparent after
high dose infusion.
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Comparing magnitude of response between different endothelin antagonists in
different patient populations is difficult but these data have demonstrated in this
head-to-head study that selective endothelin blockade had greater effects on the
systemic vasculature than dual endothelin antagonism.
11.4.2 The ETb receptor is a clearance receptor
There is increasing evidence that the ETB receptor has a role in the clearance of
plasma ET-1. In keeping with previous work, selective ETa receptor blockade had no
effect on plasma ET-1 concentrations whereas they were increased by dual blockade
(Chapter 10). Because there was no change in plasma big ET-1 concentration,
elevation of plasma ET-1 is likely to reflect interference with its clearance rather than
an increase in its synthesis and release. Thus, selective ETA blockade has a
theoretical benefit of leaving the endothelin clearance receptor (ETB) functional.
Nevertheless, if the ETA receptor is also effectively blocked, during ETB receptor
blockade, then the high circulating concentrations of ET-1 may not be of clinical
importance.
11.4.3 Clinical implications of selective ETA vs ETA/B blockade
Although selective ETA receptor blockade had greater effects on systemic vascular
resistance, there may be clinical situations in which blockade of the ETB receptor is
desirable. There is a higher density of ETB receptors in the pulmonary vasculature,
and these may be upregulated in pulmonary arterial hypertension [McCulloch et al
1995], Also, endothelin-1 release across the pulmonary vascular bed correlates
strongly with the pulmonary vascular resistance in chronic heart failure [Tsutamoto
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et al 1994], Raised pulmonary artery pressure is an independent risk factor in chronic
heart failure and responds poorly to conventional therapies. Here, we have
demonstrated that both selective ETA and dual ETa/b receptor blockade reduced
pulmonary artery pressures.
Endothelin antagonism might, therefore, be of benefit in patients with heart failure
and raised pulmonary artery pressures. Indeed, the dual antagonist, bosentan, has
recently been approved for use in the treatment of primary pulmonary arterial
hypertension based on its effectiveness in this situation. The long-term clinical
effects of endothelin receptor blockade in patients with pulmonary hypertension
secondary to chronic heart failure are unknown but it is tempting to speculate that it
may also be more effective in this setting. We have failed to demonstrate
convincingly whether there are true haemodynamic differences between selective
ETa and dual ETa/b receptor antagonism in the pulmonary circulation. However,
none of the patients in the present study had significant pulmonary hypertension. We
believe that the role of endothelin antagonism now warrants further careful
assessment in a much larger trial of patients with both heart failure and a significant
degree of pulmonary hypertension.
The clinical impact of these haemodynamic changes is, of course, uncertain and can
only be clarified in the context of large-scale clinical outcome studies. In Chapter 10
it was shown that selective ETA blockade caused more marked systemic
vasodilatation than dual ETa/b receptor blockade in NYHA grade II/III patients with
heart failure. To date, there have been only two, as yet unpublished, large scale,
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randomized controlled trials of endothelin receptor blockade in patients with heart
failure (NYHA grade III/IV), both of which have demonstrated no major clinical
benefit of either bosentan (ETA: ETB selectivity ~ 10) [Coletta et al 2002] or
darusentan (ETA : ETB selectivity > 500) [Luscher et al 2002].
In this study both selective ETA and dual ETVs blockade cause acute systemic and
pulmonary haemodynamic changes in patients with heart failure. However, important
differences exist and selective ETA blockade causes greater systemic haemodynamic
effects than dual ETA/B blockade. If ET antagonists are to have a future as therapies,
there is now a need for further trials to determine whether selective or dual
endothelin antagonism has greater potential efficacy in the treatment of patients with
heart failure. Indeed there may be subsets of patients with differential activation of
neurohormonal systems which would show greater benefit from endothelin blockade.
11.4.4 ET-1 [i_3i | in patients with chronic heart failure
Plasma big ET-1 concentrations are elevated in patients with CHF and correlate with
disease severity [Wei et al 1994], In Chapter 7 plasma from a different cohort of
patients with heart failure was compared with age and sex matched controls. Plasma
concentrations of big ET-1 were found to be elevated, consistent with these prior
data [Wei et al 1994], although plasma ET-1 [ i -2 i ] concentrations were not elevated.
This was unexpected as plasma ET-l[i_2i] concentrations are also reported to be
elevated in patients with chronic heart failure [Wei et al 1994]. However, big ET-l[i_
38] plasma concentrations are a more reliable marker of chronic heart failure and, in
our study, these were increased by ~2 fold. We have also recruited stable patients
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who were well controlled on medical therapy. It is likely, therefore, that our patient
population had less neurohormonal activation and may have had less generation of
big ET-1 [i-38] than those enrolled into previous studies.
In patients with chronic heart failure, there does not appear to be a general increase
in generation of ET-lp-31]. This study does not however exclude the possibility of
local increases in ET -111.31 ] production, such as within areas of inflammation.
Moreover, local ET-1 [1-31] generation may be specific to those tissues with increased
chymase activity such as failing human myocardium [Urata et al 1990], In addition,
increased chymase activity is seen in mast cells at the shoulder regions of coronary
atheromatous plaques [Kovanen et al 1995, Kaartinen et al 1994], and ET-1 [ 1-31] may
be implicated in the aetiology of coronary artery spasm at the time of plaque rupture.
Further studies are clearly required to determine how ET-1 is processed and to
identify situations where increased local ET-l[i_3i] generation may occur.
In conclusion, data in Chapter 7 have shown that plasma ET-l[i_3i] concentrations
can be measured reliably but, in contrast to big ET-1 [ 1 -38], do not appear to be
elevated in patients with heart failure. These data suggest that ET-1 [ 1 -31 ] may not be
useful as a predictive test and that generation is not sufficient to increase circulating
plasma concentrations in patients with stable chronic heart failure.
However, current assessment of patients with heart failure does not include detailed
neuroendocrine assessment and whether there are subsets of patients with
preferential activation of either endothelin, angiotensin or beta-adrenergic systems is
2]7
unknown. Indeed, these systems interact in a complex manner which may not be the
same in different patients groups. In Chapter 8, data from isolated human
myocardium demonstrated that there may be antagonism between the endothelin and
beta-adrenergic stimulation. Thus, in certain situations, elevated endothelin
concentrations may actually be protective, and associations between severity and
prognosis in heart failure may represent associations due to beneficial adaptations
rather than a causal link.
11.5 Effects of the ET and beta-adrenergic system in the heart
In Chapter 8, interaction between the endothelin and beta-adrenergic system were
investigated and the results discussed. This study confirmed that ET-1 and beta-
adrenergic stimulation increases force of contraction in isolated human myocardium,
but that ET antagonism does not appear to affect basal tone in isolated myocardium,
suggesting either that there is no resting ET-1 mediated inotropy or that this
mechanism is saturated at baseline. We have observed, for the first time, that ET-1
functionally attenuates the inotropic effects of isoprenaline in human myocardium.
This reduction in force was observed after maximal stimulation of the beta-
adrenergic system. The underlying mechanism is likely to be interaction at the level
of adenylate cyclase as seen in isolated membrane studies where ET-1 was shown to
inhibit the effect of betai-adrenoceptor activation on this enzyme.
These results suggest that, in the human myocardium, ET-1 functionally antagonises
the effects of beta-adrenergic stimulation. However, care should be taken when
interpreting these results as supra-physiological concentrations of agonists were
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used, although, it appears that there is functional antagonism between these two
hormone systems, presumably at the level of receptor, or post receptor cross-talk.
11.5.1 Clinical implications
The results of this study may have important consequences in conditions such as
CHF where both ET-1 and the beta-adrenergic systems are up-regulated and drugs
blocking their actions are being developed. Catecholamine release and therefore
beta-adrenergic stimulation is increased in CHF and also in episodes of acute heart
failure and acute coronary syndromes. This can lead to increases in arrythmias and
sudden cardiac death, the most common cause of death in patients with CHF. In CHF
there is a reduced responsiveness to beta-agonists, probably due to combination of
reduced receptor number and post receptor changes. It could be that some of these
changes are due to an interaction with the ET system which is also up-regulated in
CHF. The importance of this interaction may be that ET-1 while a marker of disease
severity in CHF actually protects against catecholamine stimulation. It is known that
catecholamine blockade with drugs such as beta-blockers confers mortality and
morbidity benefits. With the possible future introduction of ETRAs for the treatment
of CHF, the physiological and patho-physiological interactions between these two
systems is of importance. Indeed, the first trial of endothelin antagonist in patients
with heart failure, many of whom were on beta blocker treatment was negative,
demonstrating no mortality benefit [Coletta et al 2002, Luscher et al 2002], Clearly
these experiments require further investigation, but beyond the scope of simple
isometric force contraction experiments.
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11.6 Endothelin in 'predisease' states
Results from the trials of endothelin antagonists in patients with clinical disease such
as chronic heart failure have been disappointing. However, data in Chapter 9 suggest
that there may be a role for modulation of the endothelin system in high risk patients
or 'pre-disease' states such as hypercholesterolaemia.
This study demonstrated that 8 weeks of statin therapy caused a trend towards a
reduction in arterial stiffness and increased vasodilatory responses to selective ETA
receptor blockade. There were no differences in responses to selective ETB receptor
or combined ETa/b receptor between the placebo and statin treatment periods.
Consistent with studies in healthy volunteers, selective ETA receptor blockade with
BQ-123 increased forearm blood flow. However, there was a trend towards an
increase in this vasodilation after treatment with cerivastatin. These preliminary
results are of interest. If the balance of effect at the ETB receptor is indeed
vasodilatation then the vasodilatation seen with ETA receptor blockade may have two
components, firstly the reduction in ET-1 tone mediated through the ETA receptor
when blocked and secondly there will be an increase in ETB receptor mediated
vasodilatation due to increased availability of ET-1 due to ET-1 displacement and
reduction in the number of target receptors. The trend towards an increase in ETA
mediated vasodilatation following cerivastatin would support the hypothesis that
statin therapy increases NO mediated vasodilatation via the ETB receptor, given that
there is no difference between groups when the ETB receptor is concomitantly
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blocked by combine BQ123 and BQ788 infusion. It has been previously shown that
hypercholesterolemia causes an impairment of NO mediated vasodilation and that
this can be at least partially reversed by lipid lowering therapy [O'Driscoll et al
1997]. However, there may also be structural changes to the arterial wall which
would be less likely to be reversed after 8 weeks of lipid lowering and therefore a
longer treatment period may be expected to have greater effects. The potential
interaction between endothelin antagonists and statin therapy is of interest and
deserves further investigation.
In summary, investigation of the endothelin system has been disappointing in terms
of identifying groups of patients who would benefit from endoothelin antagonism.
Except for primary pulmonary hypertension, endothelin antagonists have failed to
find a clinical niche. However, there is much focus on prevention of clinical disease
and endothelin antagonists may yet find an important role in clinical medicine.
11.7 Future directions
Endothelin antagonists have not fulfilled their expected potential. Other than in
primary pulmonary hypertension they have not yet found a role in therapeutics.
While endothelin antagonists have been shown to reduce blood pressure in man and
modify atherosclerosis in animal models, initial clinical studies in patients with
cardiac disease (eg chronic heart failure) have been disappointing. Nevertheless, the
endothelin system is activated in a variety of conditions such as hypertension,
diabetes and renal failure and its blockade may yet prove of benefit in a subgroup of
patients
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The work presented in this thesis demonstrates that there are functionally active
endothelin intermediaries (ET-1 [1-31]), as well as potentially important interactions
between the endothelin system and other neurohormal systems (beta-adrenergic).
Furthermore, differences exist between the effects of selective and dual endothelin
receptor blockade in patients (chronic heart failure). These findings may guide future
research involving the endothelin system. However, whether manipulation of the
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Objective: To investigate the potential differential effects of selective endothelin (ET) A and dual ET-A/B
receptor blockade in patients with chronic heart failure.
Methods: Nine patients with chronic heart failure (New York Heart Association class II—III) each received
intravenous infusions of BQ-123 alone (selective ET-A blockade) and combined BQ-123 and BQ-788
(dual ET-A/B blockade) in a randomised, placebo controlled, three way crossover study.
Results: Selective ET-A blockade increased cardiac output (maximum mean (SEM) 33 (12)%, p < 0.001)
and reduced mean arterial pressure (maximum -13 (4)%, p < 0.001) and systemic vascular resistance
(maximum —26 (8)%, p < 0.001), without changing heart rate (p = 0.38). Dual ET-A/B blockade
significantly reduced the changes in all these haemodynamic variables compared with selective ET-A
blockade (p < 0.05). Selective ET-A blockade reduced pulmonary artery pressure (maximum 25 (7)%,
p = 0.01) and pulmonary vascular resistance (maximum 72 (39)%, p < 0.001). However, there was no
difference between these effects and those seen with dual ET-A/B blockade. Unlike selective ET-A
' blockade, dual ET-A/B blockade increased plasma ET-1 concentrations (by 47 (4)% with low dose and 61
(8)% with high dose, both p < 0.05).
Conclusions: While there appeared to be similar reductions in pulmonary pressures with selective ET-A
and dual ET-A/B blockade, selective ET-A blockade caused greater systemic vasodilatation and did not
affect ET-1 clearance. In conclusion, there are significant haemodynamic differences between selective ET-
A and dual ET-A/B blockade, which may determine responses in individual patients.
Endothelin (ET) 1 is a potent endogenous vasoconstrictorin humans and contributes to the maintenance of basalvascular tone' and blood pressure2 in healthy people and
patients with systemic arterial hypertension.3 4 It acts
through two receptor subtypes: the ET-A and ET-B receptors.
While both receptors are expressed on vascular smooth
muscle cells and mediate vasoconstriction, only the ET-B
receptor is located on the endothelium, where it produces a
prostanoid and nitric oxide mediated vasodilatation. Thus,
ET-B receptor mediated effects are complex and include
vasoconstriction, endothelium dependent vasodilatation, and
a role in the clearance of ET-1.5 In healthy people, in contrast
to the vasodilator and vasodepressor effects of ET-A receptor
blockade,6 7 systemic ET-B receptor blockade has vasocon¬
strictor and pressor effects,8 suggesting that the vascular
balance of basal ET-B receptor activation favours vasodilata¬
tion.
Chronic heart failure is associated with neurohumoral
activation as a consequence of reductions in cardiac reserve,
systemic blood pressure, and renal perfusion. This leads to
peripheral vasoconstriction, increased systemic vascular
resistance, and sodium and water retention, which together
increase cardiac work and further compromise cardiac
performance. Many regulatory mechanisms are involved in
this maladaptive response, including the renin-angiotensin,
sympathetic nervous, and vasopressin systems. The ET
system also appears to contribute to the pathophysiology of
heart failure, which is associated with increased plasma ET-1
concentrations'10 that correlate with haemodynamic
changes," 12 reduced exercise capacity," and a poor prog¬
nosis.14
In patients with chronic heart failure, systemic adminis¬
tration of both selective ET-A""7 and non-selective ET-A/B
blockade18"2' reduces systemic vascular resistance and
increases cardiac output. In patients with acute decompen¬
sated heart failure systemic administration of non-selective
ET-A/B blockade has been shown to have beneficial effects.22
However, systemic ET-B blockade increases systemic vascular
resistance and has potentially detrimental effects, in patients
with chronic heart failure.23 Therefore, the question arises as
to whether differences between selective ET-A and non¬
selective ET-A/B blockade can influence haemodynamic
responses to ET blockade, which in turn might have
contributed to the recent failure of ET blockade as a
treatment approach for patients with chronic heart fail¬
ure.24 25 However, to date, there have been no direct studies
comparing these two approaches.
The objectives of this placebo controlled study, in patients
with stable chronic heart failure, were to compare in a head
to head manner the effects of selective ET-A blgckade with




Nine patients with chronic heart failure (New York Heart
Association (NYHA) class II-III) caused by left, ventricular
dysfunction were recruited if they had an ejection fraction
< 35% (by echocardiography with the biplanar Simpson's
rule) and had been stable with treatment, including
angiotensin converting enzyme inhibitor or angiotensin
receptor antagonist, for at least three months. Patients were
all in sinus rhythm and no patient had a pacemaker or
implantable cardiac defibrillator. Patients were excluded if
they had insulin dependent diabetes mellitus, abnormal liver
function, renal impairment (creatinine > 200 pmol/1 for
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men; > 180 pmol/1 for women) or a systolic blood pressure
> 190 or <90 mm Hg, or within three months had under¬
gone coronary artery bypass graft surgery or percutaneous
coronary intervention or had an acute coronary syndrome,
myocardial infarction, or cerebrovascular accident.
The study was undertaken with the approval of the local
research ethics committee and in accordance with the
Declaration of Helsinki. Written informed consent was
obtained from each patient before entry into the study.
Measurements
Blood pressure and heart rate were measured non-invasively
with a Dynamap compact TS (Critikon LLC, Ascot, UK).
Cardiac output, mean pulmonary artery pressure, pulmonary
artery wedge pressure, and central venous pressure were
measured continuously with a single multilumen thermo-
dilution cardiac output pulmonary artery catheter (Swan-
Ganz CCOmbo—CCO/SV02; Edwards Lifesciences, Irvine,
California, USA). Cardiac output was calculated automati¬
cally (Vigilence, Edwards Critical Care, Baxter's Healthcare
Corporation, Irvine, California, USA) and, at each time point,
the cardiac output was taken as the mean of" three
measurements.
Protocol
All patients attended fasted at 7.30 am on three occasions at
least one week apart. ^Patients were asked to omit their
regular medications on the morning of the study. The studies
were conducted in a quiet, draught-free room maintained at
a constant temperature (22-24°C). A pulmonary artery
catheter was inserted through a 9 French femoral venous
sheath into the right pulmonary artery and was flushed with
0.9% heparinised saline. Before starting drug administration,
patients underwent an equilibration period of > 90 minutes
until blood pressure, heart rate, and cardiac output were
stable, with three consecutive measurements within 10%.
Study drugs were administered by 15 minute infusion in two
incremental doses 60 minutes apart.
Drug administration
A venous cannula for drug administration was inserted under
local anaesthesia. Pharmaceutical grade BQ-123 and BQ-788
(Clinalfa AG, Laufelfingen, Switzerland) were dissolved in
0.9% saline (Baxter Healthcare Ltd, Thetford, UK). On each
study day, patients received a low dose infusion at t = 0 for
15 minutes followed by a high dose infusion at t = 60
minutes for 15 minutes. On different study days and in
Table 1 Patient characteristics and medications
MPAP (mm PAWP (mm
Patient Agei (years) BM) (kg/m^BP (mm Hg) HR (beats/min) Hgl Hgl Cause of HF NYHA Drugs and dose*
1 75 26 186/79 52 20 11 Ischaemic III ASA75, En20, Bui, Sim20
2 63 23 120/74 64 13 6 Idiopathic II ASA75, En20
3 60 27 122/58 62 17 12 Ischaemic III Val80, Frus40
4 43 30 98/64 77 12 8 Ischaemic II ASA75, LislO, Frus40
5 56 29 139/88 96 11 6 Ischaemic III ASA75, Lis20, Frus40, Carl 2.5,
Dig250, Sim20
6 61 26 136/77 66 16 . 12 Ischaemic III ASA75, lislO, Frus40, Spir25,
Digl25, Sim20
7 52 36 184/106 94 • 25 23 Ischaemic III Lis 15, Frus20, Aten 100
8 74 33 143/75 58 14- 10 Ischaemic III ASA75, LislO, Frus40, Bis 10,
Siml 0
9 67 21 154/78 65 14 10 Ischaemic II ASA75, LislO, Aten50, Pra20
Average 61 28 142/78 70 16 11
SEM 3 1 9/4 5 1 2
•Doses in mg except for digoxin fug).
ASA, aspirin; Aten, atenolol; Bis, bisoprobl; BMI, body mass index; BR, blood pressure; Bu, bumetanide; Car, carvedilol; Dig, digoxin; En, enalapril; Frum,
furosemide/amiloride; Frus, furosemide; HF, heart failure; HR, heart rate; Lis, lisinopril; MPAP, mean pulmonary artery pressure; NYHA, New York Heart
Association; PAWP, pulmonary artery wedge pressure; Pra, pravastatin; Sim, simvastatin; Spir, spironolactone; Val, valsartan.
random order, patients received saline placebo, BQ-123 (low
dose, 1.5 pmol; high dose, 15 pmol) alone or the co-infusion
of BQ-123 (low dose, 1.5 pmol; high dose, 15 pmol) and BQ-
788 (low dose, 0.45 pmol; high dose, 4.5 pmol). These doses
were selected following studies in healthy volunteers given
BQ-123 and BQ-788. This dose of BQ-123 was sufficient to
reduce systemic vascular resistance and block the effects of
local infusion of ET-1 into the forearm.7 This dose of BQ-788
was sufficient to reduce systemic vascular resistance.8 The
detailed rationale for these doses has been discussed
elsewhere.26
Blood sampling and plasma assays
Venous blood for ET-1 and big ET-1 (the 38 amino acid
precursor of ET-1) assay was taken from the femoral vein.
Blood was collected into 0.16% EDTA (Sarstedt, Aktiengesell
Schaft & Co, Germany) and immediately separated by
centrifugation (2500 g for 20 minutes at 4°C) and stored at
-80°C until analysis. Following extraction in Bond Elut
columns (Varian, Harbor City, California, USA), ET-1
(Peninsula Laboratories Europe Ltd, St Helens, UK) and big
ET-1 (Peninsula Laboratories Europe Ltd) concentrations
were determined by radioimmunoassay as previously
described.27 The intra-assay coefficients of variability were
7.0 and 7.2%, respectively, and the interassay coefficients of
variability were 9.0 and 9.3%, respectively.
Table 2 Baseline parameters
BQ-123 + BQ-
Parameter Placebo (n = 9) BQ-123 (n=9) 788 (n = 9)
HR (beats/mini 64 (5! 62 (4) 63 (5)
MAP (mm Hgl 91 (7) 87 (6) 90(7)
SBP (mm Hg) 106 (8) 104(9) 106(9)
DBP (mm Hg) 69 (4) 68 (6) 71 (4)
CVP (mm Hg) 5(1) 5(1) 3(2)
CO (1/min) 5.0 (0.3) 5.5 (0.4) 5.3 (0.3)
SVR (dyn.s/cm"5) 1462(150) 1266(138) 1344(138)
MPAP (mm Hg) 16(1) 16(1) 17(2)
PAWP (mm Hg) 11 (2) 11 (U 12(3)
PVR (dyn.s/cm" 6) 83(12) 91 (14) 78(18)
Data are mean {SEM).
CO, cardiac output; CVP, central venous pressure; DBP, diastolic blood
pressure; MAP, mean arterial pressure; PVR, pulmonary vascular
resistance; SBP, systolic blood pressure; SVR, systemic vascular
resistance.
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Data and statistical analyses
Data are expressed as mean (SEM) change from baseline or
mean (SEM) area under the curve (AUC) unless otherwise
specified. Data were examined by analysis of variance with
repeated measures over time and Student's t test with
correction for multiple measures where appropriate (Excel
version 5.0, Microsoft, Redmond, Washington, USA).
Significance was taken at the 5% level.
RESULTS
Table 1 shows baseline patient characteristics and medica¬
tions. There were no adverse events and the study was well
tolerated by all patients. There were no significant differences
in baseline haemodynamic variables between study visits
(table 2). Placebo administration caused no significant
changes in haemodynamic variables throughout the course
of the study (analysis of variance p > 0.9).
Cardiac output and heart rate
In comparison with placebo, BQ-123 alone (AUC p < 0.001),
but not BQ-123/788 (AUC p = 0.08), increased cardiac
output with a maximum increase of 33 (12)% at 75 minutes.
Infusion of BQ-123 alone increased cardiac output compared
with BQ-123/788 (AUC p < 0.001) (fig 1C, fig 2). There was
no significant change in heart rate with either BQ-123 alone
(AUC p = 0.38) or BQ-123/788 (AUC p = 0.39) (fig 1A,
fig 2).
i.
Left ventricular filling pressure and systemic
haemodynamic variables
In comparison with placebo, BQ-123 alone (AUC p = 0.01)
and BQ-123/788 (AUC p < 0.01) reduced pulmonary artery
wedge pressure by a maximum of 19 (7)% at 150 minutes
and 26 (7)% at 105 minutes, respectively (fig 2, fig 3C). There
was no difference between the magnitude of reduction in
Topics: 16; 17; 180; 183
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pulmonary artery wedge pressure between BQ-123 alone and
BQ-123/788 (AUC p = 0.47). BQ-123 alone (AUC
p < 0.001) and BQ-123/788 (AUC p < 0.05) reduced mean
arterial pressure by a maximum of 14 (5)% and 12 (4)%,
respectively, at 150 minutes. BQ-123 alone reduced mean
arterial pressure to a greater degree than BQ-123/788 (AUC
p < 0.05) (fig IB, fig 2).
BQ-123 alone (AUC p< 0.001) and BQ-123/788 (AUC
p < 0.05) reduced systemic vascular resistance by a max¬
imum of 26 (8)% and 16 (5)%, respectively, at 75 minutes in
comparison with placebo. BQ-123 alone reduced systemic
vascular resistance to a greater degree than BQ-123/788 (AUC
p < 0.05) (fig ID, figs 2 and 3).
Right ventricular filling pressure and pulmonary
haemodynamic variables
In comparison with placebo, neither BQ-123 alone (AUC
p = 0.17) nor BQ-123/788 (AUC p = 0.69) changed central
venous pressure (fig 2, fig 3A). BQ-123 alone (AUC
p = 0.01) and BQ-123/788 (AUC p = 0.02) reduced mean
pulmonary arterial pressure by a maximum of 25 (7)% and 26
(6)%, respectively, at 90 minutes. There was no significant
difference between these responses (AUC p = 0.98) (fig 2,
fig 3B).
In comparison with placebo, both BQ-123 alone and BQ-
123/788 (AUC both p < 0.001) reduced pulmonary vascular
resistance by a maximum of 72 (39)% and 40 (16)%,
respectively, at 75 minutes. There was no significant
difference between these responses (AUC p = 0.49) (fig 2,
fig 3D).
Plasma ET-1 and big ET-1
There was no change in plasma concentrations of big ET-1
with placebo, BQ-123 alone, or BQ-123/788. There was no
significant change in plasma ET-1 concentrations with
C D
Figure 1 Effect of selective endothelin (ET) A blockade (open circles), dual ET-A/B blockade (solid circles), and placebo (solid squares) on (A) heart
rate (HR), (B) mean arterial pressure (AMP), (C) cardiac output (CO), and (D) systemic vascular resistance (SVR) at low dose (ID) and high dose (HD).
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Figure 2 Comparison of the
haemodynamic effects of placebo
(white), selective ET-A blockade (grey),
and dual ET-A/B blockade (black) on
HR, CO, MAP, SVR, pulmonary arterial
wedge pressure (PAWP), mean
pulmonary artery pressure (MPAP) and
pulmonary vascular resistance (PVR).
AUC, area under the curve. *p < 0.05
BQ-123 v placebo; tp < 0.05 BQ-
123/788 v placebo; tp < 0.05 BQ-
123 v BQ-123/788.
HR CO MAP SVR PAWP MPAP PVR
placebo or BQ-123 alone, whereas BQ-123/788 caused an
increase in" plasma ET-1 concentrations (47% with low dose
and 61% with high dose, both p < 0.05) (fig 4).
DISCUSSION
In this randomised placebo controlled crossover study, we
have shown, for the first time, that there are small but
significant haemodynamic differences between the responses
to selective ET-A and non-selective ET-A/B receptor blockade
in patients with chronic heart failure. Both selective ET-A
and non-selective ET-A/B receptor blockade increased cardiac
output and reduced mean arterial pressure and systemic
vascular resistance. However, selective ET-A receptor block¬
ade caused a greater increase in cardiac output and reduction
in systemic vascular resistance than non-selective ET-A/B
receptor blockade. In contrast, selective ET-A and non¬
selective ET-A/B blockade caused similar reductions in both
pulmonary artery pressure and pulmonary vascular resis¬
tance. There was a greater reduction in pulmonary artery
pressure with non-selective blockade than with selective ET-
A blockade after low dose infusion, although this difference






















Figure 3 Effect of selective ET-A blockade (open circles), dual ET-A/B blockade (solid circles), and placebo (solid squares) on (A) central venous
pressure (CVP), (B) MPAP, (C) PAWP, and (D) PVR at low dose (LD) and high dose (HD).
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Figure 4 Effects of placebo (white), selective ET-A blockade (grey), andcombined ET-A/B blockade (black) on plasma concentration of (A) big
ET-1 and (B) ET-1. *p < 0.05 v baseline.
This is the first study to directly compare systemic selective
ET-A and non-selective ET-A/B blockade in patients with
heart failure. Our findings are consistent with other short
term studies, which have shown that both selective ET-A17
and non-selective ET-A/B20r22 blockade increase cardiac out¬
put and reduce systemic vascular resistance, importantly
with no change in heart rate, and that both selective ET-A16 17
and non-selective ET-A/B20"22 blockade reduce pulmonary
vascular resistance and pulmonary artery wedge pressure.
Comparing magnitude of response between different ET
antagonists in different patient populations is difficult but we
have shown in this head to head study that selective ET
blockade had greater effects than non-selective ET antagon¬
ism on the systemic vasculature.
There is increasing evidence that the ET-B receptor has a
role in the clearance of plasma ET-1. Plasma ET-1 concentra¬
tion increases after systemic selective ET-B blockade in
healthy people8 and after non-selective ET-A/B blockade in
healthy people28 and in patients with hypertension4 and with
chronic heart failure.18 20 However, the effects of systemic ET-
A blockade alone are less consistent with little, if any,
increase in plasma ET-1 concentrations in most studies,615 16
although one study did report an increase at higher degrees
of ET-A blockade.17 These results are confirmed in our study,
in which selective ET-A receptor blockade had no effect,
whereas plasma ET-1 concentrations were increased by non¬
selective blockade. Because there was no change in plasma
big ET-1 concentration, increased plasma ET-1 is likely to
reflect interference with its clearance rather than an increase
in its synthesis and release. Thus, selective ET-A blockade has
a theoretical benefit of leaving the ET clearance receptor (ET-
B) functional. Nevertheless, if the ET-A receptor is also
effectively blocked during ET-B receptor blockade then the
high circulating concentrations of ET-1 may not be of clinical
importance.
Although selective ET-A receptor blockade had greater
effects on systemic vascular resistance, there may be clinical
situations in which blockade of the ET-B receptor is desirable.
There is a higher density of ET-B receptors in the pulmonary
vasculature and these may be upregulated in pulmonary
arterial hypertension,29 though selective ET-A and non¬
selective ET-A/B receptor blockade have not yet been
compared head to head in this condition. Also, ET-1 release
across the pulmonary vascular bed correlates strongly with
the pulmonary vascular resistance in chronic heart failure.10
Raised pulmonary artery pressure is an independent risk
factor in chronic heart failure and responds poorly to
conventional treatments. Here, we showed that both selective
ET-A and non-selective ET-A/B receptor blockade reduce
pulmonary artery pressures.
These observations suggest that ET antagonism may
benefit patients with heart failure who also have raised
pulmonary artery pressures, although we did not directly
address this condition in our study. Indeed, the non-selective
antagonist bosentan has recently been approved to treat
primary pulmonary arterial hypertension based on its
effectiveness in this situation.31 The long term clinical effects
of ET receptor blockade in patients with pulmonary
hypertension secondary to chronic heart failure are
unknown, but it is tempting to speculate that ET receptor
blockade may also be more effective in this setting. We have
failed to show convincingly whether there are true haemo-
dynamic differences between selective ET-A and non¬
selective ET-A/B receptor antagonism in the pulmonary
circulation. However, none of the patients in the present
study had significant pulmonary hypertension. We believe
that the role of ET antagonism now warrants further careful
assessment in a much larger trial of patients with both heart
failure and a significant degree of pulmonary hypertension.
Many studies use agents that, while termed "selective" or
"dual" inhibitors of ET-A and ET-B receptors, have a range of
receptor selectivities, mostly inhibiting the ET-A receptor at
much lower concentrations than at the ET-B receptor.2" In
this study we have used two receptor antagonists, BQ-123
and BQ-788, given separately and with selectivity for the ET-
A and ET-B receptor, respectively. Therefore, it is important
to recognise that we have examined mechanistically the
influence of major blockade of the ET-B receptor on
responses to full ET-A blockade. This may not exactly
represent the clinical situation that exists with non-selective
antagonists, such as bosentan, which are relatively selective
for the ET-A receptor (ET-A:ET-B selectivity > 10). The doses
of BQ-123 given here have been shown to produce maximum
systemic haemodynamic effects and to block responses to
forearm artery infusion of ET-1, but not to increase plasma
ET-1 concentrations. Given that BQ-123 caused greater
systemic vasodilatation than the combination with BQ-788,
the overall haemodynamic effect of ET-B blockade in patients
with heart failure is likely to be vasoconstriction, a finding
consistent with other work.23 32
As a limitation, this was an acute haemodynamic study
and we have not assessed whether these effects are sustained
in the long term. Nevertheless, previous haemodynamic
studies indicate that the acute effects of both selective ET-A24
and non-selective32 ET receptor blockade are maintained, or
even enhanced, over several weeks and therefore likely to be
sustained. The clinical impact of these haemodynamic
changes is, of course, uncertain and can only be clarified in
the context of large scale clinical outcome studies. We have
shown that selective ET-A blockade causes more major
systemic vasodilatation than non-selective ET-A/B receptor
blockade in New York Heart Association (NYHA) class II—III
patients with heart failure. To date, there have been only two
as yet unpublished large scale, randomised controlled trials of
ET receptor blockade in patients with heart failure (NYHA
class III—IV), both of which observed no major clinical benefit
of either bosentan (ET-A:ET-B selectivity ~10)25 or darusen-
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tan (ET-A:ET-B selectivity > 500).24 The results of these
longer term studies were disappointing, although perhaps it
is not surprising that two agents with 10 to > 500 selectivity
for the ET-A receptor yielded similar results given the small
haemodynamic differences found in the current study, when
much greater relative ET-B receptor blockade was achieved.
Nevertheless, bosentan has found utility in the treatment of
primary pulmonary hypertension and whether it may have
utility in a subset of patients with CHF with secondary
pulmonary hypertension remains to be seen.
Conclusions
In this study both selective ET-A and non-selective ET-A/B
blockade cause acute systemic and pulmonary haemody¬
namic changes in patients with heart failure. However,
differences exist and selective ET-A blockade causes greater
systemic haemodynamic effects than non-selective ET-A/B
blockade.
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The Effect of Cerivastatin Therapy on Vascular
Responses to Endothelin Antagonists in Humans
Stephen J: Leslie, James C. Spratt, Lynn Grieg, Teresa Attina, Martin A. Denvir, and David J. Webb
Abstract: Endothelin blocking drugs have vasodilator effects
mediated at least in part via the nitric oxide system. Hyper-
cholesterolaemia is associated with vascular dysfunction manifest
as impaired nitric oxide-mediated vasodilatation and arterial
stiffness. Treatment with HMG CoA reductase inhibitors (statins)
has proven mortality benefits in a range of patient populations.
Subjects (n = 5) received either placebo or 800 pg cerivastatin for
an 8-week period in a double-blind, placebo-controlled, cross-over
study. Cerivastatin reduced the total plasma cholesterol compared
with baseline by 27% (5.4 ± 0.4 mmol/L versus 7.3 ± 0.4 mmol/L,
7> = 0.04). Selective endothelin-A receptor blockade caused an
increase in forearm blood flow (FBF) (18.0 ±7.2%, = 0.04).
Compared with placebo, cerivastatin therapy caused a trend towards
a further increase in FBF (18.0 ±7.2% versus 52.0 ±19.0%,
P = 0.06). Selective endothelin-B receptor blockade reduced FBF
(— 11.0 ± 3.9%, P = 0.02) with no difference between placebo and
cerivastatin therapy (-11.0 ±3.9% versus -13.0 ±3.6%, P = 0.9).
Combined endothelin-A/endothelin-B receptor blockade increased
FBF (39.8 ± 13.4%, P<0.01) with no difference between placebo
and cerivastatin therapy (39.8 ± 13.4% versus 42.4 ±19.0%,
P = 0.7). There was a trend towards a reduction in the augmentation
index between cerivastatin and placebo (6.2 ± 2.7 versus 9.1 ± 2.4,
n = 5, P = 0.4) compared with baseline (7.2 ± 1.0). In conclusion,
statin therapy may decrease large artery stiffness and increase the
vasodilating effects of endothelin-A receptor blockade.
Key Words: endothelin receptor blockade, statin, cerivastatin
(J Cardiovasc Pharmacol™ 2004;44(suppl 1 ):S410—S412)
Endothelin-1 (ET-1) causes vasoconstriction via theendothelin-A (ETA) and endothelin-B (ETB) receptors
located on vascular smooth muscle cells, and vasodilatation
via the ETB receptor on endothelial cells, through a prosta¬
noid and nitric oxide (NO)-mediated effect. Thus, ETA
receptor blockade causes vasodilatation while the effects of
ETb receptor blockade will depend on the balance between
vasodilating and vasoconstricting effects at different sites.
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In healthy subjects, brachial artery administration of
BQ-123, a selective ETA antagonist, results in a forearm
vasodilatation of -40%,1-3 whereas administration of BQ-
788, a selective ETB antagonist, causes a modest
vasoconstriction of -10%.3 If the mechanism of the
vasodilatation is NO mediated, then in an NO-deficient state
the dilatation to ET-1 at the endothelial ETB receptor may be
reduced, resulting in less vasoconstriction to BQ-788 and less
vasodilatation to BQ123. Many studies have previously
demonstrated evidence of endothelial dysfunction and an
NO-deficient state in patients with hypercholesterolaemia.4 6
Hypercholesterolaemia is also associated with a reduction in
vascular compliance and a reduced response to vasoactive
therapies such as nitrates. Some of these responses can be
improved following lipid-lowering therapy.7'8 In addition, it
has been clearly demonstrated that reduction of plasma
cholesterol reduces mortality in several patient groups.9-11
The aim of this study was to examine whether treatment
of hypercholesterolaemia with an HMG CoA reductase
inhibitor (cerivastatin) could increase vascular compliance
and improve vasodilator responses to endothelin receptor
antagonists.
MATERIALS AND METHODS
Five non-smoking, otherwise healthy, hypercholes-
terolaemic subjects were studied. Subjects were rejected if
they had diabetes mellitus, renal impairment (creatinine, men
> 180 prnol/L, women > 160 pmol/L), a 10-year coronary
heart disease risk > 30%, a history of severe allergic reaction,
a systolic blood pressure > 180mmHg or <90 mmHg, or
were taking any regular medications. The study was
undertaken with the approval of the local research ethics
committee and in accordance with the Declaration of
Helsinki. Written informed consent was obtained from each
subject before entry into the study. Subjects attended fasted
for each study visit, which was performed in a quiet, draught-
free, temperature-controlled room (22-24°C).
The techniques of venous occlusion plethysmography
to measure forearm blood flow12 and pulse wave analysis to
measure the augmentation index and arterial stiffness'3 have
been described in detail elsewhere. Subjects received, in a
randomized, double-blind, cross-over manner, 8 weeks of
treatment with either sucrose placebo or 800 jig cerivastatin
nocte (Bayer Pic, Newbury, U.K.). BQ123 and BQ788
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FIGURE 1. Plasma concentrations of low-density
lipoprotein (LDL) and high-density lipoprotein (HDL) after
8 weeks of treatment with placebo or cerivastatin.
(Clinalfa AG, Laufelfingen, Switzerland) were diluted in
0.9% saline (Baxter Healthcare Ltd, Thetford, U.K.) and
infused via an intra-arterial needle over 80 minutes. Subjects
received BQ123 (10 mol/minute), BQ-788 (1 mmol/minute)
or both in a random order by 80-minute intra-arterial infusion
at weeks 6, 7 and 8 and at weeks 14, 15 and 16. The order of
intra-arterial drug infusion at the end of each treatment
period was randomized and kept the same within patients (i.e
the order of endothelin antagonist forearm studies was
consistent between treatment periods). Pulse wave analysis
was performed and venous blood samples taken at weeks 0,
8 and 16. Data were examined by Student's / test (Excel v5.0;
Microsoft). Results are expressed as the mean ± standard
error of the mean. Forearm blood flow and pulse wave
analysis results are expressed as the percentage change from
baseline. Statistical significance was taken at the 5% level.
RESULTS
Cerivastatin therapy for 8 weeks resulted in a reduction
in total plasma cholesterol compared with baseline of 27%
(5.4 ± 0.4 mmol/L versus 7.3 ± 0.4 mmol/L, P = 0.04); this
was achieved by a reduction in low-density lipoprotein
cholesterol (Fig. 1). There was no effect after 8 weeks of
placebo treatment (7.4 ± 0.4 mmol/L versus 7.3 ± 0.4 mmol/L,
P = 0.9). Selective ETA receptor blockade caused an increase
in forearm blood flow (FBF) (18.0 ±7.2%, Z3 = 0.04).
Compared with placebo, 8 weeks of cerivastatin therapy
caused a trend towards a further increase in FBF
(18.0 ±7.2% versus 52.0 ±19.0%, P = 0.06) (Fig. 2).
Selective ETB receptor blockade reduced FBF
(-11.0 ± 3.9%, P = 0.02) with no difference between placebo
and cerivastatin therapy (-11.0 ± 3.9% versus -13.0 ± 3.6%,
P = 0.9). Combined ETA/ETB receptor blockade increased
FBF (39.8 ± 13.4%, P<0.01) with no difference between
placebo and cerivastatin therapy (39.8 ±13.4% versus
42.4 ±19.0%, J3 = 0.7). There was a trend towards a
reduction in augmentation index between cerivastatin and
placebo (6.2 ± 2.7 versus 9.1 ± 2.4, n = 5, P = 0.4) compared
with baseline (7.2 ± 1.0).
DISCUSSION
This study has demonstrated that 8 weeks of statin
therapy caused a trend towards increased vasodilatory











- BQ123 + BQ788
FIGURE 2. Change in forearm blood flow from baseline with intra-arterial infusion of BQ123 (open circles), BQ788 (open
diamonds) or the combination of BQ123 and BQ788 (closed circles) following 8 weeks of treatment with (A) placebo or (B)
cerivastatin.
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arterial stiffness. There were no differences in responses to
selective ETB receptor or combined ETA/ETB receptor
blockade between the placebo and statin treatment periods.
Consistent with studies in healthy volunteers, selective
ETa receptor blockade with BQ-123 increased the FBF.
However, there was a trend towards an increase in this
vasodilatation after treatment with cerivastatin. These
preliminary results are of interest, and there are several
possible explanations for them. If the balance of effect at the
ETb receptor is indeed vasodilatation, then the vasodilatation
seen with ETA receptor blockade may have two components:
first, the reduction in ET-1 tone mediated through the ETA
receptor when blocked and, second, an increase in ETB
receptor-mediated vasodilatation due to increased availability
of ET-1 due to ET-1 displacement. The trend towards an
increase in ETA-mediated vasodilatation following
cerivastatin would support the hypothesis that statin therapy
increases NO-mediated vasodilatation via the ETB receptor,
given that there is no difference between groups when the
ETb receptor is concomitantly blocked by combined BQ123
and BQ788 infusion. It has been previously shown that
hypercholesterolaemia causes an impairment of NO-
mediated vasodilatation and that this can be at least partially
reversed by lipid-lowering therapy.8 However, there may also
be structural changes to the arterial wall that would be less
likely to be reversed after 8 weeks of lipid lowering, and
therefore a longer treatment period may be expected to have
greater effects. Unfortunately this study was stopped
prematurely as cerivastatin was withdrawn from the market
due to concerns over interaction with fibrates. Despite this,
the potential interaction between endothelin antagonists and
statin therapy is of interest and deserves further investigation.
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Supplement Article
Endothelin-1[1_3l] is Not Elevated in Men with Chronic
Heart Failure
Stephen J. Leslie, Neil Johnston, Fiona E. Strachan, Alan Bagnall, Gillian A. Gray, David E. Newby,
Martin A. Denvir, and David J. Webb
Abstract: Endothelin-ljl3l] is a recently discovered member of
the endothelin family with vasoactive properties in several animal
models and in man in vivo. It is generated from big endothelin-1 by
human mast cell chymase and may be a novel intermediary peptide
in the production of endothelin-l[| 2,j. Given that both big
endothelin-l[138j and chymase activity are increased in chronic
heart failure, the aim of this study was to determine whether plasma
endothelin-l[l 31] concentrations are elevated in patients with
chronic heart failure. Plasma endothelin- 1[,_3I] concentrations were
measured by enzyme-linked immunosorbent assay in nine patients
with chronic heart failure, and nine age- and sex-matched control
subjects. Consistent with previous studies, plasma concentrations of
big endothelin-l[138j were elevated in patients compared with
controls (17.1 ± 4.4 pg/mL vs 8.9 ± 3.4 pg/mL, P = 0.002),
although there were no differences in plasma endothelin-1[| 21]
(3.3 ± 0.4 pg/mL vs 3.4 ± 0.7 pg/mL, P = 0.7) or endothelin-lj, 31]
(both 1.1 ± 0.1 pg/mL, P = 0.2) concentrations. We have
demonstrated that patients with chronic heart failure have normal
plasma endothelin-lj, 31] concentrations. This suggests that, in
contrast to big endothelin-1[138], plasma endothelin-lj, 31] is
unlikely to be a useful prognostic marker in patients with chronic
heart failure.
Key Words: endothelin-lfl 31] (ET-1[13Ij), chronic heart failure
(CHF), assay, neuroendocrine
(J Cardiovasc Pharmacol™ 2004;44(suppl 1 ):S96 S99)
New derivatives of endothelin have recently beencharacterized in humans. In contrast to the generation of
endothelin-1 (ET-l^^j) by cleavage of the inactive
precursor big endothelin-1 (big ET-lj, 38]), ET-lj, 31] is
generated following the cleavage of big ET-lj, 38] at the
Tyi^'-Gly32 bond by human chymase.1 This endothelin (ET)
intermediary peptide may be of clinical importance in
conditions such as chronic heart failure (CHF) where there is
increased generation of big ET-1[I38] and increased chymase
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activity in tissues including the heart2 and blood vessels.3 In
addition, there is an increased amount of mast cells and
human mast cell chymase at the shoulder regions of unstable
coronary artery plaques,4'5 and ET-lj, 3I] may also contribute
to the pathogenesis of ischemic heart disease and acute
coronary syndromes.
In-vitro studies have shown that ET-1 [i_3i] is a
vasoconstrictor in isolated porcine coronary arteries,6 rabbit
pulmonary arteries7 and monkey trachea.8 Endothelin-lj131j
increases intracellular calcium in cultured human coronary
artery smooth muscle cells9'10 and human mesangial cells."
In addition, ET-1,, 31] causes vasoconstriction in human
umbilical arteries and we have previously reported that
ET-1 [i_3i] is a vasoconstrictor in the human skin micro¬
circulation in vivo.12 It is likely that ET-lj, 3lj causes
vasoconstriction via endothelin-A (ETA), and perhaps the
endothelin-B (ETB), receptors either directly or following
conversion to ET-lr12]j.
Recently, a new sensitive and selective enzyme-linked
immunosorbent assay (ELISA) has been developed to detect
ET-1
[i 31]-13 The aims of this study were, therefore, to
validate the measurement of plasma ET-l[lm31j using this
ELISA, and to quantify circulating plasma ET-lj, 3I]




Nine male patients with moderate to severe chronic left
ventricular dysfunction who had been stable on therapy for at
least 3 months were recruited. They had a left ventricular
ejection fraction of < 35%, shortening fraction of < 20% or
left ventricular end diastolic diameter > 5.6 cm. Patients were
compared with age- and sex-matched healthy controls. The
study was undertaken with the approval of the local research
ethics committee and in accordance with the Declaration of
Helsinki. Written informed consent was obtained from each
subject before entry into the study.
Blood Sampling and Plasma Extraction
All subjects omitted their medications on the day of
study and attended after an overnight fast. Venous blood
samples were collected into ethylenediaminetetraacetic acid
J Cardiovasc PharmacoTM • Volume 44, Supplement 1, November 2004
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(Sarstedt AG, Numbrecht, Germany), placed on ice and
plasma was immediately separated by centrifugation (2500 g
for 20 minutes at 4°C). Plasma samples were stored at -80°C
until analysis. Plasma was acidified with an equal volume of
20% acetic acid before being extracted using methanol-
activated Bond Elut CI8 columns (Varian, Harbor City, CA,
USA). The columns were perfused with deionized water and
10% acetic acid prior to the addition of plasma samples. The
columns were then washed with 10% acetic acid and ethyl
acetate, and the bound ET was eluted with 80%
methanol:20% ammonium bicarbonate. The eluate was dried
down under a continuous stream of nitrogen at 37°C and the
dried eluates were reconstituted with assay buffer. Recovery
fraction was estimated by adding known quantities of ET-
1 [,_3i] to plasma.
Peptides
ET-l [i_3i] (Peptide Institute Inc., Osaka, Japan), big ET-
1 [i-38] (Clinalfa, Laufelfingen, Switzerland) and ET-1],_21]
(Clinalfa) were dissolved in physiological saline (0.9%
Baxter Healthcare Ltd, Thetford, U.K.) and used to assess
assay cross-reactivity.
Assays
The assay for plasma big ET-1[,_38j and ET-1||21j has
been previously described with intra-assay coefficients of
variability of 7.0% and 7.2% respectively and inter-assay
coefficients of variability of 9.0% and 9.3% respectively.14 A
commercially available solid phase sandwich ELISA for
ET-l[i J,] (Immuno-Biological Laboratories Co. Ltd, Tokyo,
Japan) was used. This technique was performed on
reconstituted samples by using anti-human ET-lf25 3|] rabbit
immunoglobulin G. Briefly, 100 (iL of sample extract,
standard or quality control as well as 100 p.L of ET-1], 31]
antibody, was incubated for 24 hours at 4°C. Following
incubation, the wells were vigorously washed with buffer,
100 pL of labelled antibody was added, followed by
incubation for a further 30 minutes at 37°C. After further
washing, tetramethylbenzidine buffer was added, and
incubated for 30 minutes in the dark. Finally, 100 pL of 2 M
sulfuric acid was added and the wells were read using an
automated plate reader at 450 nm.
Data Handling and Statistical Analysis
Cross-reactivity was determined by calculating area
under the curves for big ET-1(1_38], ET-1 [| 31], and ET-1], 21],
and was expressed as a percentage of area under the curve for
ET-1 J, 3i]. Intra-assay coefficients of variation were
calculated from mean values divided by standard deviation
and expressed as a percentage. Plasma concentrations are
expressed as mean ± standard error of the mean. Data were
examined by analysis of variance (ANOVA; Excel® v5.0,
Microsoft). Statistical significance was taken at the 5% level.
RESULTS
Patient details are shown in Table 1.
Recovery of ET-1[1_31j
Recovery of ET-lj, 3|] during extraction was 73%. This
is comparable to the extraction efficiency for big ET-1 and
ET-1.14
Specificity of ELISA for ET-1[1_31]
Standard curves for big ET-1 [,_38], ET-1[131j, and
ET-1
[i_2i] were constructed (Fig. 1). The cross-reactivities for
the assay were 3.8% for big ET-1],38], 100% for ET-1 j131|,
and 0% for ET-1], 21]. Intra-assay coefficients of variation
were 14.7%, 8.8% and 6.7% at plasma ET-11, 3J] concentra¬
tions of 10 pg/mL, 20 pg/mL and 40 pg/mL, respectively.
Plasma Concentrations of Big ET-1, ET-1 and
ET-V31]
Plasma big ET-1], 38] concentrations were elevated in
patients compared with controls (17.1 ±4.4 vs
8.9 ± 3.4 pg/mL, P = 0.002). However, there were no
differences in the plasma concentrations of ET-1],_2,j
(3.3 ± 0.4 vs 3.4 ± 0.7 pg/mL, P = 0.7) or ET-1],_3,] (both
1.1 ±0.1 pg/mL, P = 0.2) (Fig. 2).
DISCUSSION
This study confirms that a new ELISA has high
specificity for ET-1 [ ,_3,] with low cross-reactivity for both
ET-1
[i 2,] and big ET-1], 38]. In addition, we have demon¬
strated, for the first time, that ET-1 [,_3,j immunoreactivity is
present in human plasma of both CHF patients and healthy
subjects. Despite elevation of the precursor peptide big
ET-1], 38], plasma ET-1], 3,] concentrations were normal in
patients with CHF.
We have demonstrated that the commercially available
assay for ET-1 [,_3,] has a high degree of specificity for this
form of endothelin compared with big ET-1],_38] and
ET-1],-2,]. The ELISA utilizes an antibody that recognizes
the 7 amino acid carboxy terminus of ET-1 [, 3,]- Given that
big ET-1], 3g] also shares this common sequence, it may have
been anticipated that significant cross-reactivity might occur.
However, we report a very low level of cross-reactivity and
this is likely to reflect differences in immunoreactivity
conferred by the tertiary structure of big ET-1 ],_38] and
Plasma big ET-1 concentrations are elevated in patients
with CHF and correlate with disease severity.15 Our findings
are consistent with these earlier data, although plasma
ET-1 [i _2i] concentrations were not elevated. This was
unexpected as plasma ET-lj,_21] concentrations are also
reported to be elevated in patients with CHF.15 However, big
ET-1],_38] plasma concentrations are a more reliable marker
of CHF and, in our study, these were increased by
© 2004 Lippincott Williams & Wilkins S97
Leslie et al J Cardiovasc Pharmacol™ * Volurne 44, Supplement 1, November 2004
TABLE 1. Test results for patients and age- and sex-matched controls
Age BMI Choi BP
(years) (kg nT2) (mmol/L) Smoker (mmHg) NYHA Drugs
Patient
1 67 22 6.9 N 143/105 III ASA, EN, BU, AMIO
2 78 26 6.4 N 195/95 II DIS, BU
3
. 57 28 4.2 'N 116/68 III ASA, EN, FRU, SIM, DIG, ISMO
4 47 26 6.1 Y 112/72 II ASA, EN, FRU, ISMO
5 69 29 6.1 N 121/68 II ASA, EN, FRUS, BIS
6 76 25 5.3 N " 140/80 III ASA, EN, FRU
7 80 26 5.0 Y 190/90 II ASA, LOS, FRU, DIG
8 77 28 4.2 Y 175/80 III ASA, CAP, AMIO
9 81 23 5.5 N 120/60 II ASA, EN, DIG, SIM
Average 70 26 5.5 146/80
SEM 4 1 0.3 11/5
Control
1 67 26 4.8 N 124/80 NA. None
2 77 29 5.8 N 158/90 NA None
3 73 24 4.3 N 132/88 NA None
4 48 25 5.1 N 128/80 NA None
5 67 26 4.7 N 145/87 NA None
6 73 23 7.0 N 135/72 NA None
7 81 27 5.4 N 127/64 NA None
8 77 27 6.7 N 117/77 NA None
9 79 29 4.4 N 103/72 NA None
Average 71 26 5.4 130/79
SEM 3 1 0.3 5/3
o 0 , -A , ° ,
0 50 100 150
Concentration pg/ml
FIGURE 1. Standard curves for big endothelin-1
(ET-1)[i_38], ET-1 [1_3i] and ET-1 [1_2i]-
approximately twofold. We have also recruited stable patients
who were well controlled on medical therapy. It is likely,
therefore, that our patient population had less neurohormonal
activation and may have had less generation of big ET-lj, 38]
than those enrolled into previous studies.
S98
Chronic Heart Failure Matched Controls
FIGURE 2. Concentrations of plasma big endothelin-1
(ET-1 )[i_38], ET-1 [1_31] and ET-1 [t_21] in patients with chronic
heart failure and matched controls.
In patients with CHF, there does not appear to be a
general increase in generation of ET-lj, 31]. This study does
not however exclude the possibility of local increases in
ET-1 [!-3!] production, such as within areas of inflammation.
Moreover, local ET-ljj 31] generation may be specific to
© 2004 Lippincott Williams & Wilkins
BMI, body mass index; Choi, serum cholesterol; BP, blood pressure; N YHA, New York Heart Association; ASA, aspirin; EN, enalapril; BU, bumetanide; AMIO,
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those tissues with increased chymase activity such as failing
human myocardium.2 In addition, increased chymase activity
is seen in mast cells at the shoulder regions of coronary
atheromatous plaques4'5 and ET-lj, 31] may be implicated in
the etiology of coronary artery spasm at the time of plaque
rupture. Further studies are clearly required to determine how
ET-1[, 31] is processed and to identify situations where
increased local ET-lj, 31] generation may occur.
In conclusion, this study has shown that plasma
ET-1
[J ji] concentrations can be measured reliably but, in
contrast to big ET-lj, 38], do not appear to be elevated in
patients with heart failure. These data suggest that ET-ljj 31]
is not useful as a predictive test and that generation is not
sufficient to increase circulation plasma concentrations in
patients with stable CHF.
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Non-invasive measurement of cardiac output in patients with
chronic heart failure
Stephen J. Leslie, Sinead McKee, David E. Newby, David J. Webb and
Martin A. Denvir
Objectives The measurement of cardiac output by thoracic
bioimpedance has been previously assessed in several
studies. However, there continues to be disagreement as
to whether this technique is sufficiently accurate for use in
clinical practice or research. The current study aimed to
compare thoracic bioimpedance (COTb) with
thermodilution (COTd) in patients with stable chronic
heart failure.
Methods and results A total of 282 paired measurements
of cardiac output from 11 patients were analysed. There
was good correlation between COTB and COTD (r=0.76,
P< 0.0001). However, Bland-Altman analysis revealed an
average difference between values of 0.3(2.2)l/min
(P=0.02), suggesting a small average bias but marked
variability in results. There was no significant correlation
when results were expressed as percentage change from
baseline and a significant average difference between
values of 10.1 (30.1)%. There was no difference in
between-day repeatability between thermodilution and
thoracic bioimpedance [-0.2(1.2) versus 0.1 (1.0) l/min,
P=0.7].
Conclusions This study demonstrates a correlation
between the techniques but shows a poor level of
agreement The method of COTB underestimated cardiac
output compared with COTD, and this difference appeared
greater with higher cardiac outputs. Agreement was worse
when results were expressed as change from baseline.
The present study does not support the use of thoracic
bioimpedance in its current form as an alternative to
thermodilution in stable patients with chronic heart
failure. Blood Press Monit 9:277-280 © 2004 Lippincott
Williams & Wilkins.
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Introduction
The most popular method for measurement of cardiac
output is the thermodilution technique although it may
not be suitable for use in certain situations, such as
volunteer research studies, because of its invasive nature.
In contrast, thoracic bioimpedance is a relatively simple,
non-invasive technique for measuring cardiac output,
which has been employed in several clinical studies.
However, there continues to be disagreement as to
whether this technique is sufficiently accurate and
precise to be of use in clinical practice or research.
Many studies have supported the use of thoracic
bioimpedance [1-6], while others suggest it is not
sufficiently accurate [7-9]. The applicability of thoracic
bioimpedance has been assessed in several groups of
unstable patients such as those following cardiac surgery
[3], in acute heart failure [1] and in critically ill patients
on intensive care units [3], In addition, some workers
have based assessment of clinical applicability on single
point measurements rather than trends [4,8]. This may
limit their applicability since thoracic bioimpedance may
1359-5237 © 2004 Lippincott Williams & Wilkins
be more accurate at measuring changes in cardiac output
rather than absolute values [2]. There are few studies
comparing thoracic bioimpedance with thermodilution for
determining absolute, as well as relative changes in
cardiac output in stable patients with chronic heart
failure. The aim of this study was to compare the
techniques of thoracic bioimpedance and thermodilution
for the measurement of cardiac output in patients with




Eleven patients with chronic heart failure (New York
Heart Association Grade II/III) due to left ventricular
dysfunction attended for a total of 30 visits (maximum
three visits per patient). All patients had an ejection
fraction < 35% (by echocardiography using the biplanar
Simpson's rule) and were stable on treatment for at least
three months. All patients were in sinus rhythm and none
had a cardiac pacemaker. The study was undertaken with
the approval of the local research ethics committee and in
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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accordance with the Declaration of Helsinki. Written
informed consent was obtained from each subject before
entry into the study.
Measurements
Thermodilution
Cardiac output was measured by the thermodilution
technique using the semi-continuous single multi-lumen
thermodilution cardiac output pulmonary artery catheter
(Swan-Ganz CCOmbo-CCO/SV02; Edwards Life-
sciences LLC, Irvine, California, USA) [10,11]. This
device has a thermal filament which transfers a safe level
of heat to the surrounding blood in a pulsed, on-off
manner every 30 s. Changes in the temperature of the
blood distal to this are measured by a distal rapid-
response thermistor in the pulmonary artery. The cardiac
output is then calculated automatically using a modified
Stewart-Hamilton equation [12].
Thoracic bioimpedance
Thoracic bioimpedance was performed using the Bo-
Med® NCCOM3 system (BoMed Medical Manufacturer
Ltd., Irvine, California, USA). Four pairs of low impe¬
dance electrodes are used, two on either side of the
thorax at the level of the xiphoid sternum in the mid
axillary line and two on the lateral aspect of the base of
the neck. In each pair, the upper electrode delivers a
small current that is sensed by the lower electrode, thus
impedance is measured and the cardiac output can be
calculated.
Protocol
Patients were asked to attend after an overnight fast and
to omit their regular medications on the morning of the
study. The studies were conducted in a quiet room
maintained at a constant temperature (22-24°C). A
pulmonary artery catheter was inserted, via a 9F femoral
venous sheath, into the right pulmonary artery. Before
starting the drug infusion, patients underwent an
equilibration period of > 90 min until blood pressure,
heart rate and cardiac output were stable, with three
consecutive measurements within 10%. Systemic con¬
centrations of endothelin antagonists were administered
intravenously at low dose then high dose over 15 min, 1 h
apart. Endothelin blockade causes vasodilatation and in
patients with heart failure an increase in cardiac output.
These results have been described elsewhere [13].
Data analysis and statistics
Near simultaneous measurements of CO were obtained
from the mean of three consecutive recordings at each
period for both COtd and COTB. Data are expressed as
mean value (standard error of the mean; SEM).
Percentage changes in cardiac output from baseline were
also studied. Within device repeatability was assessed by
analysing baseline measurements of cardiac output in the
same patient on difference days. The method of Bland
and Altman was used to describe the relationship
between COtd and COtb- Bland-Altman analysis can
be used to evaluate two techniques where the mean of
the differences between two values is a measure of
accuracy (or bias) and the standard deviation of these
values gives a measure of precision [14]. Statistical
analysis was performed using Student's /-test repeat¬
ability. Statistical significance was taken at the 5% level.
Results
There were no adverse events and the study was well
tolerated by all patients. Ten (91%) of the patients were
male, and three (27%) had a NYHA score of II with the
remaining eight (73%) having a score of III. The other
characteristics of the patients are presented in Table 1.
The results of the haemodynamic effects of the study
have been reported elsewhere [13]. In brief, administra¬
tion of systemic doses of endothelin antagonist resulted
in peripheral vasodilation and an increase in cardiac
output by a maximum of approximately 30%. The use of
both selective and non-selective endothelin blockade at
low and high dose allowed for a range of changes in
cardiac output to be investigated.
Comparison between thoracic bioimpedance and ther¬
modilution
There was good correlation between COtb and COtd
(r=0.76, P< 0.0001) although Bland-Altman analysis
revealed an average difference between values of
0.3 (2.2) 1/min (P = 0.02), suggesting a small average bias
but marked variability in results (Fig. 1). There was no
significant correlation when results were expressed as
percentage change from baseline and a significant average
difference between values of 10.1 (30.1)% (Fig. 2).
Repeatability of baseline measurements
Within device repeatability was assessed by analysing
baseline measurements of cardiac output in the same
patient on difference days. There was no difference in
Table 1 Baseline patient characteristics
Parameter Mean (SD)
Age (years) 61 ±9
BMI (kg/m2) 2712
HR (bpm) 63 ±9
SBP (mmHg) 136±21
DBP (mmHg) 77 ± 12
CVP (mmHg) 5± 1
MPAP (mmHg) 16± 2
CO (l/min) 5.310.7
CI (l/min per m2) 2.610.2
SVR (dynes.s.cm-5) 13581274
PVR (dynes.s.cm-5) 84125
PCWP (mmHg) 11 13
Body mass index (BMI), heart rate (HR), systolic blood pressure (SBP), diastolic
blood pressure (DBP), central venous pressure (CVP), mean pulmonary artery
pressure (MPAP), cardiac output (CO) by thermodilution, systemic vascular
resistance (SVR), pulmonary vascular resistance (PVR), pulmonary capillary
wedge pressure (PCWP) (Invasive measurements made by thermodilution
technique)
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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between-day repeatability between thermodilution and
thoracic bioimpedance [-0.2(1.2) versus 0.1 (1.0) l/min,
P = 0.7].
interest in the non-invasive technique of thoracic
bioimpedance. Thoracic bioimpedance has the advantage
that it is relatively inexpensive and easy to use. However,
its accuracy has been questioned.
This study has compared the techniques of thoracic
bioimpedance against thermodilution in stable patients
with chronic heart failure undergoing an acute haemody-
namic intervention study. A meta-analysis of thoracic
bioimpedance studies found a good correlation between
thoracic bioimpedance and reference techniques
(r = 0.66) [15]. In keeping with these studies we have
found a good correlation between thoracic bioimpedance
and a thermodilution technique (r— 0.76). However,
while there is a positive correlation between the
techniques, there is a poor level of agreement. The
method of thoracic bioimpedance systematically under¬
estimated cardiac output compared with thermodilution,
and this difference appeared to be greater with higher
cardiac output. Several studies have supported the use of
thoracic bioimpedance when measuring trends in cardiac
output [1-6]. However, the current study does not
support this finding, with poor agreement between values
when expressed as percentage change from baseline
despite reasonable repeatability of baseline measure¬
ments.
We observed an unacceptably low level of agreement both
for absolute and changes in cardiac output. Previous
studies have assessed thoracic bioimpedance in critically
ill patients or patients after mechanical ventilation or
undergoing cardiac surgery. Pulmonary oedema and
mechanical ventilation can affect thoracic bioimpedance
and many previously studied patients may have been
unsuitable for measurement of cardiac output by thoracic
bioimpedance. The patients in this present study had
stable chronic heart failure, were in sinus rhythm and in
the controlled setting of an acute haemodynamic inter¬
vention study. It would have been expected that these
optimal conditions would provide the best opportunity
for thoracic bioimpedance to be comparable with
thermodilution, given that patients were stable, self-
ventilating and had no pulmonary oedema. However, the
findings suggest that thoracic bioimpedance is not
comparable to thermodilution in patients with stable
chronic heart failure. Furthermore, invasive monitoring
using pulmonary artery catheters may have additional
advantages over non-invasive thermodilution in that they
allow direct measurement of blood pressure and allow
sampling of blood from the pulmonary artery.
Discussion
There is no 'perfect' method for measuring cardiac output
although the technique of thermodilution is most
commonly used. However, due to the invasive nature of
pulmonary artery catheterization there is considerable
Some of the differences noted in our study may be due to
slight difference in the timing of cardiac output
measurements, as thoracic bioimpedance cannot be
measured at exactly the same time as thermodilution.
However, measurements were within 60 s of each other
Copyright© Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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and therefore this is unlikely to explain the degree of poor
agreement between these two techniques, given that
overall changes in cardiac output throughout the study
were slow to develop in response to intravenous infusion
of the endothelin antagonist.
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Leslie, Stephen J., Teresa Attina, Ellen Hultsch, Luc Bolscher,
Matthias Grossman, Martin A. Denvir, and David J. Webb.
Comparison of two plethysmography systems in assessment of fore¬
arm blood flow. J Appl Physiol 96: 1794—1799, 2004. First published
January 29, 2004; 10.1152/japplphysiol.00567.2002.—Venous occlu¬
sion plethysmography is widely used to assess forearm blood flow
(FBF). We compared the established Hokanson system (HEC4) with
a newly developed Filtrass 2001 system (F2001). The F1EC4 uses
mercury-in-Silastic strain gauges, whereas F2001 detects volume
changes with a nonmercury linear displacement device. The aim of
this study was to evaluate the new F2001 against the HEC4 in terms
of repeatability and systematic bias. Ten subjects were studied on 4
separate days in random order using either the F1EC4 on both arms,
the F2001 on both arms, the HEC4 on the right arm with the F2001
on the left, or the F2001 on the right arm and the HEC4 on the left.
Stroop's colored word conflict test and postocclusive hyperemia were
used to increase FBF, and lower body negative pressure was used to
lower FBF. Stroop's colored word conflict test and lower body
negative pressure increased (24.6 ± 1.5%, n = 240, P < 0.0001) and
decreased (18.7 ± 0.8%, n = 240, P < 0.0001) FBF, respectively.
Postocclusive hyperemia after occlusion times of 5, 8, and 13 min
substantially increased FBF by 390 ± 86, 756 ±217, and 851 ±
132%, respectively. Repeatability was not different between the
devices (0.10 ± 2.37 vs. -0.47 ± 1.92 1/min, n = 125, P > 0.05), and
there was no systematic bias. The F2001 is a newly developed
plethysmography system that does not utilize mercury and is suitable
for assessing changes of FBF in physiological studies.
validation; Stroop's colored word conflict test; lower body negative
pressure
venous occlusion plethysmography has been used to study
forearm blood flow (FBF) for almost 100 years (4). The
underlying principle is simple: by obstructing venous outflow,
but not arterial inflow, the forearm volume initially increases in
proportion to the FBF. The standard technique for the assess¬
ment of this change in FBF, using a circumferential mercury-
in-Silastic strain gauge as part of a Wheatstone bridge to detect
increases in forearm circumference and derive volume
changes, has remained essentially unchanged for 50 years (24).
Venous occlusion plethysmography is now a well-validated
(19) and widely used tool to study mechanisms of human
vascular control, particularly when coupled with brachial ar¬
tery infusion to study effects of drugs and mediators on the
forearm vasculature (12). In humans, this approach to vascular
pharmacology has a distinct advantage over other techniques in
that vessels are studied in their physiological environment (1,
Address for reprint requests and other correspondence: D. J. Webb, Clinical
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12). A commonly used and well-validated device employing
the above principles is the Hokanson EC4 system (HEC4) (5,
7, 10, 17, 20, 22).
Recently, a new device, the Filtrass 2001 system (F2001),
has been developed, particularly to measure capillary perme¬
ability. However, this device may also be useful for measuring
FBF. It is based on similar principles as HEC4 but with some
important differences. With the F2001, forearm circumferential
measurement is measured by displacement of a freely move¬
able core of a linear variable displacement transducer (LVDT)
attached to a circumferential plastic monofilament (Fig. 1). A
linear relationship exists over a large range of calibration move¬
ments (6). The system is mechanically and electrically calibrated
to measure differences of 10 p,m and undergoes internal calibra¬
tion for changes in temperature and tissue compliance at each time
point. The potential utility of this device in forearm venous
occlusion plethysmography has not previously been assessed.
The aim of this study was to compare the F2001 against the
established HEC4 in terms of repeatability, systematic bias,
and ease of use. To compare the F2001, subjects underwent
simple, noninvasive systemic interventions to reduce or in¬
crease FBF. It was assumed that systemic hemodynamic
changes would result in similar changes in FBF simultaneously
in both arms (9). To assess higher blood flows, postocclusive
hyperemia (POH) was used. In this study, the repeatability of
each individual device could be assessed when,the same device
was used on both anus. Comparison of one system against the
other on different arms allowed examination for systematic
bias between devices.
METHODS
Subjects. Ten healthy subjects (9 men) aged 22-30 yr were re¬
cruited for this study, which was undertaken in accordance with the
Declaration of Helsinki and with the approval of the local research
ethics committee. Written, informed consent was obtained from each
subject. All subjects abstained from vasoactive drugs for at least 1 wk,
from alcohol and cigarettes for 24 h, and from food and caffeine for
at least 3 h before each study visit.
Study design. Volunteers attended for two separate study periods of
four visits each. The protocol was similar on each of the first four
study days except for the plethymography device used. The devices
were studied in random order using either the HEC4 on both arms, the
F2001 on both arms, the HEC4 on the right arm with the F2001 on the
left arm, or the F2001 on the right arm and the HEC4 on the left arm.
During the second four study visits, POH was employed to cause a
range of increases in FBF.
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Monofilament
F2001 LDVT
Fig. 1. Filtrass 2001 plethysmography device and Filtrass 2001 zigzag band
and linear displacement device
Study protocol. The study visits were performed on different days
in a quiet, draft-free, temperature-controlled room (22-24°C). During
the low-flow experiments, the volunteer was subjected to either
Stroop's colored word test (SCWT), lower body negative pressure
(LBNP), or a rest period. Mean arterial pressure and heart rate were
measured during minute 6 and FBF was measured during the last 3
min of each 10-min time period. During the high-flow experiments,
volunteers were exposed to 5, 8, and 13 min of arterial occlusion
resulting in postocclusive reactive hyperemia.
Venous occlusion forearm plethysmography. Both devices were
employed in a similar manner using the standard methodology em¬
ployed in our unit (25). In brief, venous occlusion was achieved by
inflating cuffs around the upper arm to above venous but below
arterial pressure (—40 mmHg). The arm was placed above the level of
the right atrium, and the upper arm cuff was inflated for 10 s then
deflated for 5 s. This cycle was repeated for the last 3 min of each
10-min study time period. Hand blood flow was predominantly
through skin blood vessels rather than skeletal muscle and thus had
different control mechanisms than FBF (21, 23, 24). Therefore, the
hands were excluded from the circulation by inflating cuffs around the
wrists to above systolic pressure (—200 mmHg) before FBF measure¬
ment. The strain gauges were placed around the forearm at the point
of greatest circumference.
There were some features unique to each device. HEC4 (D. E.
Hokanson, Bellevue, WA) consists of several discrete components:
two HEC4 plethysmographs, two Hokanson E20 rapid cuff inflators,
a Hokanson AG 101 cuff inflator air resource, strain gauges, and
Hokanson wrist and upper arm cuffs. HEC4 uses electrically cali¬
brated mercury-in-Silastic strain gauges, which were calibrated at the
beginning of each study. HEC4 occupies a total volume of 1.4 m3.
The F2001 LVDT (DOMED Medizintechnik, Munich, Germany)
was positioned on the forearm skin at a similar position to the
mercury-in-Silastic strain gauges and fixed to the forearm with adhe¬
sive tape. The plastic monofilament component surrounding the fore¬
arm was supported on the skin by a "zig-zag band" (Fig. 1). Before the
start of measurements, the surface of the monofilament was coated
with synthetic oil (DOMED Medizintechnik) to reduce friction and
then inserted into the main body of the LVDT. The LVDT was
calibrated at the beginning of each study, and the resting tension on
the monofilament was adjusted automatically at each time point. The
F2001 is a smaller, more compact device than the HEC4, with
all components contained within a single housing with a volume of
0.22 m3.
LBNP. The lower body of the subject was placed in an airtight steel
chamber and sealed with a pneumatic belt around the waist. Suction
was applied by a low-pressure vacuum device, and the negative
pressure within the chamber was kept constant by a servomechanical
pressure regulator (Department of Medical Physics, Western General
Hospital, Edinburgh, UK). LBNP (15 mmHg) was applied for 10 min
to reduce FBF. LBNP caused venous pooling, which, via baroreceptor
unloading and selective activation of elements of the sympathetic
nervous system, results in an increase in systemic vascular resistance
and forearm vascular resistance and thus a reduction in FBF. Previous
work (13) has shown that there is no effect on mean arterial pressure
or heart rate at this level of negative pressure.
SCWT. SCWT consists of several pages of the words "blue," "red,"
"yellow," and "green," each printed in different colors of ink (blue,
red, yellow, and green) in a random order. The subject is asked to state
the color of the ink in which the word is printed not the printed word.
Mental conflict arises because the learned response is to read the word
rather than report the color. This task was performed at a steady rate
of — 100 words/min with a metronome and observer acting as a guide
to encourage volunteers to keep to the pace. To induce reproducible
mental stress in our subjects, we applied the SCWT for 10 min.
Responses to the SCWT include a decrease in forearm vascular
resistance and a marked increase in FBF (14). SCWT also causes an
increase in mean arterial pressure, heart rate, and cardiac output and
a fall in systemic vascular resistance. Increases in FBF are stable and
reproducible after 9 min (8). However, forearm vasodilator responses
to SCWT may become diminished with repeated exposure (11) and, to
cause a range of FBF changes, three 10-min exposures to SCWT were
performed at each study visit.
POH. Postocclusive hyperemia (POH) can cause marked increases
in FBF (16). Brachial artery occlusion was applied by manually
inflating an upper arm cuff to at least 60 mmHg above systolic
pressure. POH of the forearm resulted after the occlusion was re¬
leased. A range of occlusion times (5, 8, and 13 min) were used to
assess the devices over a range of FBF.
Data acquisition and statistical analysis. FBF was obtained from
the mean of the last five consecutive recordings of each period. Both
systems allow the manual rejection of curves if rendered unsuitable
for analysis by movement artifact. Each slope recording was taken
from the steep linear part of the response curve. In the high-flow
experiments, the plateau phase was reached more quickly, but the
steep linear portion of the curve was still easily identified and assessed
over three or more heartbeats. Data obtained from the Hokanson
plethysmograph were stored on a Macintosh computer using the Chart
version 3.3 software (MacLab, ADInstruments). Data were further
analyzed offline using the Chart version 3.3 software and a template
spreadsheet (Excel 5.0, Microsoft). Data from the F2001 were ana¬
lyzed in a similar manner using a PC-based automatic analysis
program, which fits a curve to the measured slope and produces a
mean value for FBF.
There is no "gold standard" for the noninvasive measurement of
FBF. Repeatability of the devices was quantified by the average
difference between the changes in FBF from the preceding rest period,
in response to stimuli, measured by the same device when used
simultaneously on left and right arms (HEC4 on both arms or the
F2001 on both arms). Therefore, assuming stimuli will affect the FBF
in each arm to a similar degree, the closer to zero the difference in
J Appl Physiol • vol 96 • may 2004 • www.jap.org
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FBF between each arm and the smaller the standard deviation of
results, the more repeatable the device. Systematic bias between
devices was determined by the average of the differences from the
mean when different devices were simultaneously used to measure the
changes in FBF (HEC4 on the right arm with the F2001 on the left
arm or F2001 on the right arm and the HEC4 on the left arm) and
presented as Bland-Altman plots (3).
The effects of the SCWT, LBNP, and POH on FBF were assessed
using all data from both devices on left and right arms and expressed
as mean percentage changes from baseline ± SE. Mean differences
were assessed by using Student's /-test. Statistical significance was
taken at the 5% level. The study had 80% power to show a 7.5%
difference between the devices, assuming a 15% standard deviation in
FBF measurement.
RESULTS
None of the subjects were obese. All were right handed with
correspondingly larger right forearm circumferences (264 ± 5
vs. 259 ± 5 mm, P < 0.01). However, there was no difference
between baseline blood flow between the left and right arms
(3.1 ± 0.2 vs. 2.6 ± 0.1 ml • 100 mH1 • min ', P = 0.1). The
HEC4 cuff is broader than the F2001 cuff and inflates in < 1 s,
whereas the F2001 cuff takes s to inflate. There did not
appear to be any difference in cuff artifacts between the two
systems as a result.
LBNP and SCWT caused the expected changes in FBF, which
were repeatable within study visits (Fig. 2A). LBNP caused a
decrease in FBF (—18.7 ± 0.8%, n = 240, P < 0.0001), and
SCWT caused an increase in FBF (24.6 ± 1.5%, n = 240, P <
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Fig. 2. A: effect of lower body negative pressure (LBNP) and Stroop's color
word test (SCWT) on forearm blood flow (FBF). B: effect of postocclusive
hyperemia on FBF. Changes are expressed as percentage change from the
preceding baseline.
min substantially increased FBF by 390 ± 86, 756 ±217, and
851 ± 132%, respectively (all P < 0.0001) (Fig. 25).
Comparison between HEC4 and F2001. When used to
measure changes in the left and right arm, HEC4 showed no
difference in the absolute change in FBF between arms (0.10 ±
2.37 1/min, n = 125, P > 0.05). When used to measure
simultaneous changes in the left and right arm, F2001 showed
no difference in absolute changes in FBF between arms
(—0.47 ± 1.92 1/min, n = 125, P > 0.05). There was no
difference between HEC4 and F2001 (0.10 ± 2.37 vs.
-0.47 ± 1.92 1/min, n — 125, P > 0.05). There was good
correlation between the devices (Fig. 3). Bland-Altman plots
reveal no systematic bias between the devices or in relation to
flow values when used to measure simultaneous changes in
response to the systemic stimuli described above (Fig. 4).
DISCUSSION
FBF measurement is widely used in physiological and phar¬
macological studies in the clinical laboratory setting (12).
Existing mercury-in-Silastic (24) and Dohn air-filled cuffs
have been widely used and appropriately validated (18) for
measuring baseline and relative changes in blood flow. The
present study was designed to assess repeatability and system¬
atic bias using a new device for measuring FBF by venous
occlusion plethysmography. This device, the F2001, uses a
new and sensitive technique for measuring forearm circumfer¬
ence, is relatively compact, and has been validated for use in
assessing capillary permeability (6). The important finding of
this study was a demonstration of comparable repeatability, as
measured by differences in blood flow between left and right
arms, when the F2001 was used compared with a standard
mercury-in-Silastic device, the FTEC4. In addition, there was no
systemic bias between the devices as assessed by Bland-Altman
analysis (3).
Stimuli to effect changes in blood flow. To effect small
physiological increases and decreases in blood flow in the two
arms, we used SCWT and LBNP, respectively. These tech¬
niques are well characterized and widely used for this purpose.
However, they produced only small changes of blood flow,
with generally a <30% change. Because plethysmography
techniques are often used to detect much larger changes in
blood flow, especially when responses to exogenously admin¬
istered vasodilators and vasoconstrictors are examined (2, 12),
it was necessary to seek an additional stimulus to effect greater
increases in blood flow than seen with SCWT. Here, an
established ischemia model was used, and the POH response
was assessed (16) to graded ischemia. This achieved our aim
by producing increases of local FBF of—800% after 13 min of
occlusion, equivalent to responses to potent vasodilator agents
in the forearm.
Comparison between arms. In studies with SCWT and
LBNP, we compared responses between arms, both for studies
of repeatability and systematic bias. This can be justified from
many studies showing that the forearm response to systemic
stimuli affects both arms equally. Indeed, this is one of the
principles underlying the use of the opposite arm as a control
in plethysmography studies (1,9). Importantly, data from this
study confirm the similarity in responses between arms, with
only an —1% difference in percentage change in FBF from
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Fig. 3. Correlation graphs of Hokanson EC4 (right arm) vs.
Hokanson EC4 (left arm) (Hi vs. H2; A), Bland-Altman com¬
parison ofFiltrass 2001 (right arm) vs. Filtrass 2001 (left arm)
(Fi vs. FY; B), Bland-Altman comparison ofFiltrass 2001 (right
arm) vs. Hokanson EC4 (left arm) (Fi vs. H2; C), and Bland-
Altman comparison of Hokanson EC4 (right arm) vs. Filtrass
2001 (left arm) (Hi vs. F2; D).
baseline between left and right arms to SCWT and LBNP when
measured by HEC4.
In the case of POH, however, the stimulus is local and not
systemic, and there may be differences between arms related
to hand dominance. Therefore, in this situation, only com¬
parisons within one arm were made in the present study to
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Fig. 4. Bland-Altman comparison of Hokanson
EC4 (right arm) vs. Hokanson EC4 (left arm) (Hi
vs. H2; A), Bland-Altman comparison of Filtrass
2001 (right arm) vs. Filtrass 2001 (left arm) (Fi vs.
F2; B), Bland-Altman comparison of Filtrass 2001
(right arm) vs. Hokanson EC4 (left arm) (H2 vs. F1;
C), and Bland-Altman comparison of Hokanson
EC4 (right arm) vs. Filtrass 2001 (left arm) (F2 vs.
Hi; D). Light dotted lines indicate mean values, and
dashed lines indicate 95% confidence limits.
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Comparison between devices. The main aim of this study
was to explore the comparability between devices for the
measurement of blood flow by plethysmography. Because
there is no readily usable gold standard for measuring FBF, we
chose to compare the F2001 with one of the most widely used
devices in current use, the HEC4. Many studies using forearm
plethysmography involve multiple measurements of blood
flow in the same individual to be performed on separate
occasions. Therefore, a high degree of repeatability is required
across a wide range of blood flows. LBNP and SCWT could be
used to examine small decreases and increases in blood flow,
respectively, and POM could be used to examine large in¬
creases. The study design allowed within-device as well as
between-device comparison of effects of external stimuli on
blood flow to assess both repeatability and systematic bias.
The studies show a high level of correlation (>90%) be¬
tween devices that was similar to that for within-device corre¬
lations. More importantly, there was no difference in baseline
blood flow or in the response to the various stimuli (LBNP,
SCWT, and POH) between devices and no difference between
measurements even at the high blood flows associated with
POH. Furthermore, Bland-Altman analysis revealed no sys¬
tematic bias. These datfi, taken together, show a high level of
repeatability that is sufficient to allow either device to be used
for plethysmographic studies.
Potential advantages of the F2001. The recently developed
F2001 is designed to measure FBF and can also be used to
measure capillary permeability. The F2001 device is more
compact and portable than the HEC4. This may be of advan¬
tage in certain circumstances, such as in intensive care units or
in studies where the equipment has to be moved between
locations. Both types of strain gauge were easy to use, although
the F2001 required greater manual dexterity to insert the
monofilament into the body of the LVDT. With either device,
the subject must remain still throughout the study, because
movement of the forearm can dislodge the strain gauges.
However, the HEC4 strain gauge may be simply replaced with
little disruption to the study, whereas disruption of the F2001
strain gauge requires recalibration. This might be problematic
if displacement occurred during a critical part of an interven¬
tional study. In terms of mechanical reliability, one F2001
strain gauge failed during the study (total of 40 study days),
whereas there were no failures of the HEC4 strain gauges. The
upper cuff air inlet of the F2001 mechanically interfered with
the strain gauge on inflation, and the rate of arm and wrist cuff
inflations was slower than the HEC4 (3-4 vs. < 1 s). Slowly
inflating cuffs can result in venous engorgement if arterial
occlusion is significantly delayed, which could then cause
discomfort and potentially affect results. However, neither of
these problems appeared to occur in our study, suggesting the
slower rate of cuff inflation is not of practical importance, even
at high flows. Although there may be local variations, there
was no major cost difference between the two devices. In
addition, unlike the HEC4, the F2001 does not use mercury in
its construction and, therefore, has the advantage that its use
would not be restricted in the future were the use of mercury in
medical instruments to be banned (15).
Potential limitations ofthe study. For ethical reasons, it was
not possible to assess intra-arterial responses to vasodilator and
constrictor agents directly in these studies. Therefore, postis-
chemic hyperemia was used as the surrogate stimulus for
effecting large increases in flow. It is necessary, and probably
reasonable, to make the assumption that these observations can
be extrapolated to such studies. Similarly, studies here were
performed in the forearm circulation, and we cannot be certain
that they also apply to the calf, although this again would seem
a reasonable assumption.
In summary, the F2001 seems a promising and reliable new
addition to the systems available to measure blood flow by
strain-gauge plethysmography, with potential advantages in
terms of size, mobility, data analysis, and its capacity to be
used to measure capillary permeability.
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Endothelins and their inhibition in the human skin
microcirculation: ETti_31], a new vasoconstrictor peptide
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Endothelin-1 (ET-1 [,-2i]) is an extremely potent vasoconstrictor in the human skin
microcirculation and is generated from larger precursor peptides. The aims of the
present study were to assess the vasoactive effects of these precursors as well as
endothelin blockade in the human skin microcirculation, in vivo.
Methods
Six healthy volunteers received intradermal injections of a range of doses of big ET-
1 [,-38], ET-1 [1-31], ET-1 [i_2i], BQ-123 (ETA receptor antagonist), BQ-788 (ETB receptor
antagonist), phosphoramidon [endothelin converting enzyme (ECE) inhibitor] or
saline control (0.9%). Skin blood flow (SBF) was measured using standard laser
Doppler flowmetry.
Results
Big ET-1 [,_38], ET-1 [1.31] and ET-1 [,_2,] reduced SBF when compared with saline control
(P < 0.01 for all). Big ET-1 [,-38] and ET-1 [,_3i] were less potent than ET-1 [,_2i] as defined
by skin vasoconstriction. Phosphoramidon, BQ-123 and BQ-788, given alone, all
caused vasodilatation in the human skin microcirculation (P < 0.01 for all).
Conclusions
In the human skin microcirculation, big ET-1 [,_38] and ET-1 [,-3,] are less potent
vasoconstrictors than ET-1 n-21]- The effects of big ET-1 [,_38j and phosphoramidon
suggest the presence of endogenous ECE activity in the skin. In contrast to skeletal
muscle resistance vessels, ET-1 (,_2i] contributes to the maintenance of skin microvas¬
cular tone through both ETA and ETB receptor-mediated vasoconstriction.
Introduction
Endothelin-ld-21] (ET-1) is a potent vasoconstrictor in
several vascular beds including the skin microcircula¬
tion [1, 2]. It is formed by the action of endothelin
converting enzyme (ECE) on its inactive precursor ET-
l[i-38j (big ET-1) (Figure 1). There are two distinct
endothelin receptors subtypes; ETA and ETB. Both are
present on vascular smooth muscle cells mediating vas¬
oconstriction, while ETb is also present on endothelial
cells mediating vasodilatation. Thus, the cardiovascular
effects of ET-l[1_2i] will depend, in part, on the balance
of action at these two receptors, and in particular the
Br J Clin Pharmacol | 57:6 | 720-725 | 720
balance between the vasodilating and vasoconstricting
actions of the ETB receptor.
The endothelin system may be involved in the patho¬
physiology of several cardiovascular diseases, including
hypertension [3], renal failure [4], pulmonary hyperten¬
sion [5], and chronic heart failure (CHF) [6]. Blockade
of the system remains an area of major interest. In par¬
ticular, whether selective or dual receptor antagonism or
ECE inhibition will provide the best treatment strategy
remains unclear. Initial efforts have been focused mainly
on endothelin receptor blockade. Endothelin receptor
antagonists have benefits in patients with primary pul-
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Figure 1
Pathway of endothelin processing. Agents in boxes are enzyme inhibitors/
receptor antagonists
monary hypertension [7], although results in patients
with CHF have so far been disappointing [8]. Clinical
development of ECE inhibitors continues but there are,
as yet, no fully published data on their clinical efficacy.
Recently, ET-1[1_31], a new derivative of big ET-l, has
been identified in humans. It is generated following the
cleavage of big ET-1 at the Tyr31-Gly32 bond by human
chymase [9] and may represent an active intermediary
in an alternative pathway of ET-1 production (Figure 1).
In cultured human coronary artery smooth muscle cells
[10, 11] and human mesangial cells [12], ET-ln_31]
increases intracellular calcium. ET-ln_31] causes vaso¬
constriction in isolated porcine coronary arteries [13],
monkey trachea [14], human umbilical arteries [15] as
well as human coronary and mammary arteries [16].
Data suggest that ET-ln_31] may be cleaved to ET-l^i]
for its biological activity in cultured bronchial smooth
muscle cells [17] and in both guinea pig [18] and human
arteries [16]. However, to date there have been no in vivo
clinical studies to assess the cardiovascular effects of
ET-1[i_3J].
The aims of this study (Fig. 1) were to investigate the
in vivo vascular effects of ET-l[1_2i], its precursors big
ET-ln_38] and ET-1[|_3I], and blockade of endogenous
ET-1 activity by BQ-123 (a selective ETA receptor
antagonist) [19], BQ-788 (a selective ETB receptor
antagonist) [20] and inhibition of ET-1 generation by




Six healthy men (age range 20-30 years), with no risk
factors for vascular disease, participated in each study.
Written informed consent was obtained and studies were
performed with the approval of the local research ethics
committee and in accordance with the Declaration of
Helsinki. No subject was taking regular medication and
all avoided medication for 1 week before each study. All
subjects abstained from alcohol for 24 h and from food,
caffeine and tobacco for at least 12 h before each study.
Skin blood flow measurement
Skin blood flow was assessed using standard laser Dop-
pler skin flowmetry (2 channel, MBF 3D; Moor Instru¬
ments Ltd, Axminster, UK) at baseline and every 2 min
for the first 10 min and then every 5 min up to 60 min.
Voltage output from the Doppler flowmeter was cali¬
brated with standard flux solution (Moor Instruments Ltd)
and transferred to a Macintosh personal computer (Clas¬
sic II; Apple Computer Inc., Cupertino, CA, USA) with
a MacLab analogue-to-digital converter and 'CHART'
software (v.3.28; AD Instruments, Castle Hill, Australia).
Signals were averaged over 20 s at each time point.
Study drugs
ET-l[i_31] (Peptide Institute, Osaka, Japan), and big ET-
1 [3 38], ET-l[i_2i], BQ-123, BQ-788 and phosphoramidon
(Clinalfa, Laufelfingen, Switzerland) were dissolved in
physiological saline (0.9%; Baxter Healthcare Ltd,
Thetford, UK), which was also used as the vehicle con¬
trol. Phosphoramidon was poorly soluble, allowing a
limited dose range to be examined.
Study protocol
Subjects rested recumbent in a quiet room maintained
at a constant temperature of 22-24 °C for 15 min to
allow stabilization of skin blood flow. Four sites for
injection were identified and marked on the volar aspect
of each forearm. Care was taken to avoid underlying
veins (demonstrated by high baseline Doppler signals)
and arteries (demonstrated by pulsatile Doppler signals).
A laser probe holder was attached to the skin using
adhesive tape to reduce probe movement during the
study. All study drugs were administered by 10 p.1 intra¬
dermal injection [0.33-mm (29.5 SWG) needle; Becton
Dickinson, Dublin, Ireland], Following dose-ranging
pilot studies, subjects received, in random order, either
saline control or study drug over a range of concentra¬
tions; big ET-1 ti_38] (0.1-30 pmol), ET-l^ij (1 pmol to
0.3 nmol), ET-lti_2i] (1 amol to 1 pmol), BQ-123 (0.1-
30 nmol), BQ-788 (0.1-30 nmol) and phosphoramidon
(0.1-10 nmol). The maximum dose of phosphoramidon
was limited by solubility.
Data handling and statistical analysis
Results are expressed in arbitrary perfusion units (PU).
Intradermal injection of saline placebo causes an
increase in laser Doppler signal [1] and therefore all
Br J Clin Pharmacol 57:6 721
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results are presented as placebo corrected mean ± SEM.
Area under the curve (AUC) for the response between
0 and 30 min was used to determine potency. Potency
was estimated as the dose required to cause a significant
vasoconstriction in the skin compared with saline pla¬
cebo. Statistical difference was tested by anova with
repeated measures over time and paired Student's f-test
with correction for repeated measures (Excel 5.0;
Microsoft Ltd, Seattle, WA, USA). A P-value <0.05 was
considered to be statistically significant.
Results
Intradermal drug delivery was well tolerated by all vol¬
unteers. Transient discomfort occurred at some injection
sites but was unrelated to injectate and did not persist
for longer than 10 s. This discomfort was not associated
with impaired tissue viability and did not appear to
affect responses.
Effect of endothelin agonists
Big ET-1(I_38], ET-1[1_31] and ET-l^i] caused vasocon¬
striction that was visually evident on the skin, causing
an area of marked pallor. Big ET-1[,_38] and ET-l[i_31]
were -30-fold less potent than ET-l[1_2i] (Figure 2a).
Compared with control, sustained reduction in blood
flow was caused by big ET-1[1_38] (30 pmol; maximum
decrease 25±8PU, P = 0.04), ET-1(1.31] (0.3 nmol;
maximum decrease 13 ± 3 PU, P = 0.04) and ET-1 ri-21]
(1 pmol; maximum decrease 17±4PU, P = 0.003)
(Figure 2b). At these concentrations, vasoconstriction
was sustained and was still visibly present at 24 h,
although the duration of response beyond 60 min was
not formally assessed.
Effect of endothelin blockade
BQ-123 and BQ-788 caused vasodilatation (Figure 3a).
Compared with control, a sustained increase in blood
flow was caused by BQ-123 (300 nmol; maximum
increase 30 ± 5 PU, P = 0.002) and BQ-788 (300 nmol;
maximum increase 18 ± 5 PU, P = 0.004) (Figure 3b).
Compared with control, phosphoramidon caused a
small increase in blood flow at the highest dose
(10 pmol; maximum increase 11±2PU, P = 0.009;
Figure 3a,b).
Discussion
In the human skin microcirculation, we have confirmed
that ET-1[1_2i] is a potent vasoconstrictor and shown for
the first time that ET-ln_31] and big ET-l[i_38] also cause
skin vasoconstriction in vivo. Our results suggest that
there is ECE activity in the skin as demonstrated by the
vasoconstriction following intradermal administration
722 | 57:6
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(a) Dose-response (AUC) to big ET-1 [,-38] (0.1-30 pmol) (□), ET-1 [i_3i]
(1 pmol to 0.3 nmol) (A), and ET-1 [,_2i] (1 amol to 1 pmol) (•). (b)
Effect of maximum dose of endothelin agonist on skin blood flow;
Er-lp-38] (30 pmol), ET-1[1_31] (0.3 nmol) and ET-lp^ii (1 pmol).
*P < 0.05; **P<0.01 i*. placebo
of big ET-l^s] and vasodilatation with ECE inhibition.
In addition, we have confirmed that selective blockade
of the ETa receptor caused skin microvasculatory
vasodilatation [2] and shown directly that selective
blockade of the ETB receptor also results in vasodilata¬
tion. In contrast to observations in resistance vessels,
this suggests that ETB receptors in the skin contribute to
ET-1-mediated vasoconstriction not only in arterial dis¬
ease [2] but also in healthy blood vessels.
The novel finding that ET-lri_311 is a vasoconstrictor
is of interest, and the first evidence of its vasoactive
properties in vivo in man. If ET-1[,_31] is converted to
ET-ln_2i] by a non-ECE pathway and if this contributes
importantly to ET-1 generation, then specific receptor
blockade may offer greater functional inhibitory activity
than ECE inhibition. Alternatively, ET-1 tl_31] may have
vasoconstricting activity of its own at endothelin recep¬
tors. Recently, the vasoconstricting effects of ET-l[i_3i]
have been shown to be mediated via the ETA receptor in
rabbit renal resistance vessels [21], an effect which was
unaffected by phosphoramidon. Although ET-l[i_31] is
less potent than ET-1[1_2i] as a vasoconstrictor, local pro¬
duction of ET-ln_31, may occur specifically in tissues
that express human chymase, such as from the mast cells
Br J Clin Pharmacol
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(a) Dose-response (AUC) to BQ-123 (0.1-30 nmol) (O), BQ-788 (0.1-
30 nmol) (A), phosphoramidon (0.1-10 nmol) (□). (b) Effect of
maximum dose of endothelin blockade on skin blood flow; BQ-123
(30 nmol), BQ-788 (30 nmol), phosphoramidon (10 nmol). *P< 0.05;
**P<0.01 ls. placebo
within the shoulder region of coronary atheromatous
plaques [22, 23], Therefore, generation of ET-1[1_31]
could contribute to coronary artery spasm at the time of
plaque rupture. Indeed, ET-1[1_31] may be cleaved to ET-
1 [1-2U f°r its biological activity in cultured bronchial
smooth muscle cells [17] and in both guinea pig [18]
and human arteries [16].
The fact that big ET-ln_38] has affinity for the endot¬
helin A receptor which is 1000-fold less than ET-lu_2i]
[20], and that big ET-1(1_38] was ~ 30-fold less potent
than ET-lj^i], makes it unlikely that big ET-1[,_38]
caused a major direct vasoconstrictor action and sug¬
gests that there is some conversion of big ET-1 to ET-
1 [1-21] in the skin. It has previously been demonstrated
that big ET-lp^s, is vasoactive in human arteries [3] but
not veins [25], and that this vasoconstriction can be
blocked by ECE inhibition [26]. The presence of ECE
activity in the skin is further supported in this present
study by the vasodilatory effects of phosphoramidon.
This is also consistent with preliminary clinical studies
where systemic ECE inhibition caused systemic vasodi¬
latation and a reduction in blood pressure [27], In our
study there appeared to be a transient vasoconstriction
to phosporamidon, although this was not consistent and
did not reach statistical significance. This observation
may warrant further investigation.
Endothelin antagonists have been studied in the skin
by other groups. The selective ETA receptor antagonist
PD147953 and the nonselective endothelin receptor
antagonist PD145065 caused vasodilatation and attenu¬
ated the vasoconstrictor effects of ET-l[1_2i] in the
human skin in vivo [1, 28], BQ-123 is a selective ETA
receptor antagonist and has been shown in many vascu¬
lar beds [29] to be a vasodilator by blocking the effects
of ET-l[i_2i]. There are few data on the effects of endot¬
helin antagonists in the skin [1,2,28]. The present study
demonstrates that BQ-123 causes vasodilatation, con¬
firming that ET-1 contributes to the maintenance of
basal vascular tone in the skin of healthy volunteers.
BQ-788 also caused skin vasodilatation. This result was
unexpected, as selective ETB receptor antagonism
causes vasoconstriction in skeletal muscle [30] and
when given systemically [31]. In addition, previous data
on the skin microcirculation have demonstrated that ET-
1 mediates vasoconstriction via the ETA receptor with
little contribution from the ETB receptor [28, 32], How¬
ever, our data indicate that the dominant effect of ET-
l[i-2i] on the ETb receptor is vasoconstriction in the
human skin microcirculation, and that blockade of the
ETb receptor results in vasodilatation. It is possible that
some of this effect may be a result of displacement of
ET-1 from ETB receptors and a reduction of available
ETb receptor binding sites, thereby increasing vasocon¬
striction via the ETA receptor. This finding may require
further investigation.
Endothelin receptor antagonists have proven benefits
in patients with primary pulmonary hypertension [7]
and reduce blood pressure in hypertensive patients [33].
To date, clinical trials investigating the potential benefits
of endothelin receptor antagonists in CHF have been
disappointing [8]. ECE inhibitors inhibit endothelin pro¬
duction and provide a potential alternative to endothelin
receptor antagonism. Unlike receptor blockade, which
can increase plasma ET-l(i_2i] concentrations, ECE
inhibitors have the advantage that they block ET-1 []-21]
production, thus reducing plasma ET-1[|_21] concentra¬
tions and leaving clearance receptors unblocked. How¬
ever, the effects of raised plasma concentration of
ET-ltl_21], associated with ETb receptor blockade [30],
may not be relevant if ETA receptors are also blocked.
However, if there are clinically significant non-ECE
pathways of production with vasoactive intermediary
Br J Clin Pharmacol I 57:6 I 723
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peptides such as ET-1[1_31], then ECE inhibition may be
a less attractive treatment strategy.
While the doses of peptides used in these experiments
are known, the concentration when injected into the skin
cannot be measured, due to the unknown volume of
distribution in the skin. However, as the same volume
of injectate was used for each dose, comparing the rel¬
ative potencies of each peptide is probably justified.
Furthermore, true potency may vary depending on
whether compounds are full or partial agonists. Highly
selective antagonists of each receptor were not available
to us. Although BQ-788 might have blocked ETA recep¬
tor function, its 100-fold greater affinity for the ETB
receptor [34] compared with the ETA receptor, and the
equal potency of BQ-123 and BQ-788 in this study,
suggest that BQ-788 does indeed mediate vasodilatory
effects via blockade of the ETB receptor. Another limi¬
tation is that phosphoramidon is not only an inhibitor of
ECE but also an inhibitor of neutral endopeptidase
(NEP). However, whether in health or cardiovascular
disease [3, 35, 36], the inhibition of NEP tends to cause
vasoconstriction and therefore if anything lead to an
underestimate of the vasodilator effects of selective ECE
inhibition.
In summary, the discovery of a vasoactive intermedi¬
ary endothelin peptide may have importance for the
further development of endothelin blockers as clinical
therapies. The skin microcirculation provides an oppor¬
tunity to investigate the vasoactive properties of a com¬
pound, in vivo, in a relatively safe manner due to the
small doses which are administered. However, further
studies are required to determine whether ET-1[1_3i] is
vasoactive in other vascular beds. In particular it will be
of interest to note whether ET-1[i_3i] causes vasocon¬
striction in resistance blood vessels.
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Endothelin-1 Antagonises Beta-Adrenergic Stimulation
in Human Right Atrial Myocardium
S.J. Leslie1, S. Prasad2, C. Campanella2, D.J. Webb1, M. A. Denvir1
Plasma concentrations ofendothelin-1 (ET-1) are elevatedin chronic heart failure (CHF) and correlate with a poor
prognosis [1], Short-term systemic ET blockade in CHF
patients causes potentially beneficial haemodynamic effects;
increasing cardiac output and reducing vascular resistance
[2]. However, the initial results from longer term clinical tri¬
als have been disappointing. In the ENABLE and EARTH
clinical trials preliminary reports indicate that there was no
major benefit when an endothelin receptor antagonist
(ETRA) was added to conventional heart failure therapy.
Beta-blockers improve mortality in CHF patients and
while the mechanisms for these benefits are not fully under¬
stood they may involve betaj-adrenoreceptor upregulation.
Betai-adrenergic stimulation increases adenylate cyclase (AC),
increasing cAMP, activating protein kinase A, resulting in
phosphorylation of several intracellular proteins ultimately
leading to an increase in intracellular calcium. The positive
inotropic effect of ET-1 is mediated predominantly via the
ETa receptor resulting in activation ofprotein kinase C via G
proteins. However, in isolated myocardial membrane studies
ET-1 also inhibits AC and may therefore inhibit beta-adren¬
ergic stimulation [3, 4], This potentially important antago¬
nism between the two systems has not been previously stud¬
ied at a functional level.
Methods
12 right atrial appendage biopsies were harvested at the time of
coronary artery bypass surgery and placed in cold cardioplegic
solution ([mM]; NaCl 130, KC1 5.4, NaHP04 0.56,
MgCL,I RO 3.5, CaCl 2, Glucose 10, FLEPES 5, 2,3-butane-
dione-monoxime 30 [mM] corrected to pH 7.4 with NaOH).
Free running trabeculae were mounted for electrical stimulation
at 3 Hz at a voltage = 10 % above threshold and allowed to stabi¬
lise for 1 hour in a vertical 7 ml chamber (World Precision In¬
struments, UK) containing modified Tyrodes (NaCl 130, KC1
5.4, NaHPCL 0.56, MgCL^O 3.5, CaCl 2, Glucose 10,
HEPES 5 [mM]) corrected to pH 7.4 with NaOH and continu¬
ously bubbled with 100 %02at35 °C.ET-1 (NeosystemSNPE
England, UK) was reconstituted in 0.9 % saline and isoprenaline
(Sigma-Aldrich Chemicals, UK), a betai-adrenoreceptor ago¬
nist, was dissolved in physiological solution with ascorbic acid (1
mM) to reduce oxidation. Drug concentrations were chosen
from previous dose ranging studies. Trabeculae were exposed to
either isoprenaline (10 nM), ET-1 (10 nM) or isoprenaline fol¬
lowed by ET-1. When possible two trabeculae were dissected
from a single atrial appendage.
Statistical difference was tested by Student's t-test (Excel
5.0, Microsoft). A value ofp < 0.05 was considered to be sta¬
tistically significant. All values are expressed as mean ± SEM.
The study was approved by the local research ethics com¬
mittee and written informed consent obtained from each
subject.
Results
ET-1 (10 nM) increased force by 12.6 + 5.0 %, n = 5, p = 0.04.
This was preceded by a transient non-significant decrease in
force (-3.6 + 1.9 %, p = ns). Isoprenaline (10 nM) increased
force from baseline 65.7 ± 29.2 %, n = 5, p = 0.01. The in¬
crease in force with isoprenaline was of more rapid onset,
with a maximal effect seen after 5 min (Fig. 1). When added
to maximally beta-adrenergic stimulated trabeculae, ET-1
significantly attenuated the effect of isoprenaline causing a
reduction in force (96 ± 39 %, n = 5, p < 0.01) (Fig. 2).
Discussion
Both ET-1 and isoprenaline increased isometric force in
human RA myocardium. ET-1 increased force following a
transient negative inotropic response, and although this has
been described by other groups [4, 5] the mechanism
remains unclear. Isoprenaline increased force, which was of
faster onset and larger magnitude than ET-1. We have
observed, for the first time, that ET-1 functionally attenu¬
ates the inotropic effects of isoprenaline in human myocar¬
dium. This reduction in force was observed after maximal
stimulation of the beta-adrenergic system. The underlying
mechanism is likely to be interaction at the level of AC as
seen in isolated membrane studies where ET-1 was shown
Figure 1. Effect of isoprenaline (10 nM) and endothelin-1 (10 nM)
on force of contraction of human right atrial trabeculae
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to inhibit the effect of betai-adrenoreceptor activation on
this enzyme.
This study has some limitations in that we were unable to
study normal human ventricular myocardium due to a lack of
suitable samples. Previous isolated membrane studies have
confirmed differences between atrial and ventricular tissue so
ET-1 may not inhibit AC in ventricular tissue [5]. In addi¬
tion, the concentrations ofET-1 used were higher than those
in the plasma of CHF patients but may be similar to those
occurring at a local level in myocardium.
The interaction between endothelin and adrenergic sys¬
tems in the human myocardium may be significant in
patients with CHF where both systems are activated. ET-1
may protect from catecholamines over-stimulation and may
be anti-arrhythmic. With the possible introduction ofETRAs
for the treatment of CHF the physiological and patho-physi-
ological interactions between these two systems may be of
clinical importance as unintended deleterious effects may
occur with ET blockade in the absence of betai-adreno-
receptor blockade.
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Figure 2. Effect of endothelin-1 (10 nM) on isoprenaline (10 nM)
stimulated human right atrium; black arrow indicates the addition of
endothelin-1 (10 nM)
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Abstract Objective'. To determine the reproducibility of
laser Doppler flowmetry coupled with intra-dermal sal¬
ine delivery.
Methods'. Delivery of saline was judged visually by two
operators («= 100), using a graduated syringe (Becton-
Dickinson), by expelling saline onto a weighing boat.
Volume was assessed by weight. Skin blood flow fol¬
lowing intra-dermal injection of saline was assessed in 18
healthy volunteers; 10 attended twice to assess between-
day reproducibility, ahd 8 attended once to assess be-
tween-site reproducibility. Results are expressed as mean
value ±SEM and 95% confidence interval for mean
differences.
Results'. There was no difference between operators in
mean injection weight, both weights being 10.3 ±0.1 mg
(mean difference 0.08, 95% confidence interval, CI -0.23
to 0.39 mg; n= 100, P = 0.9). Intra-dermal saline caused
a nine-fold increase in blood flow (0.03 ±0.003 to
0.27±0.02 perfusion units, PU; n=18, /><0.001). This
response had a rapid onset, with the maximal effect seen
at 4 min and a duration of greater than 30 rnin. There
was no difference in the magnitude of the response be¬
tween the dominant and non-dominant arms, AUC was
2.9 ±0.4 and 2.9 ±0.4, respectively (mean difference
-0.05, 95% CI -0.8 to 0.73 PU; «= 18, P = 0.93).
However, there was a trend towards differences between
study visits 1 and 2: AUC was 3.2 ±0.6 and 2.0±0.5,
respectively (mean difference 1.2, 95% CI -0.03 to 2.43
PU; n= 10, P=0.1). There was no difference in the
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magnitude of responses between different sites on the
forearm (n = 64, P = 0.6).
Conclusions'. These studies demonstrate that the tech¬
nique of laser Doppler flowmetry coupled with intra¬
dermal injection is a safe, well-tolerated technique with
good reproducibility. A trend towards reduced between-
day reproducibility emphasizes the importance of vehicle
control sites when investigating the effects of vasoactive
compounds. This technique provides a reliable method
for the intra-dermal delivery of drugs, despite the direct
effect of injection of saline on blood flow.
Keywords Skin blood flow • Laser Doppler
flowmetry • Intra-dermal injection
Introduction
Laser Doppler flowmetry is a well-validated technique
used for the investigation of the effects of vasoactive
substances on the skin microcirculation [1, 2, 3, 4, 5, 6, 7,
8, 9, 10]. It has several potential advantages over other
techniques for the initial study of drugs in humans in
that it is minimally invasive and relatively safe, because
it uses very small doses of study compounds with a
mainly local action. It allows separate sites on the skin
to be studied simultaneously and thus the investigation
of a range of concentrations on the same occasion.
While it is possible to deliver some vasoactive substances
such as acetylcholine and noradrenaline by skin ionto¬
phoresis, many peptides cannot be delivered by this
means due to their large size, poor solubility, or lack of
electrical charge. In these situations, intra-dermal injec¬
tion can be used. Physiological saline is commonly used
in studies as a drug vehicle, and there are a variety of
high-precision syringes that can be used for intra-dermal
injection. However, these are expensive and when used
in human studies can, by necessity, be used only for a
single subject. In the current studies, we used standard
clinical insulin syringes with a 29.5 SWG-gauge needle
100
to administer local intra-dermal injections. The advan¬
tages of these syringes are that they are relatively inex¬
pensive and easy to use. These syringes have been used
by other groups in skin blood flow (SBF) studies [7, 8, 9]
but have not been validated for use for intra-dermal
injection in pharmacological studies. There are potential
sources of error in the injection technique, because the
plunger is depressed by only 1 mm to deliver 10 pi and
is judged visually. The reproducibility of intra-dermal
delivery in terms of volume delivered and the effect of
intra-dermal saline injection on SBF using these syringes
has not been, reported previously.
The aim of these studies was to determine the intra- and
inter-operator reproducibility of saline administration in
terms of injection volume and to determine reproduc¬
ibility of SBF responses to intra-dermal injection of saline.
Methods
Subjects
Eighteen right-handed, healthy men (22-45 years) were studied.
Studies were performed with the approval of the local research
ethics committee and in accordance with the Declaration of Hel¬
sinki of the World Medical Association. Written informed consent
was obtained from each subject before entry to the study. None of
the subjects were taking regular medication and all avoided any
medication for 1 week prior to study. All subjects abstained from
alcohol for 24 h and from food, tobacco, and caffeine-containing
drinks for at least 12 h before each study.
Injection volume
Graduated 29.5 SWG syringes (Becton-Dickinson, Dublin, Ire¬
land) were used for saline delivery. Each 1-mm graduation on the
0.5-ml syringe represents 10 pi, thus, to deliver this volume, the
syringe plunger was depressed by 1 mm. The reproducibility of
volume delivered was assessed by injecting 10 pi saline, judged by
depressing the syringe plunger by one graduation, onto a weighing
boat placed on a balance (Mettler Toledo MT5). This balance has
an accuracy and precision of 1 pg and therefore can measure
changes of 1 nl assuming a specific gravity of saline of 1.00. A new
syringe was used for each saline delivery and care was taken, as in
our clinical studies, to expel any air bubbles from the syringe before
injecting. Two operators each performed blind 100 injections.
Laser Doppler flowmetry and intra-dermal injection
Subjects lay supine with the arms supported and the volar aspect of
the forearm facing upwards. Sites for injection were chosen, taking
care to avoid underlying arteries (assessed by palpation and pul¬
satile Doppler signal) or veins (assessed visually and by high-
baseline Doppler signal). Four laser probe holders were attached to
the skin of each forearm with adhesive tape to ensure no dis¬
placement of the probe during the study.
Protocol
Studies were performed in a quiet, temperature-controlled,
draught-free room (23-25°C). Each subject was allowed to rest for
at least 20 min before the study protocol was started. Baseline
recordings were made. Subjects then received a number of intra¬
dermal injections of 10 pi saline (0.9%; Baxter Healthcare, Thet-
ford, UK) and laser Doppler signal recorded every 2 min until
10 min and every 5 min until 30 min. To assess between-day
reproducibility, ten subjects attended for two study visits. To assess
between-site reproducibility, eight of the subjects received four in¬
tra-dermal injections of saline on the volar aspect of each forearm.
Data handling and statistical analysis
Increases in weight on the balance following saline injection were
recorded manually and entered onto a spreadsheet (Excel v5.0;
Microsoft). The accuracy was assessed by mean values and repro¬
ducibility by assessing the spread of results. For the SBF studies,
analogue voltage output from the laser Doppler flowmeter was
processed by a MacLab analogue-to-digital converter and Chart
v3.3 software (AD Instruments, Castle Hill, Australia), and further
analysis was performed off-line. The average signal for 30 s at each
time point was recorded and entered into a spreadsheet (Excel v5.0;
Microsoft). Area under the curve (AUC) over 30 min was calculated
for each SBF response curve and used to determine differences be¬
tween them and expressed in arbitrary perfusion units (PU). These
were assessed using the method of Bland and Altman [11]. Bland-
Altman analysis allows the assessment for agreement and systematic
bias. Coefficients of reproducibility were determined for 95% con¬
fidence intervals (CI). Results are expressed as mean ± SEM and
95% CI for mean differences. Statistical analysis was performed
using Student's /-test and single-factor ANOVA for between-site
reproducibility. Statistical significance was taken at the 5% level.
Results
Accuracy and reproducibility of injection volume
Two operators performed 100 injections each. There was
no difference in mean injection weight between opera¬
tors, both weights being 10.3 ±0.1 mg (mean difference
0.08, 95% CI -0.23 to 0.39 mg; //= 100, P = 0.9).
Tolerability of intra-dermal drug delivery
The technique was well tolerated by subjects, with only
mild discomfort experienced during the injection of
saline at some of the sites. This discomfort was variable
in intensity. In the majority of subjects, the trauma from
intra-dermal injection did not leave any discernable
mark on the skin by the end of the study, although
several injections did cause a small degree of bleeding
along the track of the needle. This did not appear to
affect the results in terms of reproducibility.
Skin blood flow responses: effect of intra-dermal
injection of saline
Saline caused a nine-fold increase in SBF (0.03 ±0.003
to 0.27 ±0.02 PU; «=18, P< 0.001). This effect was
rapid in onset, with maximal response seen at 4 min
(Fig. la).
Within-subject same-day reproducibility: between-site
reproducibility
The area under the curve was constructed for the
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Fig. 1 a Effect of intra-dermal saline on skin blood flow (SBF)
between dominant and non-dominant arm on the same study visit,
b Effect of intra-dermal saline on SBF on the dominant arm on the
different study visits
subjects. There was no difference in the magnitude of
responses between sites on the forearm as assessed by
AUC (n -- 64, P=().6; Fig. 2).
Bctween-arm reproducibility
There was no difference in the magnitude of the response
between the dominant and non-dominant arms, AUC
was 2.9 ±0.4 and 2.9 ±0.4. respectively (mean difference
-0.05, 95% CI -0.8 to 0.73 PU; n = 18, P = 0.93; Fig. la).
Bland-Altman analysis was performed demonstrating no
systematic bias and a co-efficient of reproducibility of
3.54 (Fig. 3a).
Between-day reproducibility
Fig. 2 Simultaneous effect of intra-dermal saline injection on SBF
between 8 sites on the same day. Sites 1 4 were chosen on the
dominant arm (numbered proximal to distal on forearm), sites 5-8
were chosen on the non-dominant arm (numbered proximal to
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Fig. 3a, b Bland Altman plots for a between-arm reproducibility
and b between-day reproducibility
There was a trend towards a difference between study-
visits 1 and 2: AUC was 3.2 ±0.6 and 2.0 ±0.5, respec¬
tively (mean difference 1.2, 95% CI -0.03 to 2.43 PU;
«=1(), P = 0.7; Fig. lb). Bland-Altman analysis was
performed and tended to show systematic bias and a
co-efficient of reproducibility of 3.48 (Fig. 3b).
Discussion
In this study we have demonstrated that saline delivery
using the Becton-Dickinson syringe is accurate and
repeatable with low intra-operator variability. In addi¬
tion, we have demonstrated that intra-dermal injection
of saline causes a clear increase in Doppler signal but
that the magnitude of this increase is similar between
different sites on the forearm. There is good within-day
and between-arm reproducibility.
There was occasionally mild discomfort, of variable
intensity, experienced by the subjects at the time of
injection. However, there did not appear to be any
pattern to explain the fact that some sites developed
more pain than others. Although the- non-uniform
102
distribution of cutaneous nerves may explain this find¬
ing, this was not formally assessed but did not appear to
affect the results in terms of reproducibility.
While there is often greater interest in the systemic
effects of vasoactive compounds, there are potential
risks with administration of systemic doses of vasoactive
compounds. The use of local techniques such as intra¬
dermal administration with laser Doppler microcircula-
tory blood flow measurement has allowed the relatively
safe observation of the in vivo effects of vasoactive
compounds, without causing confounding compensa¬
tory systemic effects. While the SBF may be under dif¬
ferent mechanisms of control to other vascular beds and
responses can differ [12], in general, effects of com¬
pounds in the skin have been reflected in other less-
accessible vascular beds [7, 8]. Therefore, the skin
microcirculation offers a safe, well-tolerated, easy-to-use
approach to the initial investigation of vasoactive com¬
pounds.
The Becton-Dickinson syringe is commonly used to
deliver intra-dermal injections in clinical practice. Al¬
though it has the advantage that it is inexpensive and
easy to use, its accuracy has not previously been de¬
scribed. Here, we found good agreement between oper¬
ators as seen by mean values that were similar and close
to the intended volume of 10 pi, with most injections
very close to this volume. We conclude that this syringe
can be used to deliver intra-dermal injections in a clinical
research setting with sufficient accuracy and reproduc¬
ibility.
Intra-dermal injection of saline causes an increase in
laser Doppler signal. In this study, we have demon¬
strated that the technique of laser Doppler fiowmetry
coupled with intra-dermal injection is a repeatable
technique and that responses between subjects are sim¬
ilar. There was no difference in SBF in response to intra¬
dermal saline injection between sites on the same arm or
in the same patient on different study visits. There was,
however, a trend towards a small difference in SBF be¬
tween study visits which emphasizes the importance of
vehicle control when investigating the effects of vaso¬
active compounds. The reasons for this between-day
variability are not clear, as ambient temperature was
controlled, and subjects were fasted and studied under
similar conditions during each study visit. Although
careful attempts were made to keep room temperature
and conditions constant, the skin is more sensitive than
other vascular beds to changes in ambient conditions,
and small temperature changes, draughts, or emotional
factors may be more important than in other vascular
beds. Nevertheless, these between-day differences did
not reach statistical significance and the within-subject
and between-day coefficients of reproducibility were
similar (3.54 versus 3.48). We conclude' that, despite only
a small difference between days, vehicle injections should
be performed as controls during each study visit.
In conclusion, the technique of intra-dermal drug
delivery with saline vehicle coupled with laser Doppler
flowmetry to measure skin microcirculatory blood flow
offers a safe, well-tolerated, repeatable technique for
the investigation of vasoactive compounds in human
in vivo.
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